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Abstract 
Neurological heterotopic ossification (NHO) is a frequent complication of spinal cord and 
traumatic brain injuries (15-25% of patients) and manifests as abnormal ossification of soft 
tissues near joints. NHO is very debilitating and further delays rehabilitation as it causes 
pain, joint deformation and ankylosis and vascular and nerve compression. In the absence 
of an animal model the mechanisms leading to NHO are unknown and consequently there 
is no preventive treatment. The only effective approach to eliminate HO is complicated and 
expensive surgical resection. However these surgeries are delicate and can be 
challenging as they are performed once the NHO are mature, often large and 
incapacitating entrapping large blood vessels and nerves. 
To elucidate NHO pathophysiology, we have developed the first animal model of NHO in 
genetically unmodified mice. Mice underwent a spinal cord transection (SCI); muscular 
inflammation was induced by intramuscular injection of cardiotoxin in limbs (IM-CTX). 
Formation of NHO was followed by μCT and immunohistology. 
SCI alone or muscular inflammation alone did not induce NHO in mice. The combination of 
both SCI and muscular inflammation was necessary to induce NHO. This is consistent with 
clinical observations as NHO incidence is higher in patients with severe trauma or 
concomitant infection. Abundant F4/80+macrophages, which can provide pro-anabolic 
support in bone formation, were detected within the inflamed muscle and associated with 
areas of intramuscular bone formation (confirmed by von Kossa and collagen type 1 
staining). In vivo depletion of phagocytic macrophages with clodronate-loaded liposomes 
prevented NHO formation whereas Zoledronate treatment exacerbated NHO. This 
supports our hypothesis that macrophage-mediated inflammation is a key activator of NHO 
following SCI. To further identify the source and type of macrophages, involved in the bone 
formation after SCI and test some potential treatment options different knock-out mouse 
models were investigated. My data suggest that local muscle residential macrophages 
potentially play an important role in NHO. 
In addition we identified several populations of muscle progenitor cells that are prone to 
osteogenic differentiation in vitro. These data suggest that the mesenchymal progenitors 
that differentiate into osteoblasts in HO following spinal cord injury are already present in 
healthy muscles and therefore can be derived from local muscle progenitor cells rather 
than being recruited from the remote site, such as bone marrow. 
iii 
 
Finally we investigated why SCI was necessary for NHO development. My hypothesis was 
that SCI causes release of systemic factors priming NHO. In support of this, I showed that 
NHO developed in non-paralysed inflamed front limbs of mice with SCI. Also, blood 
plasma from mice with SCI and IM-CTX induced osteogenic differentiation of cultured 
muscle mesenchymal progenitor cells (mMPC) sorted from naïve mice. This suggests that 
systemic factors facilitating NHO, such as substance P and G-CSF are released following 
SCI. These factors were then specifically targeted them in our mouse model to trial 
different types of treatment for prevention of bone formation. 
In conclusion, our model suggests that NHO is a 2-insult process with 1) SCI inducing the 
release of factors that sensitize muscle progenitor cells to abnormal osteogenic 
differentiation and 2) macrophages accumulating in inflamed muscles then triggering 
abnormal osteogenic differentiation of mMPC. This study represents a significant advance 
in the understanding of NHO, revealing two targetable pathophysiologic mechanisms. 
iv 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published 
or written by another person except where due reference has been made in the text. I 
have clearly stated the contribution by others to jointly-authored works that I have included 
in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional 
editorial advice, and any other original research work used or reported in my thesis. The 
content of my thesis is the result of work I have carried out since the commencement of 
my research higher degree candidature and does not include a substantial part of work 
that has been submitted to qualify for the award of any other degree or diploma in any 
university or other tertiary institution. I have clearly stated which parts of my thesis, if any, 
have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University 
Library and, subject to the policy and procedures of The University of Queensland, the 
thesis be made available for research and study in accordance with the Copyright Act 
1968 unless a period of embargo has been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the 
copyright holder(s) of that material. Where appropriate I have obtained copyright 
permission from the copyright holder to reproduce material in this thesis. 
 
 
v 
 
Publications during candidature 
Kulina I, Genet F, Vaquette C, Torossian F, Millard S, Pettit AR, Sims NA, Anginot A, 
Guerton B, Winkler IG, Barbier V, Lataillade JJ, Bousse-Kerdiles MC, Hutmacher DW, 
Levesque JP. Neurological heterotopic ossification following spinal cord injury is triggered 
by macrophage-mediated inflammation in muscle. J Pathol, 2015 Feb 25. doi: 
10.1002/path.4519. 
 
Publications included in this thesis 
Kulina I, Genet F, Vaquette C, Torossian F, Millard S, Pettit AR, Sims NA, Anginot A, 
Guerton B, Winkler IG, Barbier V, Lataillade JJ, Bousse-Kerdiles MC, Hutmacher DW, 
Levesque JP. Neurological heterotopic ossification following spinal cord injury is triggered 
by macrophage-mediated inflammation in muscle. J Pathol, 2015 Feb 25.  
doi: 10.1002/path.4519. 
 
Contributor Statement of contribution 
Irina Kulina (Candidate) Designed and performed experiments 
F Genet Designed and performed experiments  
C Vaquette  Produced immunohistochemistry image 2D 
F Torossian Assisted execution of experiments in patients 
S Millard  Produced immunohistochemistry images; assisted 
execution of experiments 
AR Pettit  Produced immunohistochemistry images; assisted 
execution of experiments 
NA Sims  Produced immunohistochemistry images; assisted 
execution of experiments 
A Anginot Assisted execution of experiments in patients 
B Guerton Assisted execution of experiments in patients 
IG Winkler Designed experiments; edited the paper 
V Barbier Assisted execution of experiments 
JJ Lataillade  Assisted execution of experiments in patients 
MC Bousse-Kerdiles  Assisted execution of experiments in patients 
DW Hutmacher  Assisted execution of experiments 
vi 
 
JP Levesque  Designed experiments; wrote the paper 
Wrote the paper 
vii 
 
Contributions by others to the thesis  
All members of the Stem Cell and Cancer and Stem Cell Biology groups and supervisory 
team contributed to this thesis. Associate Professor Jean-Pierre Levesque and Associate 
Professor Ingrid Winkler conceptualised this project. Associate Professor Jean-Pierre 
Levesque, Associate Professor Ingrid Winkler and Dr Allison Pettit assisted with the design 
and interpretation of experiments. Dr Francois Genet introduced the animal model used in 
the project. Mrs Bianca Nowlan, Dr Susan Millard provided technical assistance with PCR 
work and immunohystochemical analysis. Dr Cerdyck Vaquette from the Queensland 
University of Technology provided technical assistance with microCT scan of animals and 
3D μCT reconstitution. Some technical assistance was also provided by Dr Dalia Khalil 
and Mr Robert Wadley in regards to Flow cytometry. Non-routine technical work was 
provided by Mr Lawrie Wheeler from the University of Queensland Diamantina Institute for 
performing the microarray service required for Chapter 5. Assistance with analytical 
interpretation of transcriptome research data (Chapter 5) was provided by Dr Gethin 
Thomas from the University of Queensland Diamantina Institute. The laboratory groups in 
the Biological Therapies program at the Mater Research Institute also assisted with 
intellectual input into this project. 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
None 
 
viii 
 
Acknowledgements 
Firstly I would like to thank my family and my partner who have supported me, encouraged 
me and coped with me throughout my PhD. Thank you for your endless love and 
understanding. Thank you Mom, Dad and Dima for teaching me never give up, go forward 
overcoming obstacles and for pushing me to succeed. Thank you Christopher Donnelly for 
putting up with me being a student again and for giving me the love and motivation. 
 
I wish to express my sincere appreciation and thanks to my supervisors Dr Jean-Pierre 
Levesque and Dr Ingrid Winkler for their continual support, guidance and patience 
throughout my candidacy. I have learnt a lot during my time with you. Thank you to Dr 
Gethin Thomas for being my PhD milestone reviewer and providing me with some very 
handy suggestions. Many thanks to Dr Allison Pettit, for your guidance, help and advice 
you have given me throughout this project and for being my PhD milestone reviewer. 
 
I wish to express my sincere appreciation and thanks to my first supervisor, Professor 
Kerry Atkinson who believed in me in the first place and gave me an opportunity to start 
my degree in Australia.  
 
In addition, I wish to thank all past and present members of the Stem Cell Biology and 
Stem Cell and Cancer teams and all the staff and students at the Mater Research Institute 
for their assistance, advice, expertise in unfamiliar techniques, and of course friendship. A 
very special thanks to Bianca Nowlan for being helpful and encouraging no matter how 
busy you are and to Dr Celena Heazlewood for teaching me first protocols, for always 
being up for a chat and for being such an amazing friend. 
 
Lastly, I would like to acknowledge and thank the funding bodies that have provided 
financial assistance for me throughout my PhD. I received a University of Queensland 
International Scholarship and a Top-up scholarship from the Mater Medical Research 
Institute. I would also like to acknowledge the Mater Research Institute and The Australian 
Stem Cell Foundation who have financially contributed towards the consumables of this 
project.  
ix 
 
Keywords 
spinal cord injury (SCI), heterotopic ossification (HO), bone formation, macrophage, 
inflammation 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 110314 Orthopaedics, 45% 
ANZSRC code: 110903 Central Nervous System, 45% 
ANZSRC code: 110704 Cellular Immunology, 10% 
 
Fields of Research (FoR) Classification 
FoR code: 1103, Clinical Sciences, 50% 
FoR code: 1109, Neurosciences, 40% 
FoR code: 1107, Immunology, 10% 
 
x 
 
Table of Contents 
Abstract ................................................................................................................................ ii 
Declaration by author .......................................................................................................... iv 
Publications during candidature ........................................................................................... v 
P .......................................................................................................................................... v 
Contributions by others to the thesis .................................................................................. vii 
Statement of parts of the thesis submitted to qualify for the award of another degree ...... vii 
Acknowledgements ........................................................................................................... viii 
Keywords ............................................................................................................................ ix 
Australian and New Zealand Standard Research Classifications (ANZSRC) ..................... ix 
Fields of Research (FoR) Classification .............................................................................. ix 
List of Figures .................................................................................................................... xv 
List of Tables .................................................................................................................... xix 
List of Abbreviations used in the thesis .............................................................................. xx 
Chapter 1: Introduction ........................................................................................................ 1 
1.1 Heterotopic ossification ........................................................................................... 1 
1.1.1 Description of disease ...................................................................................... 1 
1.1.2 Epidemiology .................................................................................................... 1 
1.1.3 Pathogenesis ................................................................................................... 1 
1.1.4 Current mouse models for FOP and HO .......................................................... 4 
1.1.5 Treatment ......................................................................................................... 5 
1.2 Cell types that may be involved in HO ........................................................................ 7 
1.2.1 Mesenchymal progenitor cells ............................................................................. 7 
1.2.2 Skeletal muscle mesenchymal progenitor cells ................................................. 10 
1.3 Macrophages are essential regulators of bone formation ......................................... 13 
Chapter 2: Material and Methods ....................................................................................... 15 
2.1 Ethics and cell source .............................................................................................. 15 
2.2 Mouse Model of SCI induced HO ............................................................................. 15 
xi 
 
2.3 Micro-computerized tomography imaging (µCT) ...................................................... 16 
2.3.1 Whole mouse body harvest for computerized tomography ................................ 16 
2.3.2 Micro-computerized tomography analysis ......................................................... 16 
2.4 Cell isolation, sorting and culture.............................................................................. 17 
2.4.1 Isolation and sorting of muscle satellite cells (SC) interstitial cells (IC) and bone 
marrow mesenchymal stromal cells (bmMSCs) .......................................................... 17 
2.4.2 Culture of muscle SC, IC and bmMSCs ............................................................. 18 
2.5 Osteogenic differentiation of harvested cells ............................................................ 18 
2.6 Adipogenic differentiation of harvested cells ............................................................ 19 
2.7 Tissue harvesting ..................................................................................................... 19 
2.7.1 Blood collection .................................................................................................. 19 
2.7.2 Hind limb for immunohistochemistry .................................................................. 19 
2.8 RNA extraction from mouse muscle ......................................................................... 21 
2.9 RNA extraction from sorted cells .............................................................................. 21 
2.10 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) ............ 22 
2.11 Protein extraction from mouse muscle ................................................................... 22 
2.12 Processing and analysis of microarray data ........................................................... 23 
2.12.1 Illumina microarray hybridisation and labelling ................................................ 23 
2.12.2 Normalisation and Background Correction ...................................................... 24 
2.12.3 Microarray analysis and validation ................................................................... 24 
2.13 Statistical analyses ................................................................................................. 25 
Chapter 3: Establishment of a mouse model of NHO ........................................................ 26 
3.1 Introduction .............................................................................................................. 26 
3.1.1 Aims and Objectives .......................................................................................... 27 
3.2 Methods specific for this chapter .............................................................................. 27 
3.2.1 Muscle injury induced by cardiotoxin ................................................................. 27 
3.2.2 Muscle injury induced by LPS ............................................................................ 28 
3.2.3 Muscle injury induced by mechanical impact ..................................................... 28 
xii 
 
3.3 Results ..................................................................................................................... 28 
3.3.1 NHO requires both SCI and muscular inflammation .......................................... 28 
3.3.2 Kinetic of NHO ................................................................................................... 31 
3.3.3 Physiological model of NHO .............................................................................. 32 
3.4 Discussion ................................................................................................................ 35 
Chapter 4: Role of Macrophages in Heterotopic Bone Formation after Spinal Cord Injury 39 
4.1 Introduction .............................................................................................................. 39 
4.1.1 Aims and Objectives ...................................................................................... 39 
4.2 Methods specific for this chapter .............................................................................. 40 
4.2.2 SCI surgery and mouse strains used in this chapter .......................................... 40 
4.2.3 Splenectomy technique and sham surgery ........................................................ 41 
4.2.4 Treatment options .............................................................................................. 41 
4.2.5 G-CSF quantification in mouse plasma ............................................................. 42 
4.3 Results ..................................................................................................................... 42 
4.3.1 Macrophage depletion considerably reduces NHO in mice ............................... 42 
4.3.2 Effect of G-CSF on NHO ................................................................................... 44 
4.3.3 Inflammatory peritoneal macrophages do not induce HO after SCI in mice ...... 50 
4.3.4 Local muscle macrophages may play an important role on NHO ...................... 51 
4.3.5 Splenectomy does not affect NHO after SCI in mice ......................................... 54 
4.3.6 E-selectin influence on NHO in mice ................................................................. 56 
4.3.7 Myeloid cell-derived Hif enhanced NHO after SCI ............................................. 58 
4.4 Discussion ................................................................................................................ 60 
Chapter 5: The comparison of gene expression profiles of operated mice and local 
changes in damaged muscles ........................................................................................... 65 
5.1 Introduction .............................................................................................................. 65 
5.1.1 Aims and Objectives .......................................................................................... 65 
5.2 Methods specific for this chapter .............................................................................. 66 
5.2.1 Processing and analysis of microarray data ...................................................... 66 
xiii 
 
5.2.2 SCI surgery and mouse strains used in this chapter .......................................... 66 
5.2.3 Treatment options .............................................................................................. 66 
5.2.4 qRT-PCR analysis ............................................................................................. 67 
5.3 Results ..................................................................................................................... 68 
5.3.1 Mouse groups with NHO, SCI only or inflammation only display a unique 
transcriptomic profiles ................................................................................................. 69 
5.3.2 Ingenuity pathway analysis confirms expression molecules of inflammation and 
cellular response signalling pathways ......................................................................... 71 
5.3.3 Differentially expressed genes ........................................................................... 83 
5.3.4 Validation of macrophage and inflammation associated markers differentially 
expressed among the groups by qRT-PCR ................................................................ 89 
5.3.5 IL-1 receptor antagonist does not improve NHO................................................ 95 
5.3.6 Combination of IL-1 receptor antagonist and TNF-α inhibitor reduced bone 
formation in NHO ........................................................................................................ 96 
5.3.7 CSF1R kinase antagonist reduced the bone density but not the volume of NHO
.................................................................................................................................... 99 
5.3.8 BMP signalling and osteogenic mRNA expression in muscle of mice with and 
without  NHO ............................................................................................................ 100 
5.4 Discussion .............................................................................................................. 105 
Chapter 6: Characterisation of muscle and bone marrow progenitor cells prone to 
osteogenic differentiation ................................................................................................. 111 
6.1 Introduction ............................................................................................................ 111 
6.1.1 Aims and Objectives ........................................................................................ 111 
6.2 Methods ................................................................................................................. 111 
6.2.1 Harvest sort and culture of muscle and bone marrow progenitors ................... 111 
6.2.2 Osteogenic differentiation of muscle and bone marrow progenitors ................ 112 
6.2.3 qRT-PCR analysis ........................................................................................... 112 
6.3 Results ................................................................................................................... 112 
6.3.1 FACS-sorting of muscle and bone marrow mesenchymal progenitors ............ 112 
xiv 
 
6.3.2 Osteogenic differentiation of muscle and bone marrow mesenchymal 
progenitors ................................................................................................................ 115 
6.3.3 Osteogenic and tissue specific mRNA expression in cultured muscle and bone 
marrow mesenchymal progenitors ............................................................................ 120 
6.4 Discussion .............................................................................................................. 122 
Chapter 7: Evidence of Systemic Factors Driving NHO following SCI ............................. 125 
7.1 Introduction ............................................................................................................ 125 
7.1.1 Aims and Objectives ........................................................................................ 126 
7.2 Methods ................................................................................................................. 127 
7.2.1 Mouse surgery and treatment .......................................................................... 127 
7.2.2 Harvest sort and culture of muscle and bone marrow progenitors ................... 127 
7.2.3 Osteogenic differentiation of muscle and bone marrow progenitors ................ 127 
7.2.4 Quantification of substance P in mouse plasma and muscle protein extract ... 128 
7.3 Results ................................................................................................................... 130 
7.3.1 Limb paralysis is not necessary for NHO development ................................... 130 
7.3.2 Plasma harvested from mice with HO promotes osteogenic differentiation of 
muscle progenitor cells ............................................................................................. 131 
7.3.3 Substance P enhances osteogenic differentiation of muscle and bone marrow 
mesenchymal progenitors ......................................................................................... 134 
7.3.4 Substance P receptor antagonist RP67580 reduced SCI-HO in vivo .............. 137 
7.3.5 Spinal cord injury and inflammation do not affect plasma and muscle 
concentration of substance P ................................................................................... 138 
7.4 Discussion .............................................................................................................. 142 
Chapter 8: General Conclusion ........................................................................................ 145 
Bibliography ..................................................................................................................... 150 
Appendix A: Animal Ethics Approval Certificate ............................................................... 164 
Appendix B: Animal Ethics Approval Certificate ............................................................... 165 
Appendix C: Mice Score Sheet ........................................................................................ 168 
Appendix D: Abstracts and presentations ........................................................................ 169 
xv 
 
List of Figures 
Figure 3.1 (A) 3D CT image of NHO in a patient with SCI; (B) Fragment of resected 
mature NHO 
Figure 3.2 Schematic image of our novel mouse model of HO after SCI  
Figure 3.3 Device used to create mechanical crush injury in our mouse model 
Figure 3.4 (A) Illustrative μCT of mouse right legs following complete or incomplete SCI 
and CDTX injection; (B) Quantification of HO volumes by 3D μCT reconstitution following 
complete or incomplete SCI and CDTX injection  
Figure 3.5 µCT of a representative mouse with (A) SCI and CDTX in the right leg 
hamstring muscles and saline in the left hamstring muscles; (B) SCI and saline in the right 
leg hamstring muscles 
Figure 3.6 Kynetic of NHO in our mouse model. (A) Illustrative µCT of right legs at 
indicated time-points following SCI and CDTX injection; (B) Quantification of HO volumes 
by 3D µCT reconstitution at indicated time-points following SCI and intramuscular CDTX 
injection 
Figure 3.7 (A) Illustrative μCT of mouse right legs following SCI, LPS injection and crush 
injury from the height of 15cm and 25cm; (B) Quantification of HO volumes by 3D μCT 
reconstitution following SCI, crush injury and intramuscular LPS injection 
Figure 3.8 (A) Illustrative μCT of mouse right legs following SCI, LPS injection alone or 
LPS injection and crush injury from the height of 15cm; (B) Quantification of HO volumes 
by 3D μCT reconstitution following SCI, crush injury and intramuscular LPS injection 
Figure 3.9 Immunohistochemistry of mouse right hind limbs harvested from mice with SCI 
and CDTX-induced inflammation. 
 
Figure 4.1 Effect of macrophage depletion on NHO 
Figure 4.2 Effect of osteoclast inactivation on NHO 
Figure 4.3 (A) Illustrative μCT of right hind limbs after SCI with injection of CDTX and 
treatment with G-CSF/Meloxicam; Quantification of HO volumes (B) and density (C) by 3D 
μCT reconstitution following SCI, intramuscular CDTX injection and treatment with G-
CSF/Meloxicam 
Figure 4.4 (A) Illustrative μCT of right hind limbs after SCI with injection of LPS and 
treatment with G-CSF; (B) Quantification of HO volumes by 3D μCT reconstitution 
following SCI, intramuscular LPS injection and treatment with G-CSF 
xvi 
 
Figure 4.5 Quantification of G-CSF in mouse plasma harvested from mice with and 
without NHO 
Figure 4.6 (A) Illustrative μCT of right hind limbs after SCI with injection of inflammatory 
macrophages; (B) Quantification of HO volumes by 3D μCT reconstitution following SCI 
and intramuscular injection of inflammatory macrophages 
Figure 4.7 (A) Illustrative μCT of right hind limbs after SCI with injection of CDTX in CCR-
2ko mice; (B) Quantification of HO volumes by 3D μCT reconstitution following SCI and 
intramuscular CDTX injection in CCR-2ko mice 
Figure 4.8 Quantification of macrophage markers in hind limb muscles of CCR-2 knockout 
and wild type mice 
Figure 4.9 Effect of splenectomy on NHO 
Figure 4.10 Effect of splenectomy on NHO in CCR-2 knockout mice. 
Figure 4.11 Role of E-selectin in NHO 
Figure 4.12 Role of M1 macrophages in NHO 
 
Figure 5.1 Principle component analysis and whole muscle gene expression arrays in 
mice that underwent SCI and or CDTX-mediated muscular inflammation 
Figure 5.2 Hierarchical clustering of mouse surgery groups based on their differentially 
expressed genes 
Figure 5.3 Clustered heatmap of significantly differentially expressed genes included in 
Msp/Ron Receptor Signaling Pathway that were up-regulated in SCI+CDTX group 
Figure 5.4 Clustered heatmap of significantly differentially expressed genes that were (A) 
down-regulated in SCI+CDTX group and (B) up-regulated in SCI+CDTX group 
Figure 5.5 Differentially expressed genes of anti-inflammatory macrophage markers in 
muscle of SCI and SHAM operated mice with and without CDTX induced inflammation at 
Day 2 after surgery 
Figure 5.6 Differentially expressed genes of inflammatory cytokines in muscle of SCI and 
SHAM operated mice with and without CDTX induced inflammation at Day 2 after surgery 
Figure 5.7 Inflammatory mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 after surgery 
Figure 5.8 Inflammatory mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 and Day 4 after surgery 
Figure 5.9 Effect of IL-1 receptor antagonist on NHO 
Figure 5.10 Effect of IL-1 receptor antagonist and TNF-α inhibitor on NHO 
Figure 5.11 Effect of CSF1R kinase inhibitor on NHO 
xvii 
 
Figure 5.12 Osteogenic mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 after surgery 
Figure 5.13 Osteogenic mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 and Day 4 after surgery 
Figure 5.14  Differentially expressed genes of osteogenic markers in muscle of SCI and 
SHAM operated mice with and without CDTX induced inflammation at Day 2 after surgery 
Figure 5.15 Effect of CSF1R kinase inhibitor on bone marrow monocytes and 
macrophages in vivo 
 
Figure 6.1 Phenotypic characterization of cell populations in mouse skeletal muscle and 
bone marrow of mice 
Figure 6.2 Morphology of cell populations sorted from mouse bone marrow and skeletal 
muscle after exclusion of erythroid cells, endothelial cells and leucocytes 
Figure 6.3 Von Kossa staining of mouse bone marrow and skeletal muscle cell 
populations. From top to the bottom: 1 week, 2 weeks, 3 weeks in culture 
Figure 6.4 Alizarin Red staining of mouse bone marrow and skeletal muscle cell 
populations  
Figure 6.5 Quantification of osteogenic differentiation of mouse bone marrow and skeletal 
muscle cell populations by Alizarin Red staining. From the top to the bottom 1 week, 2 
weeks, 3 weeks in culture 
Figure 6.6 Osteogenic myogenic and mesenchymal mRNA expression in muscle and 
bone marrow mesenchymal progenitors 
 
Figure 7.1 Evidence of systemic factors contributing to NHO 
Figure 7.2 Effect of plasma from SCI and SHAM-operated mice on osteogenic 
differentiation of interstitial cells, satellite cells and bone marrow MPCs 
Figure 7.3 Effect of plasma from SCI and SHAM-operated mice on osteogenic 
differentiation of interstitial and satellite cells 
Figure 7.4 Effect of substance P and substance P receptor antagonist on osteogenic 
differentiation of muscle and bone marrow mesenchymal progenitor cells 
Figure 7.5 Quantification of osteogenic differentiation of murine bone marrow and skeletal 
muscle cell populations supplemented with substance P or substance P receptor 
antagonist by Alizarin Red staining. 
Figure 7.6 Effect of substance P receptor antagonist on NHO. 
xviii 
 
Figure 7.7 Standard curves for plasma (A) and muscle extracted protein (B) for the 
substance P quantification assay  
Figure 7.8 Substance P quantification in plasma harvested from SCI and SHAM-operated 
mice 
Figure 7.9 Substance P quantification in protein extracted from hind limb muscles of SCI 
and SHAM-operated mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xix 
 
List of Tables 
Table 2.1 Protocol for tissue processing before paraffin embedding 
Table 2.2 Mouse hind limb RNA samples used for microarray analysis 
 
Table 3.1 HO formation requires SCI and muscular inflammation 
 
Table 4.1 Effect of G-CSF, E-selectin, CCR2 and splenectomy on NHO after SCI  
 
Table 5.1 Primers used for qRT-PCR 
Table 5.2 Pathway analysis of gene sets differentially expressed between SCI and SHAM 
groups 
Table 5.3 Pathway analysis of gene sets differentially expressed between SCI+CDTX and 
CDTX groups 
Table 5.4 Osteoblasts and macrophages expressed markers which are differentially 
expressed among classes and up-regulated in SCI+CDTX group 
Table 5.5 Osteoblasts and macrophages expressed markers which are differentially 
expressed among classes and downregulated in SCI+CDTX group 
 
Table 6.1 Primers used for qRT-PCR 
 
Table 7.1 Substance P, substance P receptor antagonist concentrations
xx 
 
List of Abbreviations used in the thesis 
-MEM 
β2M 
µCT 
3D 
7AAD 
Ab  
APC 
APC-Cy7  
BM 
bmMSC 
BMP 
BrdU 
BSA 
°C 
CBM 
cDNA 
CDTX 
Clo-lip 
CSF  
CXCL 
DAB 
DAPI  
DMEM  
DMSO 
DNA 
EDTA 
ELISA  
FACS  
FAM 
FCS 
FBS 
FGF 
Minimal Essential Medium, alpha 
β-2-microglobulin 
Micro-computerized tomography 
Three-dimensional 
7-aminoactinomycin D 
Antibody 
Allophycocyanin 
Allophycocyanin-cyanine 7 
Bone marrow 
Bone marrow mesenchymal stromal cells 
Bone morphogenetic protein 
Bromodeoxyuridine 
Bovine serum albumin 
Degrees Celsius 
Central bone marrow 
Complementary DNA 
Cardiotoxin 
Clodronate Loaded Liposomes 
Colony stimulating factor 
CXC chemokine ligand 
Diaminobenzidine 
4',6-diamidino-2-phenylindole 
Dulbecco's Modified Eagle Medium 
Dimethyl sulfoxide 
Deoxyribonucleic acid 
Ethylenediaminetetraacetic acid 
Enzyme-linked immunosorbent assay 
Fluorescence-activated cell sorter/sorting 
6-carboxyfluorescein 
Foetal calf serum 
Foetal bovine serum 
Fibroblast growth factor 
xxi 
 
FITC 
G-CSF 
gDNA  
GFP 
h 
HBSS  
Hif-1α 
HO  
hu 
IC 
IL 
INF 
M 
M1 
M2 
MSC  
Min 
mln 
MPC 
MRI  
mRNA 
NK 
OCT 
PBS 
PBTX 
 
PE 
PE-Cy7 
PenStepGlu 
PerCP 
PFA 
Poly I:C 
qRT-PCR 
R 
Fluorescein isothiocyanate 
Granulocyte-colony stimulating factor 
Genomic DNA 
Green fluorescent protein 
Hour/s 
Hanks’ balanced salt solution 
Hypoxia Inducible Factor 1α 
Heterotopic ossification 
Human 
Interstitial cell 
Interleukin 
Interferon 
Mouse 
“Classically activated” Macrophage 
“Alternatively activated” macrophage 
Mesenchymal stem cell 
Minutes 
million 
Mesenchymal progenitor cell 
Mater Research Institute 
messenger RNA 
Natural killers 
Optimal cutting temperature 
Phosphate-buffered saline 
Phosphate-buffered saline (Ca2+ and Mg2+-free), containing 0.1% (v/v) 
Triton X-100 
Phycoerythrin 
Phycoerythrin-cyanine 7 
Penicillin Streptomycin Glutamine 
Peridinin chlorophyll protein 
Paraformaldehyde 
Polyinosine:polycytidylic acid 
Quantative reverse transcriptase polymerase chain reaction 
Receptor 
xxii 
 
RNA  
RO 
RT 
RT-PCR 
rpm 
SAV 
SC  
SCF 
SCI  
SD 
SDF-1 
SEM 
t° 
TBI 
TGF 
TNF 
TRI  
UQ 
Ribonucleic acid 
Reverse osmosis  
Reverse transcriptase 
Reverse transcription polymerase chain reaction 
revolutions per minute 
Streptavidin 
Satellite cell 
Stem cell factor 
Spinal cord injury 
Standard deviation 
Stromal cell-derived factor-1 
Standard error of the mean 
Temperature 
Traumatic brain injury 
Tissue growth factor 
Tumour necrosis factor 
Translational Research Institute 
University of Queensland 
 
 
1 
 
Chapter 1: Introduction 
1.1 Heterotopic ossification 
1.1.1 Description of disease 
Heterotopic ossification (HO) was first described in patients with spinal cord injury (SCI) by 
Dejerine and Ceilier in 1918, during the First World War with the advent of X-ray 
radiography, however it started being investigated more systematically around the 1950s. 
Heterotopic ossification is described as a formation of bone tissues in “abnormal” sites, 
usually in soft tissues. HO is associated with many well-known diseases such as Guillain-
Barre [1], hypophosphataemic vitamin D resistant osteomalacia [2], fibrodysplasia 
ossificans progressiva [3], etc. Heterotopic ossification is also well described following hip 
arthroplasty/surgery [4]. In general this pathology can be divided into 3 groups on 
ethiology: genetically predisposed (e.g. fibrodysplasia ossificans progressiva), trauma 
associated (surgery, burns, multitrauma) and neurogenic (spinal cord injury, brain injury) 
[5]. 
It results in a wide array of complications, that reduce the quality of life, these include 
partial to complete joint ankylosis, regional pain syndrome, osteoporosis, vessel and nerve 
compression and soft-tissue infection, all of which result in higher morbidity and mortality. 
1.1.2 Epidemiology 
Neurogenic heterotopic ossification is reported to occur in 25% to 60% of adult patients 
with spinal cord injury [6-9], and in 10% of paediatric patients [10]. 
The main sites of heterotopic ossification after brain injury or spinal cord injury are hip, 
shoulder, elbow and knee, based on the trial performed by Garland et al. on 496 patients 
[11]. Hip was also reported to be the main ossified site after SCI in paediatric population 
[10]. Heterotopic ossification has also been described in posterior longitudinal ligament 
[12], yellow ligament [13] and vocal cords [14]. 
Male sex and young age have been suggested to be risk factors for HO [15, 16], possibly 
due to the association with military service and more risky behaviour, although to date 
there is no sufficient data about reliable association of HO with race, sex or age [17].  
1.1.3 Pathogenesis 
To date pathogenesis of NHO is unknown due to the fact that most research of NHO in 
patients is retrospective. 
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1.1.3.1 Insight to FOP 
Neurogenic HO is in some aspects similar to a very rare (1 in 2000000) genetic autosomal 
dominant disorder, leading to massive ossification of the whole body - fibrodysplasia 
ossificans progressiva. It is caused by mutations in the ACVR1 gene that encodes the 
bone morphogenetic protein (BMP) type I receptor activin A receptor-1 (ACVR1 also called 
ALK2). These activating mutations of ACVR1 cause the abnormal sensitisation of 
mesenchymal progenitor cells (MPCs) to BMPs, and stimulate their abnormal osteoblastic 
differentiation [18] [19]. As a result of these receptor is constantly active which leads to 
uncontrolled growth of bone and cartilage in muscles and joints. Also there have been 
reports that overexpression of BMP2/4 [20] together with underexpression of their 
antagonists noggin, chordin and follistatin are responsible for the symptoms of FOP [20-
22]. All these findings require further investigations as they could be potential mechanisms 
for NHO after SCI. In patients with FOP, HO generally starts in the first decade of life and 
progressively expands to completely ossify the body before 40 years of age. Small injuries or 
trauma such as immunisation, surgery, viral infections or even physical activity can flare up HO 
to dramatic proportions [23]. This suggests that innate immunity/inflammation is a triggering 
event of HO in FOP. Further supporting this notion is the beneficial clinical response to high 
dose corticosteroids within the first 36 hours of HO flare-up in FOP patients[24]. Taking 
together all aforementioned findings this is possible to suggest that two major pathways are 
causing HO in FOP: abnormally elevated BMP signalling combined with inflammation.  
Few investigations also assessed BMP-4 antagonists (noggin) inhibition [25] and inhibition 
of BMP type I receptors ALK2 and ALK3 in FOP [26].  Fontaine et al. reported a new 
mutation of the Noggin gene FOP: a guanine to adenine change that leads to substitution 
of Alanine residue by a Threonine [25]. Yu et al. have discovered a small-molecule 
inhibitor of BMP type I receptors, dorsomorphin, which selectively blocks ALK2, ALK3 and 
ALK6, followed by a discovery of a selective inhibitor of BMP type I receptor kinases, LDN-
193189. This research group showed efficacy of LDN-193189 in reducing HO in vitro and 
in vivo on caALK2–transgenic mice. The same group has also mentioned that similar to 
corticosteroid treatment LDN-193189 inhibits ossification, suggesting caALK2 expression 
and an inflammation are both required for the development of ectopic ossification in their 
mouse model [26].  
1.1.3.2 Mechanism and pathological changes in NHO following SCI 
The mechanisms of heterotopic ossification following SCI are still poorly understood. 
Pathological changes are mediated by formation of osteoblasts from the intramuscular 
cells source, which can be muscle mesenchymal stem cells or so called interstitial cells or 
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muscle satellite cells from the intramuscular fibers or alternatively migration from the bone 
marrow [27]. Chalmers et al suggested that NHO may be caused by the induction of 
muscle progenitor cells to differentiate into osteoblasts as a result of mitogenic and 
osteogenic factors in the serum of SCI patients, or to be precise by changes in balance-
ratio between pro- and anti-osteoinductive mediators [28]. Histologically HO presents as 
local microvascular alterations, vascular stasis and oedema of surrounding tissues [29]. 
Although an attractive hypothesis, still very little is known about release of osteoinductive 
biochemical factors and their influence on osteogenic differentiation of MPCs. 
In addition the mechanism of neurogenic heterotopic ossification appears to have a 
traumatic component or inflammation, such as invasive medical procedures or bone 
fractures. Shehab et al. have found that prostaglandin E2 release during inflammatory 
response can drive osteogenic differentiation of cells as a mechanism of HO [30]. 
Heterotopic ossification after spinal cord injury has also been shown to be associated with 
the presence of spasticity and pressure ulcers [31]. A case-control study of 264 patients 
performed by Citak et al. has revealed higher risk of HO based on ultrasound after higher 
lesion of spinal cord (thoracic level in comparison with lumbar), spasticity, tracheostomy, 
pneumonia and urinary tract infection. So inflammation appears to also play an important 
role in developing HO [32]. Bone fractures and mechanical ventilation have also been risk 
factors associated with a higher incidence of HO after traumatic brain injury in 176 patients 
[33]. The neurogenic factor (degree of palsy) was found to induce HO in patients with brain 
injury [34]. 
HO is reported to be associated with peripheral nerve system injury as well as CNS [35]. 
Salisbury et al. described the model of FOP in which HO are caused by injection of mouse 
fibroblasts transduced with adenovirus carrying BMP-2. Using this model the authors 
further proved that inflammation induced in sensory neuron contributes to HO [36]. These 
authors suggest that BMP2 stimulates release of substance P and calcitonin gene related 
peptide, both of which indicate induction of neuroinflammation, which contributes to HO. In 
other trials BMP2 also has been shown to induce the release of neuroinflammatory 
proteins from sensory neurons such as substance P and calcitonin gene related peptide 
[37]. 
NHO in traumatic brain injury (TBI) pathogenesis is a subject of a great interest nowadays 
and there are a few results, published recently. Several biochemical markers were found in 
human serum from patients with central nervous system injury, such as C-reactive protein, 
erythrocyte sedimentation rate, Interleukin-6, Parathyroid hormone, Alkaline Phosphatase, 
tumour necrosis factor-alpha (TNF-α), that could be potential biomarkers for NHO [38]. 
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BMP2 was found to be elevated after muscle injury and released during bone injury [39, 
40]. Increased expression of osteoblastic differentiation genes Runx-2, osterix and 
cathepsin-K has been reported in TBI patients [41]. BMPs in cerebrospinal fluid from TBI 
patients were not reported to be in high concentrations so is unlikely to be responsible for 
the osteogenic cell response that triggers HO [42]. Basic fibroblast growth factor (bFGFs) 
was shown to increase up to seven times above normal in serum of head injured patients 
with a concurrent local injury [43]. 24-hour urinary hydroxyproline, which plays important 
role in collagen stability, has been observed in spinal-cord injured patients, though its 
effect on HO has not been investigated [44]. Trentz et al have published a study of 80 
patients with TBI, where he reported a role of parathyroid hormone (PTH) in HO as a 
regulator of homeostasis of calcium and phosphate [45]. 
Leptin has been found to be low in patients with neurogenic HO [38], although it is known 
to be a promotor of bone progenitors and osteoblasts activation and was found also to 
decrease osteoblastic activity by binding to hypothalamic neurons [29]. 
Osteocalcin is another biomarker of bone remodelling, which was found to be significantly 
lower in patients with TBI [45]. 
Capmos de Paz et al. have reported that in CNS injury the mechanism of HO could be due 
to dysfunction of proprioception, so MSCs would underwent osteogenic differentiation on 
ligaments and muscle as an answer to stimuli [6]. 
To sum up, neurodamage and inflammation may both be required for the heterotopic bone 
formation. There are a number of changes in the serum of patients with SCI; however it is 
still not clear how it affects the osteogenic differentiation of cells in muscles. Also the 
definite origin of osteoprogenitors responsible for NHO is to be defined. 
1.1.4 Current mouse models for FOP and HO 
There are currently three mouse models of FOP all involving the BMP signalling pathway. 
The first one is caused by BMP4 transgene under the control of the neuron-specific 
enolase (Nse) reporter driving BMP4 expression in neurons, osteoblasts and 
macrophages [46]. Although HO spontaneously occurs in ageing nseBMP4 mice with 
progressive leukocyte infiltration in muscles, additional inflammation by subcutaneous or 
intramuscular injection of cardiotoxin considerably accelerates HO of the muscles at the 
site of injection within 2-3 weeks [47]. The next two mouse models of HO utilise activating 
R20H and Q207D mutations in the ACVR1 gene that causes FOP in humans. The first 
mutation is knocked-in the mouse Acvr1 gene [48] while the second is Cre-inducible 
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mutant transgene [26]. In both models intramuscular injection of cardiotoxin dramatically 
accelerates HO of the muscle at the site of injection. 
In summary all current models utilise mice that have been genetically modified to increase 
BMP signalling. This suggests BMP signalling is a strong candidate pathway involved in 
development of HO. All three genetic models of FOP support our hypothesis that muscular 
inflammation triggers SCI-induced HO in normal individuals.  
However these genetically driven models of FOP are not physiologically relevant to SCI 
induced NHO as its prevalence is quite high – 15-25% of SCI patients, whereas FOP is 
very rare (1 in 2000000). Also single nucleotide polymorphism (SNP) analysis has not 
revealed SNPs in BMP pathways in NHO patients. 
We are the first who developed a model that more closely matches the patients setting 
using SCI in normal mice plus an inflammatory trigger and will look at BMP signalling in 
this model. 
1.1.5 Treatment 
In many patients heterotopic ossification is so severe and debilitating that it impacts their 
lives in significant ways. Patients experience severe pain. Joint deformation occurs that 
may lead to ankylosis or grow around neurovascular bundle, compressing nerves and 
blood vessels. In paralysed patients it can even lead to inability to use a wheel chair. 
Diagnosis of HO is usually made by X-rays, using Brooker classification of HO, bone 
scintigraphy and clinical examination. Lack of standardisation in diagnosing HO and 
absence of long follow-up in many trials make hard to form guidelines about HO treatment 
and prevention. 
Treatment of HO has been divided into three main groups in one of the last review articles 
[49]. There are pharmacological treatment, non-pharmacological and the combination of 
both.  
1.1.5.1 Pharmacological treatment 
Pharmacological treatment includes NSAIDs – non-selective COX inhibitors and selective 
COX-2 inhibitors (which showed an increased risk of myocardial infarction [50]), etidronate 
(which delays calcification of heterotopic bone formation), N-acetylcystein, warfarin and 
BMP receptors inhibition, but none of them were chosen as a guideline for HO prevention 
or treatment [51]. The most popular treatment remains NSAIDs – indomethacin and 
rofecoxib, bisphosphonates such as etidronate, however these often cannot be 
administered longterm. 
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NSAIDs are a cheap option with simple way of administration, inhibiting PGE synthesis 
and bone formation. This treatment can be successfully used perioperatively and in early 
postoperative period. NSAIDs have some adverse effects. NSAIDs increase perioperative 
bleeding, have serious gastrointestinal adverse effect and can cause thrombocytopaenia 
in case of prolonged treatment. Selective NSAIDs like meloxicam have less side effects, 
though they have a risk of cardiovascular events. Rofecoxib is not used anymore in clinical 
practice due to cardiovascular adverse effects and gastrointestinal events. Furthermore 
prophylactic NSAIDs used to prevent HO can also cause delayed healing of fractures and 
decrease bone healing in other parts of the body which is undesirable effect in case of 
multiple trauma associated with SCI [51]. 
Banovac et al performed few randomised control trials studying effects of bisphosphonates 
and NSAIDs with positive results [52-55], while Garland found no evidence of improvement 
in patients with HO, who received etidronate [56]. Considering these differences Cochrane 
review was published that assessed these publications and did not find it convincing [57]. 
N-acetylcystein and allopurinol combination was compared with NSAID (indomethacin) in 
the prevention of bone formation. Significant difference between two types of treatment 
was found by day 32 [58, 59].  Authors reported the possibility to reduce HO by 
scavenging of free radicals, the amount of which increases markedly due to 
ischemia/reperfusion injury – which often accompanies SCI in severe combined trauma. 
Warfarin was used to prevent HO by one group of researchers, who suggested that it 
inhibits vitamin K activity, while osteocalcin production and maturation is associated with a 
vitamin K-dependent carboxylation [60]. However since then no one showed clinical 
benefit from warfarin use in heterotopic ossification, moreover a few reports demonstrated 
increase in vascular calcification and osteoporosis [61]. 
1.1.5.2 Non-pharmacological treatment 
Non-pharmacological treatment includes slow intensity electromagnetic field therapy [62], 
radiotherapy and physiotherapy, passive range of motion. However surgical excision 
remains the most widely practised option despite of certain complications such as wound 
infection, dehiscence, risks associated with anaesthesia etc. Surgical excision of mature 
and often large and incapacitating HO sites is the main option in most rehabilitation 
centres, although besides usual aforementioned complications associated with 
anaesthesia and surgery such as pressure sores, osteomyelitis, infection and bleeding, the 
range of motion gained after surgery is reduced with time. 
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Radiation therapy was used to treat HO in many trials, and although in some publications it 
was found successful [63-66], it doesn’t prevent bone formation in about 20% of patients 
[67] while has serious adverse effects, such as increased carcinogenesis and delayed 
healing [65]. 
Physiotherapy to improve the range of motion combined with bisphosphonates and 
surgical removal of HO has been reported to have a great benefit, though mostly in 
patients with the largest restriction preoperatively, according to De Palma [68]. 
1.1.5.3 A combination of pharmacological and non-pharmacological treatments  
The combination of treatment combines surgery with either NSAIDs or bisphosphonates. 
Another described option of combined treatment is NSAIDs and electromagnetic field 
treatment to increase oxygen level and blood supply as an aim to prevent primary and 
secondary HO accordingly [68]. 
One of the first examples of combined therapy of HO was suggested by Silver  et al. who 
has reported that anticoagulants with passive movements can prevent developing of HO 
after SCI only in early implementation before contractures developed in joints as it 
prevents inflammation associated with microtraumas [69].  
Unfortunately, in spite of the advances mentioned above, none of the treatments prevents 
or cures HO entirely. Besides all of the reviewed methods have adverse effects. As a 
result severe pain syndrome with restricted mobility and delayed rehabilitation due to NHO 
after SCI remains a major problem that causes increase in invalidity and dependance 
which in turn adversely influences quality of life and leads to earlier death. Besides, 
absence of definite treatment increases the costs of rehabilitation. In summary there are 
currently no effective methods to prevent bone formation resulting from SCI.  
1.2 Cell types that may be involved in HO 
Osteoblasts are required to formskeletal bones and presumably HO in muscles. These 
osteoblasts may derive from mesenchymal progenitors that may reside in muscles in 
healthy individuals or be recruited to damaged muscle via the blood from remote 
reservoirs such as the bone marrow. Here I review the potential all origins of osteoblasts 
during heterotopic ossification, their biology and potential mechanism of action.  
1.2.1 Mesenchymal progenitor cells 
The mesenchymal stem cells can differentiate to the cells representative of connective 
tissues of the body. True mouse MSCs have recently been described using serial 
transplantation experiments [70]. However, they are rare cells, with a frequency in bone 
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marrow of 1 in 104 to 1 in 105. To ensure sufficient numbers of mesenchymal stem cells to 
perform experiments or to transplant, most investigators expand them ex vivo in 2D 
cultures on plastic dishes. However the cells produced in culture are not true stem cells as 
they rapidly differentiate and lose multilineage potentials and markers of true MSCs [70, 
71]. In literature they are usually termed mesenchymal stromal cells, mesenchymal 
progenitor cells or transit amplifying cells. For the sake of clarity, we’ll call them 
mesenchymal stromal cells (MStroC). Some parts of this thesis will deal with 
mesenchymal stromal cells and the abbreviation “MStroC” will be used to denote this. 
1.2.1.1 Phenotype and morphology 
MStroC are plastic-adherent cells defined by the expression of CD73 and CD105 and lack 
of expression of the pan-leukocyte marker CD45 in humans. A small proportion of MStroC 
have CFU-F (colony forming unit fibroblast) activity [72, 73] suggesting the presence of a 
small number of more multipotent cells. Minimal criteria for defining multipotent human 
MStroC have been published in The International Society for Cellular Therapy position 
statement [72], as shown in a table:  
1. MStroC must be plastic-adherent when maintained in standard culture conditions 
using tissue culture flasks.  
2. 95% or more of the MStroC population must express CD105, CD73 and CD90, as 
measured by flow cytometry. Additionally, these cells must lack expression (<2% 
positive) of CD45, CD14 or CD11b, CD79a or CD19 and HLA class II.  
3. The cells must be able to differentiate to osteoblasts, adipocytes and chondroblasts 
under standard in vitro differentiating conditions.  
However this multi-potential is rarely determined at a clonal level and may not always 
occur in vivo. In most studies it is impossible to say these MStroC cultures contain actual 
multipotent cells or are a mixture of different lineage restricted progenitors.  Other cell 
surface antigens characteristic of, but not unique to, MStroC include CD49b, CD130, 
CD146, CD200. In mice these characteristic markers include nestin [70], ɑV integrin 
(CD51), PDGFRβ, etc [74, 75]. Stro-1 is present on freshly isolated bone marrow MSCs, 
as well as MStroCs from other tissues, and is lost from MSPCs during ex vivo expansion 
and cannot be considered a unique MSC marker [76].  
The marker CD34 deserves a separate attention as there are contradictory results about 
its presence on the surface of human MSCs. In a recent review of MSCs markers authors 
have discussed 10 articles which reported absence of CD34 and 5 articles that reported its 
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presence [77]. It could be associated with different phases of cell cycle or the quiescent or 
activated state of MSCs. 
Following Friedenstein’s original observation, rodent bone marrow-derived stromal cells 
have been reported as the common progenitors of mesenchymal tissues. Thus, the 
mesodermal germ layer is the origin of MSCs, which can give rise to connective tissues. 
There are different names for MSCs such as osteogenic stem cells (Friedenstein), and 
marrow stromal stem cells (Owen), as these cells have been shown to generate stromal 
cells in long-term cultures [78].  
As indicated above, MStroCs are self-renewing multipotent fibroblast-like cells that can be 
isolated by plastic adherence and can differentiate into the three mesodermal lineages 
(osteocytes, chondrocytes and adipocytes) in bulk culture [79-81]. MStroCs are present in 
many, if not all, tissues and organs (bone marrow, placenta, cord blood, heart, lung, liver 
etc) [82, 83]. Furthermore, as indicated above, the existence of true mesenchymal stem 
cells with clonal ability has been reported in the mouse [82], although during ex vivo 
expansion very few mesenchymal stem cells are present and most are committed 
mesenchymal stromal (or progenitor) cells, otherwise known as transit amplifying cells. 
The only known cells that could be closer to the true MSCs in humans are CD146+ 
pericytes described by Bianco, Sachetti [84] and Peault’s [71] groups. Sachetti et al have 
reported the ability of CD146+ cells to self-renewal, also these cells appear to be 
osteoprogenitors able to maintain vascular integrity in hematopoietic microenvironment in 
vitro [84]. CD146+ MSCs are capable of reconstituting a bone in a mouse and even form 
bone marrow after in vivo transplantation. Recently Corselli et al demonstrated that human 
CD146+ cells, which represents a small fraction of MStroC, are pericytes, supporting 
maintenance of hematopoietic progenitors and express markers of the perivascular niche 
typical for MSCs [71].  
Murine MSCs are positive for Sca-1, CD90, CD29, CD44, CD49e, CD51, CD81, CD24, 
CD105, and negative for CD45, CD11b, CD31, Ter 119, CD3, B220, Gr1 and CD117 [85]. 
Paul Frenette group has recently reported that in the bone marrow, a small population 
within this phenotype that expresses the intermediate filament protein nestin are true 
multipotent MSC capable at a clonal level to reconstitute osteoblasts, osteocytes, 
chondrocytes and adipocytes when ectopically transplanted, capable of serial 
reconstitution in serial transplant, and able to support HSC self-renewal in vivo and vitro 
[70]. 
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1.2.1.2 MSC Migration 
There is still controversy about the ability of MSCs to migrate to the sites of inflammation 
[86]. Although very few MSCs were found to be circulating in peripheral blood, there is no 
evidence of MStroC mobilisation after injury, unless various cytokines are administered. 
Moreover MSCs lack the functional homing receptors used by leukocytes and 
haematopoietic stem/progenitor cells (HSPCs) to home to sites of tissue injury. For 
instance MSCs do not interact with selectin expressed by the inflamed vasculature  
because they cannot synthesize fucosylated sialyl Lewisx sugars necessary to selectin 
ligand binding activity [87, 88]. MSCs require ex-vivo pre-treatment with fucosyl 
transferase VI in order to be able to adhere to the endothelium and home to the inflamed 
tissues and the bone marrow [89]. Thus it is not clear if and how MStroC contribute 
towards the bone formation in damaged muscles after SCI, as they do not readily migrate 
and are unable to home to sites of damage. 
1.2.2 Skeletal muscle mesenchymal progenitor cells 
Another potential origin of osteoblasts to form bone in damaged muscles are 
mesenchymal progenitor cells (MPC) residing in skeletal muscle. Two types of MPC have 
been described in the muscle: satellite cells (SC) and interstitial cells (IC). 
1.2.2.1 Phenotype and morphology 
Satellite cells are located between the basement membrane and sarcolemma, in close 
association with the plasma membrane of myofibers [90]. They are characterised by large 
nuclear-to-cytoplasmic ratio, few organelles, small nucleus and condensed interphase 
chromatin [91]. Besides giving rise to new myocytes, these cells have been found to have 
the ability for self-renewal and differentiate into cells of different lineages - two main 
features that prove their stemness [92]. Kuang et al. have recently reported that only about 
10% of satellite cells can reconstitute themselves, while the rest differentiate only towards 
myogenic lineage [93]. Adult skeletal muscle satellite cells are reported to be the 
proliferative stem cell population [94]. 
Under normal physiological conditions in adult muscle, satellite cells are quiescent and can 
be identified by the expression of the transcription factor Pax7 and cell adhesion receptor 
α7-integrin, but not MyoD in the mouse. Upon injury or pathological (autoimmune) 
damage, satellite cells start to proliferate and activate expression of the myogenic 
regulatory factors Myf5 and MyoD, re-enter the cell cycle, differentiate into “myoblasts” or 
muscle progenitor cells, and ultimately fuse to form new fibers, thus fulfilling their role 
repairing damaged muscle. Myf5 in adult myoblast proliferation and MyoD are essential for 
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differentiation. MyoD and myogenin mRNA expression in satellite cells can be induced as 
soon as 12 hours after injury [95].  
A few authors report heterogeneity of satellite cell population, based on the surface 
markers and their ability to differentiate towards myogenic lineage [91, 96]. The proposal is 
that Pax7 is required for satellite cell maintenance and self-renewal (SC niche in muscles) 
and is expressed both in quiescent and activated satellite cells [97]. Also their identification 
biomarkers include α7-integrin, Myf5, M cadherin, laminin A/C and emerin [98]. Earlier 
there were reports that not all satellite cells express CD34, M-cadherin and Myf5 [99], 
however more recent articles define satellite cells as a CD34+ population [100, 101]. 
Among other markers of skeletal muscle satellite cells it is necessary to mention Pax3 a 
close paralog of Pax7 is expressed by skeletal muscle satellite cells [101].  
Recently the sialomucin CD34 expressed highly in quiescent satellite cells (SC) and 
reduced in activated satellite cells. CD34 may act as antiadhesive molecule to facilitate 
migration and promote proliferation of satellite cells at the very early stage of muscle 
regeneration [102]. According to Mitchell et al. [100] and Monterras et al. [101] Pax7+ SC 
are CD34+ Sca1-. Unable to rule out expression of CD34 marker by satellite cells, Lee et 
al. suggested that muscle satellite cells could be originally CD34 positive but during the 
selection they differentiate into CD34 negative cells [103]. 
Muscle mesenchymal stromal cells are also called in literature as interstitial cells, due to 
their location. Their profile is similar to well-known bone marrow MSCs, as Sca1+ CD45-, 
however they express CD34 surface marker. These interstitial cells have been reported to 
be able to self-renew and differentiate towards myocytes, gaining Pax7 and M-cadherin 
markers – those of myocyte progenitors in vitro [104].  Mitchel et al. have recently 
described interstitial cells in their paper [100]. These cells express PW1 - transcription 
marker and Sca1, but not Pax7 as muscle satellite cells, which will be described later. 
Interest towards skeletal muscle satellite cells and interstitial cells has risen over the past 
decades as it is a potential source of cells for the treatment of chronic or hereditary muscle 
diseases. However there are some controversial data about this cell population, showing 
the need of further investigation of SC phenotype and properties. 
1.2.2.2 Differentiation potential and possible role of muscle satellite cells and interstitial cells in 
heterotopic ossification after SCI 
Besides repairing damaged muscle by differentiating towards myoprogenitors and fusion 
to form myocites spontaneous adipogenic differentiation of muscle satellite cells and 
interstitial cells can occur in culture [105]. Several types of cell isolated from skeletal 
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muscle have been reported to possess adipogenic differentiation potential including 
satellite cells, side population cells and MPCs. However, it is not clear whether these cells 
have the ability to induce in vivo fat formation in skeletal muscle. It is not known whether 
satellite cell plasticity or multipotency is operative in vivo, and little is known about the in 
vivo features of muscle side population cells or MPCs, such as their anatomical 
localization and pathophysiological roles. 
To determine whether human myogenic progenitor cells are able to act as osteoprogenitor 
cells, Seale et al. cultured both primary and immortalized progenitor cells derived from the 
healthy muscle of a healthy woman. The undifferentiated myogenic progenitors 
spontaneously expressed two osteoblast-specific proteins, bone-specific alkaline 
phosphatase and Runx2 in vitro, and were able to undergo terminal osteogenic 
differentiation without exposure to exogenous inductive agents such as bone 
morphogenetic proteins in vitro. They also expressed the muscle lineage-specific proteins 
Pax7 (exclusive for muscle satellite cells) [106] and MyoD, and lost their osteogenic 
characteristics in association with terminal muscle differentiation. Both myoblastic and 
osteoblastic properties are possibly simultaneously expressed in the human myogenic cell 
lineage prior to commitment to muscle differentiation when cultured in vitro [107]. 
Hashimoto et at. have also found the simultaneous expression of the exclusively satellite 
cells marker Pax7 and bone-specific alkaline phosphatise on cultured muscle MPC. They 
cultured human muscle satellite cells with β-glycerophosphate (βGP) (10 mM) only in 
comparison with a combination of βGP with BMP2 and found that βGP alone induced 
calcification on the 6th day, while BMP2 alone did not have the same results. Muscle 
derived MPCs have higher potential for osteogenic and myogenic differentiation in 
comparison with adipose tissue-derived MPCs [108]. Skeletal muscle SC can differentiate 
into both myogenic and osteogenic lineage in vitro and in vivo after transfection with 
BMP2. Murine muscle satellite cells transduced with adenoviral vector encoding BMP2 
injected into hind limbs induced ectopic bone formation within 14 days. Same cells have 
also repaired skull defect in mice at 2 weeks [103]. This suggests that muscle SC have the 
potential to generate bone in vivo when provided the right signal. Murine skeletal muscle 
satellite cells have also been found to differentiate into myocytes and osteocytes when 
cultured in Matrigel [109]. C2C12 mouse myogenic cells can differentiate into osteoblasts 
after  supplementation with  BMP-2, 4, 7 [110]. Supplementation of BMP7 in culture 
medium have also showed the osteogenic differentiation of muscle SC, proving their ability 
to turn into osteoblast in vitro [111]. In comparative analysis of adipose tissue derived stem 
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cells (ADSCs), muscle-derived stem cells exhibited higher osteogenic differentiation 
potential than ADSCs [108]. 
In vitro all human mesenchymal-like cell populations from skeletal muscle are reported to 
have equal osteogenic potential [112]. 
Of note in the single reports where the osteogenic activity of mouse/rat MPCs was directly 
compared to bone marrow MSCs or adipose tissue derived MSCs, the muscle MPCs had 
higher osteogenic activity in vitro [113]. 
Thus considering ability of muscle SC to differentiate towards all mesenchymal lineages 
and their location within muscle fibers it is likely that they can contribute towards to bone 
formation in muscles after SCI without the need for the recruitment other MPCs from 
distant tissue (such as the bone marrow) via the blood.  
1.3 Macrophages are essential regulators of bone formation 
Macrophages are plastic multifunctional cells and can adopt many different phenotypes and 
functions depending on the tissue of residence, and the state and mode of activation. While 
inflammatory macrophages are derived from circulating monocytes, there is constroversy on 
the origin of tissue resident macrophages as to whether they are regenerated from circulating 
monocytes or from locally dividing tissue macrophages [114, 115]. Tissue resident 
macrophages are generally non-inflammatory. However upon activation, macrophages can be 
activated toward one or two broad range of behaviours: M1 classically activated pro-
inflammatory macrophages or M2 alternatively activated tissue-reparative macrophages [116]. 
Freytes et al. have also investigated M1 and M2 macrophages and their effect on human 
MSCs survival and proliferation. They found that M2 macrophages and their associated 
cytokines support the growth of MSCs while M1 macrophages inhibited the growth of 
therapeutic MSCs [117]. M2 macrophages were associated also with immunoregulation, matrix 
deposition, remodelling and graft acceptance [118]. Macrophages M2 are also known to 
promote angiogenesis activating fibroblasts and endothelial cells. 
Chang et al. have reported the presence of macrophages in endosteum, periosteum in 
trabecular and cortical bones of both mice and human [114, 119]. They have also suggested 
that macrophages contribute towards differentiation of osteoblasts by increasing maturation 
and mineralisation. These macrophages - called osteomacs - form a canopy over bone-
forming osteoblasts in both the periosteum and endosteum of skeletal bones. Macrophage 
depletion using macrophage Fas-induced apoptosis (MAFIA) transgenic mice or using 
clodronate-loaded liposomes in wild-type mice causes a rapid loss of osteoblasts and 
arrest in bone formation proving that osteomacs are necessary to maintain osteoblast 
function and bone formation
 
[120]. Likewise depletion of macrophages from cultures of 
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MSCs prevents their subsequent differentiation into osteoblasts, whereas re-addition of 
purified macrophages rescues osteogenic differentiation of these cultured MSCs. Thus a 
specialised population of macrophages is necessary to both osteoblast differentiation and 
function, and bone formation in skeletal bones. 
It was previously shown that both macrophage types are recruited in bone fracture repair with 
M1 macrophages in the early stage and M2 macrophages supporting bone anabolism at later 
stages. It is possible that in HO, only one or both types of macrophages (M1, M2) are involved.  
Interestingly, osteomacs are also necessary to maintain the function of haematopoietic 
stem cell niches in the bone marrow. Indeed macrophage depletion causes the collapse of 
the haematopoietic stem cell niches that require MSCs and osteoprogenitors to function 
properly, leading to the mobilisation of haematopoietic cells from the bone marrow into the 
blood [120]. This is consistent with the observation that HO in patients with SCI contains a 
functional haematopoietic bone marrow with haematopoietic stem and progenitor cells 
(unpublished observation). 
In similar disease discussed earlier FOP in humans heterotopic ossification begins in 
childhood after an inflammatory trigger – trauma or viral illnesses [19]. FOP was found be 
associated with mutations in the activin A receptor, type I (ACVR1), also known as activin 
receptor-like kinase 2, (ALK2), one of the bone morphogenetic protein (BMP) type I 
receptors (BMPR-I) [121]. Group of researchers suggested that the mutant ACVR1/ALK2 
receptor in FOP is responsive to receptor stimulation by inflammation and possible 
macrophages play an important role. 
Taken together, these data suggest that macrophages recruited into inflamed soft tissues 
could be important players of abnormal osteogenic differentiation of MSCs after SCI.  
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Chapter 2: Material and Methods 
This chapter contains Material and methods common to all aims. Specific methods are 
described in details in the appropriate result chapters. 
2.1 Ethics and cell source 
All experiments were performed on C57BL/6J wild type mice, unless specified. Wild type 
C57BL/6J mice were purchased from the Animal Resource Centre (Perth, Australia).  All 
mice were housed within the Annex building, MMRI, and Animal facilities, TRI, and were 
maintained in conventional cages, with passive air exchange.  Mice were fed ad libitum.  
For each cell harvest, MSCs were harvested from six adult female mice, 5-6 weeks of age. 
This project was undertaken with prior approval from Animal Experimentation Ethics 
Committee of the University of Queensland (number 470/11, 054/14 – Appendices A,B). 
Mouse osteoblastic cell line MC-3T3 was a kind gift from Dr Allison Pettit’s group. 
2.2 Mouse Model of SCI induced HO 
Mice were anesthetized by intraperitoneal injection of 75mg/kg ketamine, 10 mg/kg 
xylazine, diluted in sterile saline for injections. A laminectomy was practiced on the dorsal 
spine and the spinal cord trans-sectioned with a scalpel blade between T7 and T8. 
Muscles and skin were sutured. Control animals were sham-operated with anesthesia and 
incision of the dorsal skin. 
After the surgery while mice were still anesthetized, inflammation in the right leg 
hamstring muscle was induced by intramuscular injection of 12.5µg cardiotoxin (CDTX) 
from Naja mozambica (SIGMA-ALDRICH; C0759-1MG) diluted in 100µL phosphate-
buffered saline (PBS). As control, the left leg hamstring muscles were injected with 100µL 
PBS without CDTX. At the end of the surgery, mice received a subcutaneous injection of 
20mg/kg ciprofloxacin. Mice were then left to recover from the anesthesia on a heat pad at 
37°C and then returned to their cages. 
As operated mice were paraplegic due to the SCI, their bladders were emptied 
manually by gentle squeezing of the bladder between fingers twice daily during the whole 
experiment. As prophylaxis for bladder infections, mice were given antibiotics in their 
drinking water with a weekly alternating of 125 mg/L ciprofloxacin, or 400 mg/L 
sulfamethoxazole, 80 mg/L trimethroprim and 10 mg/L fluconazole. Each mouse was then 
monitored twice daily, body weight measured and urine tested with a urinary strip. A health 
score sheet adapted for paraplegic mice was used each day during the first 3 days and 
weekly after for the monitoring of these mice. Score sheet is shown in Appendix C. At the 
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end of the experiments mice were euthanized with CO2 between day 3 and week 3 after 
surgery.  
2.3 Micro-computerized tomography imaging (µCT) 
2.3.1 Whole mouse body harvest for computerized tomography 
At specified time-points after surgery and CDTX injection, mice were euthanized by 
CO2 asphyxiation. Skin was removed and the whole mouse body was put in a 50ml tube 
filled up with freshly made 4% paraformaldehyde in PBS. After 24hr fixation on a rotator in 
the cold room at 4°C, tubes were emptied, mouse carcasses rinsed once in PBS and 
preserved in a tube full of PBS containing 0.1% NaN3 until processing for µCT or histology. 
2.3.2 Micro-computerized tomography analysis 
Whole mouse carcasses were analyzed by µCT. The scans were performed in a µCT 
scanner (µCT40, SCANCO Medical AG, Brüttisellen, Switzerland) at an energy of 45 kVp 
and intensity of 177 µA, 8W with 300 ms integration time and average integration of 1, 
which resulted in resolution of 30 µm. To cover the entire thickness of the ectopic bone, 
the number of slices was set at 350. Three-dimensional (3D) images of lower part of the 
mice bodies were reconstructed from the scans by the µCT system software package. 
Quantitative assessments of bone volumes in the muscular mass by subtraction technique 
of orthotopic mouse skeleton (hip, femur, tibia and fibula) were measured to detect and 
quantify HO as previously described [122]. Briefly, from the reconstructed cross-sectional 
images, a series of 350 slices were used for the final analysis. Manual contouring was 
used to define the outer boundary of the ectopic mineralized tissue. To detect new 
mineralized formations bone density were identified using X-ray attenuation levels as 
defined by the software as >180. Bone volume and tissue bone mineral density were 
calculated using the scanner’s software. Total volume of ectopic bone was defined as the 
sum of volumes of all mineralized tissue within the region of interest. Bone volume was 
measured in mm3; bone density was measured in mg/cm3. After scanning, the murine 
carcasses were transferred in 50 ml Falcon tubes with saline and sodium azide and stored 
in +4°C.”The area of etopic bone formation was manually defined for each cross-sectional 
image and 3D automatic registration method was applied   
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2.4 Cell isolation, sorting and culture 
2.4.1 Isolation and sorting of muscle satellite cells (SC) interstitial cells (IC) and bone 
marrow mesenchymal stromal cells (bmMSCs) 
Four to six mice, 5-6 weeks of age, were sacrificed by cervical dislocation. After 
decontamination of the fur with 70% ethanol, hamstring muscles from naïve mice were 
collected and dissociated into single cell suspensions by successive digestions with 
collagenase and dispase as previously described [96]. Briefly muscle tissue was cut into 1-
2mm3 pieces and incubated in Collagenase I, 500u/mL (Worthington Biosciences) for 30 
min. Then digested muscle tissue was retrieved with a 3mL syringe plunger and 
centrifuged at 800rpm for 5min. Supernatant was removed and the spin was repeated 
three times. The second digestion step was performed by incubation muscle tissue in 
Collagenase type I 1.5U/mL with dispase II neutral protease, grade II 2.4ml/U 
(4942078001, Roche) at 37°C for 1 hour. To collect bone marrow MSCs (bmMSCs) the 
femurs and tibias were removed, cleaned of excess tissues and transferred into -MEM 
(GIBCO Invitrogen 12561-056) on ice. All bones were crushed in a sterile ceramic mortar 
with a pestle, and were digested in a freshly-prepared solution of PBS containing 3 mg 
Type I collagenase/mL (Worthington Biosciences) and 10 ug DNase I/mL (Roche; 
04716728001) on an orbital shaker (220 rpm, 37˚C; 40 min.). The supernatant was 
transferred through a 40 µm filter into a sterile 50 mL tube.  The crushed bones were 
washed twice with -MEM medium, and the suspension was filtered into the same 50 ml 
tube that contained the supernatant. The pooled suspensions were centrifuged (350 x g; 
4C; 5 min). The supernatant was discarded and the cells were resuspended in 1mL of 
MSC culture medium (1X -MEM containing 20 % (v/v) FCS (GIBCO Invitrogen, 10099-
141), 10 U penicillin/mL, 10ug/ml streptomycin and 2mM glutamine (GIBCO Invitrogen, 
10378).  
Single cell suspensions isolated from muscles and bone marrow were then stained 
with biotinylated mouse CD45 and Ter119, CD31-APC, anti-Sca1-PECY7, CD34-FITC, 
streptavidin-PE following standard procedure [72, 123, 124]. Two µg/mL 7-
aminoactinomycin D was added 10 minutes before sorting in order to exclude dead cells. 
Cells were sorted on an Astrios cell sorter (Beckman Coulter) directly into αMEM with 20% 
FCS. Once sorted, cells were immediately washed in the same culture medium and 
cultured.  
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All three types of cells isolated from 4-6 hind limbs were plated into T25-T75 flasks 
(5000 cells/cm2), containing culture medium and were incubated in a humidified incubator 
(37˚C, 5 % CO2).   
2.4.2 Culture of muscle SC, IC and bmMSCs 
Once sorted, cells were immediately washed in the culture medium and cultured as 
described previously [100, 123]. After 72 hours the cells were washed in sterile, 1x PBS 
(Ca2+-, Mg2+-free; GIBCO Invitrogen 14190-250), to remove non-adherent cells, and were 
re-plated in fresh culture medium. Adherent cells were passaged by 1:4 split when 90% 
confluent.  Bone marrow MSCs were cultured in 1X -MEM containing 20 % (v/v) FBS 
(GIBCO Invitrogen, 10099-141), 10 U penicillin/mL, 10ug/ml streptomycin and 2mM 
glutamine (GIBCO Invitrogen, 10378). Muscle cells were cultured in 1X high glucose 
DMEM high glucose (GIBCO Invitrogen 11960-044)  containing 20 % (v/v) FCS, 10% 
horse serum, 10 U penicillin/mL, 10ug/ml streptomycin and 2mM glutamine. All cells were 
expanded up to, and including, passage 4.  Medium was aspirated and flasks were rinsed 
in 1X PBS.  The PBS was aspirated and the cells were detached enzymatically by the 
addition of TrypLE™ Select (GIBCO Invitrogen 12563-029; 5 mins; 37C; 5% CO2), washed 
and centrifuged (350 x g; 5 mins; 4°C). The supernatant was discarded and the cells were 
resuspended in 1mL of MSC culture medium, diluted 1:1 (v/v) with 0.4% (w/v) Trypan Blue 
Stain (GIBCO Invitrogen 15250-061), to determine cell viability and numbers.  Cells were 
seeded into sterile T75 flasks at a density ranging between 4,000-5,000 cells/cm2, and 
were cultivated in culture medium  At passage 4 cells were detached from the flasks with 
TrypLE™ Select, centrifuged at 350 x g (5 mins; 4°C) and were resuspended in 
cryopreservation medium (90% (v/v) FCS; 10% (v/v) DMSO (Sigma D5879)) . Cryovials 
were stored at -80°C for 24 hours in “Mr Frosty” with isopropanol and then were 
transferred to liquid nitrogen for long-term storage. 
2.5 Osteogenic differentiation of harvested cells 
The protocol for osteogenic differentiation was adapted from [123]. Cells were grown to 
90% confluence trypsinized and seeded in the same medium in 96-well plates. Once 
confluence was reached, medium was removed in each well; wells were rinsed twice with 
PBS and replaced by osteogenic differentiation medium and cultured for 3 weeks in a 
humidified incubator (37C; 5% CO2) with a medium changed every week. Osteogenic 
differentiation medium was made of 1x -MEM supplemented with dexamethasone (0.2 
μM), β-glycerol phosphate (10 mM), L-ascorbate-2-phosphate (200 μM), calcium chloride 
(2 mM), 10% (v/v) FBS and 10U penicillin/mL; 10ug streptomycin/ml; 2mM L-glutamine. 
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To establish osteogenic properties of blood plasma from operated mice, cultures of 
sorted muscle cells were established in microwells as described above but osteogenic 
differentiation was performed for 3 weeks in DMEM with high glucose supplemented with 
20% FCS and 10% horse serum and 10% mouse blood plasma but without 
phosphoascorbic acid, β-glycerophosphate or dexamethasone. 
For quantification of mineralization, medium was removed, wells were washed once 
with PBS and then fixed for 30 minutes with PBS containing 4% paraformaldehyde. Wells 
were then rinsed with PBS and milliQ water. Dried wells were then stained with 10mg/mL 
Alizarin Red S solution (Sigma; 056K0745) in water buffered to pH 4.1-4.3 with NH4OH. 
After 10 mins, wells were rinsed with milliQ water, dried and photographed.  
For detection of calcification calcium deposited by cells in a 48 or 96 well plate was then 
destained by 10% cetylpyridinium chloride dissolved in water containing 10mM sodium 
phosphate for 15 mins and absorbance was measured at 562nm. 
2.6 Adipogenic differentiation of harvested cells 
Cells were cultured in adipogenic differentiation medium (-MEM, 3-isobutyl-1-
methylxanthine (0.5 mM), indomethacin (60 µM), insulin (5 µg/ml), dexamethasone (1 µM), 
10 % (v/v) FCS, 10U penicillin/mL; 10ug streptomycin/ml; 2mM glutamine for 3 weeks, 
fixed with 4% (w/v) PFA (pH7.3), rinsed in 60% (v/v) isopropanol and stained with oil red O 
stain (Sigma; 101K3489) for 30 mins, rinsed again in 60% (v/v) isopropanol and finally in 
distilled water, as described [74, 96, 123]. 
2.7 Tissue harvesting 
2.7.1 Blood collection 
To harvest blood plasma, mice were anesthetized by inhaling isoflurane using 
anaesthetic machine VetEquip (Pleasanton, CA, USA), 0.5 to 0.8 mL blood was harvested 
in tubes containing of 225U/mL heparin and 0.014 TIU/mL aprotinin by cardiac puncture. 
Mice were then immediately euthanized by cervical dislocation and further processed as 
described above. Blood samples were centrifuged twice at 800xg at 4°C for 10 minutes to 
harvest blood plasma. Blood plasma samples were aliquoted and stored at -80°C until use. 
2.7.2 Hind limb for immunohistochemistry 
Fixed limbs (as per 2.3.1) were decalcified up to 4 weeks at 4°C in PBS containing 14% 
EDTA adjusted to pH 7.4 with weekly solution changes. Following bone decalcification, 
hind limbs were processed on the Tissue-Tek VIP 6 according to the protocol (Table 2.1), 
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embedded in paraffin and 5µm sections cut and placed on SuperFrost Plus® slides 
(Menzel, Germany). Sections were deparaffinized and re-hydrated with xylene and graded 
ethanol and washed in TBS (immunohistochemistry) or deionized water (histology). F4/80 
(rat anti-mouse F4/80, AbD Serotec) and osteocalcin (rabbit anti-mouse, Alexis 
Biochemicals, San Diego, USA) immunohistochemical staining was carried out as 
previously described [114]. In brief, a 3 step procedure using species specific biotinylated 
F(ab′)2 secondary antibodies (Santa Cruz, California, USA) and horse radish peroxidase 
conjugated streptavidin (Dako, Glostrup, Denmark) to detect primary antibodies. 
Diaminobenzidine (DAB, Dako, Glostrup, Denmark) was used as the chromogen and 
sections were counterstained with Mayer’s haematoxylin (Sigma Aldrich) and mounted 
using permanent mounting media. Specificity of staining was confirmed by comparison to 
serial sections stained with matched isotype control antibodies (Rat IgG2b, AbD Serotec 
and normal rabbit IgG, Santa Cruz, respectively). All sections were examined using a 
Nikon Eclipse 80i microscope with a Nikon D5-Ri1 camera and NIS-elements imaging 
software. 
 
 
Table 2.1 Protocol for tissue processing before paraffin embedding 
Step Reagent Temp Pressure/Vacuum Mixing Rate 12hr 
1 70% Alcohol Ambient None Slow** 1:00 
2 90% Alcohol Ambient None Slow** 1:00 
3 95% Alcohol Ambient None Slow** 1:00 
4 100% Alcohol Ambient None Slow** 1:00 
5 100% Alcohol Ambient None Slow** 1:00 
6 100% Alcohol Ambient None Slow** 1:00 
7 Xylene Ambient None Slow** 0:40 
8 Xylene Ambient None Slow** 0:40 
9 Xyene Ambient None Slow** 0:40 
10 Wax  60°C Vacuum*  Slow** 1:00 
11 Wax  60°C Vacuum*  Slow** 1:30 
12 Wax  60°C Vacuum*  Slow** 1:30 
     
12:00 
*Vacuum setting = Default Vacuum setting = 90sec vacuum; 30sec ambient pressure 
** Slow = complete drain and fill at 20min interval 
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2.8 RNA extraction from mouse muscle 
Hind limb muscles from mice were collected into 1.5mL Eppendorf tubes with 1mL of PBS 
on ice. Each muscle sample (one at a time) was transferred into 12mL tube with 2mL of 
Trizol (Ambion 15596018) and homogenized with Tissue Ruptor (QIAGEN Hilden). The 
mix was put on dry ice every 30 seconds to prevent overheating. Then 2mL of Trizol was 
added and the process was repeated. After processing all samples they were left in room 
t° for 30 mins to maximize RNA extraction. The mix was divided into 4 Eppendorf tubes 
with 1mL in each, centrifuged at 12000g, 4°C for 10 min to remove all the debris and lipids. 
Clear pink liquid was transferred to new sterile Eppendorf tube.  
Whole BM RNA was extracted from femur flushed with 1 ml of PBS followed by transfer of 
200 μL of BM cell suspension into 1mL of Trizol (Ambion 15596018). Endosteal RNA was 
collected by flushing the empty femur cavity with 1ml Trizol to solubilise and extract RNA 
from cells attached to the bone at the endosteum.  
Chloroform was added at ratio of one fifth the volume of the Trizol and samples were 
shaken and rested for 5min at room t°. Samples were then centrifuge at 12,000g, 4°C for 
15mins. Supernatant was removed, an equal volume of isopropanol was added and 
samples were rested for 10mins. Samples were then stored at -70°C until reverse 
transcription.  
For reverse transcription a quarter of RNA sample stored in isopropanol was centrifuged at 
12,000g, 4°C for 15mins, washed with 1mL of 75% ethanol, centrifuged  at 12,000g, 4°C 
for 15mins, dried at 65°C for 10mins and resuspended in 10-20μL of RNAse/DNase free 
water. Reverse transcription was performed using iScript cDNA kit (BioRad) per 
manufacturer's instructions: 5x first strand buffer (250mM Tris-HCl, 375mM KCl, 15mM 
MgCl, pH 8.3; provided with enzyme) and iScript Reverse Transcriptase in a final volume 
of 20µl at 42°C for 30mins. After 5min enzyme inactivation at 85°C, cDNA was diluted 
1/10. Primers used in this study did not detect genomic DNA (gDNA). qRT-PCR was 
performed using Taqman Universal PCR master mix (ABI) and SYBR Green PCR Master 
Mix (ABI). The protocol for the PCR consisted of one cycle of 50°C (2 min), followed by 
95°C (10 min), followed by 50 cycles each of 95°C (10 sec) and 60°C (60 sec). Results 
were normalized relative to β2-microglobulin mRNA or β-actin mRNA.  
2.9 RNA extraction from sorted cells 
Cells were harvested and sorted as per 2.3.2. After sort on Astrios cell sorter (Beckman 
Coulter) all cell populations were collected directly in the 1.5 mL Eppendorf tubes with 1mL 
of Trizol (Ambion 15596018). The sort was paused every 105 cells to mix collection tubes 
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containing Trizol phase and sorted cells in aqueous phase. Collection tubes were then left 
for 15 min at the room temperature and stored at -70⁰C before extraction of RNA for 
minimum of 72 hours. After 3 days the samples were then thawed and choloroform was 
added at one fifth the volume of the trizol and samples were shaken and rested for 5min at 
room t°. Samples were then centrifuged at 21,000g, 4°C for 15mins. Supernatant was 
removed, 0.5μg Linear Polyacrylamide for DNA/RNA Precipitation (GenElute™-LPA, 
56575-1ML, SIGMA) was added followed by adding an equal to supernatant volume of 
isopropanol. Samples were rested for 10mins at the room temperature. Samples were 
then stored at -70°C until reverse transcription, but minimum for 48 hours. For reverse 
transcription a quarter of RNA sample stored in isopropanol was processed as described 
in the section 2.8 “RNA extraction from mouse muscle”. 
2.10 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
qRT-PCR was used to determine gene expression using SYBR® Green PCR Master Mix 
(Applied Biosystems, Warrington, UK) or TaqMan® Universal PCR Master Mix (Roche, 
USA) on a 7900HT Fast Real-Time PCR machine (Applied Biosystems). Each reaction 
was analysed in a 10 µl reaction volume containing: for SYBR® Green 4µl of a 1 in 10 
dilution of cDNA (section 2.8.5), 0.5µl of each 1.0 µM forward and reverse primers and 5µl 
of Master Mix, for TaqMan® 4.5µl of a 1 in 10 dilution of cDNA (section 2.8.5), 0.5µl of 
TaqMan primer and 5µl of Master Mix. Each sample underwent amplification with an initial 
activation and denaturation at 50ºC for 2 mins and 95ºC for 15 mins; followed by 50 cycles 
of denaturation at 95ºC for 10 sec, annealing and extension at 60ºC for 45 sec unless 
otherwise noted.  Melt curve analysis was performed following every amplification to 
calculate mRNA copy number. For qRT-PCR analysis the relative to housekeeping gene 
expression as determined by ΔCt was compared between the groups.  
2.11 Protein extraction from mouse muscle 
Hind limb muscles from mice were collected into 5mL tubes and put immediately on dry 
ice. Protein lysis buffer ingredients included: TrisHCl pH7.4 (100mM), Sodium 
orthovanadate (2mM), Sodium chloride (100mM), 1%Triton-X-100 (v/v), 10% glycerol (v/v), 
0.1% SDS (v/v), sodium fluoride (1mM), sodium deoxycholate 0.5% (w/v), 1xULTRA 
tablet, EDTA-free (Roche Diagnostic, 05892953001). 
Each muscle sample (one at a time) was transferred into 10mL tube with complete protein 
lysis buffer, 2.5mL per gram of tissue and put on ice for 5 min. All samples were 
homogenized with Tissue Raptor (QIAGEN Hilden) for 20 seconds twice with 15 seconds 
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on ice in between to prevent overheating. Then samples were rotated for 20 min at 4°C 
and centrifuged at 11000rpm at 4°C for 20 min. After processing all samples clear 
supernatant was collected and stored at -20°C before used in assay. 
2.12 Processing and analysis of microarray data 
2.12.1 Illumina microarray hybridisation and labelling  
Total RNA was extracted from mouse hind limb muscles as per section 2.8. RNA was 
purified and concentrated using the RNeasy MinElute Cleanup Kit, (QIAGEN). The 
concentration and integrity of total RNA was evaluated using microfluidics analysis by the 
2100 Expert Bioanalyzer and NanoDrop. The entire electrophoretic trace of the sample 
was used by the Bioanalyzer software (Agilent Technologies, Inc.) to derive a RNA 
integrity number (RIN), which is an index between 1 and 10. A RIN threshold above 6.5 
has been chosen. All samples used had a RNA integrity number (RIN) that ranged from 
6.8 to 9.5 (Table 2.4), demonstrating high quality starting material. Briefly, 600 ng of RNA 
was amplified using the Illumina TotalPrep RNA Amplification Kit with biotin-16-UTP 
labelling, including a 14 hour in vitro transcription using T7 RNA polymerase. A total of 750 
ng of cRNA was hybridised to MOUSEREF-8 BEADCHIP KIT (8 samples per chip) 
overnight for 16 hours at 58°C (Illumina). It was then scanned on to a BeadStation 500 
System using Beadscan software Version 3.5.31 (Illumina).  
All Illumina microarray hybridisation and labelling experiments were performed by Mr 
Lawrie Wheeler (Human Genetics Group, The University of Queensland Diamantina 
Institute).  
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Table 2.2  Mouse hind limb RNA samples used for microarray analysis.  
Sample number RNA samples Concentration (ng/µl) R.I.N 
1 1.1 SCI+CDTX 358.51 8.50 
2 1.2 SCI+CDTX 117.04 8.40 
3 1.3 SCI+CDTX 324.66 9.10 
4 1.4 SCI+CDTX 175.5 8.90 
5 2.1 SCI+saline 499.57 7.70 
6 2.2 SCI+saline 463.05 6.80 
7 2.3 SCI+saline 391.89 7.00 
8 2.4 SCI+saline 383.61 7.60 
9 3.1 SHAM+CDTX 164.33 9.30 
10 3.2 SHAM+CDTX 242.7 9.50 
11 3.3 SHAM+CDTX 416.02 9.40 
12 3.4 SHAM+CDTX 397.2 8.20 
13 4.1 SHAM+saline 379.91 7.80 
14 4.2 SHAM+saline 302.39 7.90 
15 4.3 SHAM+saline 473.64 8.20 
16 4.4 SHAM+saline 331.14 8.40 
2.12.2 Normalisation and Background Correction 
The variance stabilization transformation (VST) of data, normalisation, intensity-depending 
filtering and clustering of samples were performed using the Lumi package developed by 
the North-western University. Centred correlation (Pearson correlation) was used as the 
metric to determine similarity between samples for the clustering. Dendrograms or tree 
diagrams were constructed to represent the result from clustering. The degree of similarity 
between samples was reflected in the length of the branch. Average linkage was used to 
determine the distance between clusters. 
2.12.3 Microarray analysis and validation 
Data analysis was performed in BRB ArrayTools developed by the National Cancer 
Institute. To identify difference in expression of genes between the groups of samples 
class comparison was performed. 
SOURCE annotations were used for the pathway analysis. The gene sets were defined 
based on Gene Ontology and Lymphoid signatures. 
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The candidate genes identified with differential expressions obtained from the microarray 
experiments were validated using quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) as per section 2.10. 
2.13 Statistical analyses 
Results were analyzed using the non-parametric Mann-Whitney test or the Exact 
Fisher’s test using GraphPad Prism 5 software (GraphPad Sofwares, La Jolla, CA). P 
values below 0.05 were considered significant. 
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Chapter 3: Establishment of a mouse model of NHO 
3.1 Introduction  
Dr Francois Genet who is working in the spinal cord injury clinic in France first approached 
our group in 2012 about the problem of bone formation in the muscle of his patients with 
SCI or TBI (Fig.3.1).  
 
Figure 3.1 (A) 3D CT image of NHO in a patient with SCI; (B) Fragment of resected 
mature NHO (I Kulina, F Genet, J Pathol 2015) 
 
To date the etiopathology of NHO is poorly understood for two reasons. Firstly, as studies 
on humans are retrospective, there is no study on the earliest stages of NHO to identify 
the early cellular and molecular events leading to heterotopic ossification in muscles and 
joints. Secondly, there is no unmodified animal model of NHO after central nervous system 
lesions [125, 126]. The only existing animal models of HO are genetically modified mouse 
models of  
1) progressive osseous heteroplasia, where HO is developed subcutaneously and 
caused by inactivating mutations of the GNAS gene [127], and  
2) FOP in which activating mutations of ACVR1 are introduced as a transgene or 
knocked-in the endogenous mouse Acvr1 gene [48], or in which BMP-4 or BMP-2 
are overexpressed by means of transgenes or recombinant adenoviruses [36, 125, 
128].  
As patients themselves are not genetically modified, this means to-date there is no animal 
model of NHO after CNS lesion that replicates the condition in patients. The availability of 
such a model would provide opportunity to investigate the mechanistic processes linking 
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the original neurological lesion to NHO, and ultimately provide a model for pre-clinical 
testing of treatments to prevent or reduce NHO in humans.  
Our group is the first to report the development of a model of NHO in genetically wild-type 
mice, and demonstrate that the combination of both SCI and macrophages recruited by 
concomitant muscular inflammation is necessary to initiate NHO. This more physiological 
model of NHO now allows us mice to mimic in mice the processes occurring after spinal 
trauma in patients. 
3.1.1 Aims and Objectives 
To understand etiopathology of NHO which will increase prognostic information, enhance 
diagnostic abilities and provide treatment targets we needed to develop animal model that 
would mimic NHO as it happens in patients. Firstly the aim of this chapter was to establish 
animal model of NHO in genetically unmodified mice, however the main aim was to make 
it more physiologically relevant to resemble the bone formation after SCI as it happens in 
patients. Considering that NHO develops more often in patients with severe trauma or 
concomitant infection on top of SCI we decided to combine spinal cord injury with trauma 
and mimicked bacterial infection by intramuscular injection of LPS. 
3.2 Methods specific for this chapter 
3.2.1 Muscle injury induced by cardiotoxin 
Mouse model is described in details in Chapter 2, section 2.2. Schematically our mouse 
model is represented on Fig. 3.2. To compare spinal cord transection with spinal cord 
compression we collaborated with Dr Marc Ruitenberg, The University of Queensland. 
 
Figure 3.2 Schematic image of our novel mouse model of HO after SCI 
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3.2.2 Muscle injury induced by LPS 
Spinal cord injury was performed as described in Chapter 2, section 2.2. However instead 
of cardiotoxin injection the right hind limb was injected intramuscularly with LPS 2.5mg/kg 
from Escherichia coli 0111:B4 (L4391-10x1MG, Sigma-Aldrich)  
3.2.3 Muscle injury induced by mechanical impact 
Mechanical injury was performed with the device represented on Fig.3.3 with the impulse 
of 0.23 m*kg/s or 0.29 m*kg/s. For the impactor weight of 132 g, the total energy that was 
transferred onto the mouse legs from a height of 25 cm was 0.32 J, as calculated by Dr 
Roland Steck with an impact velocity of 2.21 m/s. At a height of 15 cm impact energy was 
0.19 J, with a velocity of 1.71 m/s. The skin wounds were closed by Silk 6-0 sutures. 
Postoperative care was performed as described in Chapter 2 section 2.2. Analgesia 
included oral Tramadol diluted in drinking water at the dose 25mg/L for 5 days after 
surgery. 
 
Figure 3.3 Device used to create mechanical crush injury in our mouse model. 
3.3 Results 
3.3.1 NHO requires both SCI and muscular inflammation 
In order to establish a first model of NHO in unmodified mouse, we first performed SCI 
between T7 and T8 in a large cohort of genetically unmodified mice and followed them up 
to 4 weeks for NHO. µCT analyses revealed that none of these mice developed NHO 
despite hind limb paraplegia (Table 3.1). 
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Table 3.1 HO formation requires SCI and muscular inflammation 
  SCI alone, n (%) SCI+CDTX, n (%) CDTX alone, n (%) 
No HO 102 (100%) 1 (0.9%) 9 (100%) 
With HO 0 (0%) 112 (99.1%) 0 (0%) 
Total 102 113 9 
P-value <0.0001 <0.0001 <0.0001 
 
Thus we hypothesized that additional factors may be required to form NHO. We further 
hypothesized that muscular or peri-articular inflammation could drive NHO following SCI. 
This hypothesis was based on the following observations. Firstly, in patients with SCI or 
TBI, NHO is associated with peri-articular inflammation [5, 54, 55, 129]. This inflammatory 
state can be caused by the neurological lesion, bed sores, muscular lesions and bone 
fractures acquired in the initial accident, chronic bacteriuria, etc. Secondly, in patients with 
FOP, minor mechanical lesions (e.g. a needle injection, or minor injury) results in HO 
flares at the site of injury. Similarly, in the 3 genetically manipulated mouse models of 
FOP, additional muscular inflammation by intramuscular or subcutaneous injection CDTX 
considerably enhances HO at the site of CDTX injection [48, 130]. 
To test this hypothesis, cohorts of mice underwent SCI alone, SCI with CDTX 
intramuscular injection in the right hamstring muscles to induce inflammation, or sham 
operation with CDTX intramuscular injection. None of the mice with SCI alone or CDTX 
alone developed NHO detectable by µCT (Table 3.1). In sharp contrast, 112 out of 113 
mice with SCI and CDTX injection developed NHO (Table 3.1). The only mouse in this 
group did not develop HO, which is associated with the learning curve as surgery on this 
mouse was performed in the very beginning of our model establishing process. 
Remarkably, within this experimental group, NHO always developed in the right hind limb 
injected with CDTX and never in the contralateral left limb injected with PBS. Exact 
Fisher’s statistic demonstrated that NHO was very significantly associated with the 
combination of both SCI and intramuscular inflammation with CDTX (p<10-4). 
We have also compared bone formation in mice with complete transection of the spinal 
cord and incomplete SCI (by compression) followed by CDTX injection (Fig.3.4) 10 days 
after surgery. There was no NHO in muscles of mice with compression injury while mice 
with completely transected spinal cord showed significant bone formation in the hind limb 
muscles (p=0.0095**).  
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Figure 3.4 (A) Illustrative μCT of mouse right legs 10 days following complete or 
incomplete SCI and CDTX injection; (B) Quantification of HO volumes by 3D μCT 
reconstitution following complete or incomplete SCI and CDTX injection. Data are mean ± 
SD for each experimental group of 6 mice per group; p<0.01** 
 
Interestingly osteoporotic changes (degradation pits) in the pelvic bones and vertebrae 
were observed in all mice with SCI. This was not correlated to CDTX injection (Fig.3.5). 
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Figure 3.5 µCT of a representative mouse with (A) SCI and CDTX in the right leg 
hamstring muscles and saline in the left hamstring muscles, (B) SCI and saline in the right 
leg hamstring muscles. 
 
3.3.2 Kinetic of NHO  
As soon as three days after surgery followed by CDTX injection, small foci of 
mineralization were detected by von Kossa staining and IHC analysis disseminated 
through the hamstring muscle by µCT. These small ossifications then continued to grow 
and merged into a large mass of bone that occupied most of the hamstring muscles at the 
end of a period of 2 weeks (Fig. 3.6A,B). Again NHO developed exclusively in the right 
limb injected with CDTX. Control mice that underwent SCI without CDTX injection did not 
develop NHO during this time period. The early emergence of patches of ossification in the 
muscle that grew to progressively fuse into larger mineralized masses was similar to 
growing ossifications in patients as illustrated in Fig. 3.6C, however in much longer time 
course in comparison with mice. 
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Figure 3.6 Kynetic of NHO in our mouse model. A) Illustrative µCT of right legs at 
indicated time-points following SCI and CDTX injection. B) Quantification of HO volumes 
by 3D µCT reconstitution at indicated time-points following SCI and intramuscular CDTX 
injection. Each symbol represents a separate mouse. Bars and errors bars represent 
mean ± SD for each experimental group. C) X-ray radiographs of a SCI patient at different 
stages of NHO proximal to the hip at indicated time post-injury ((I Kulina, F Genet, J Pathol 
2015) 
 
To test whether HO required the central neurological lesion associated with the SCI or 
hind limb immobilization caused by the paraplegia resulting from SCI, Dr F Genet has 
performed bilateral sciatic nerve section with CDTX intramuscular injection in the right hind 
and PBS in the control left leg in a cohort of mice. None of these mice developed NHO 
detectable by µCT (results not shown) suggesting that hind limb immobilization is not 
sufficient to support HO following muscular injury.   
3.3.3 Physiological model of NHO  
Considering that incidence rate of NHO is higher in patients with associated trauma or 
sepsis such as infected war wounds or following a car crash [131-133] we decided to 
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replace intensive muscle injury caused by cardiotoxin injection by crush injury of 2 different 
mechanical loads, which is closer to mechanisms of multiple trauma in patients with SCI. 
However considering the effect of crush injury could not be sufficient to cause NHO we 
have also mimicked bacterial infection by intramuscular injection of LPS at the time of 
crush-injury. Thus to make our model more physiological we combined: 
 SCI 
 Trauma (crush-injury) and 
 Sepsis/inflammation 
All mice with both types of crush injury in combination with LPS injection showed 
significant bone formation (Fig.3.7) in comparison with crush injury alone (p=0.0286 for 
crush injury 1 and p=0.0131 for crush injury 2, Mann-Whitney test). Interestingly the higher 
load of injury caused significantly higher bone formation in the muscle (p=0.0428, Mann-
Whitney test) (Fig.3.7 A,B). It was also obvious that LPS injection alone was insufficient to 
cause HO formation (p-value=0.0043**, Mann-Whitney test) (Fig.3.8 A,B). 
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Figure 3.7 (A) Illustrative μCT of mouse right legs 10 days following SCI, LPS injection 
and crush injury from the height of 15cm (Impact1) and 25cm (Impact2), p<0.05*; (B) 
Quantification of HO volumes by 3D μCT reconstitution following SCI, crush injury and 
intramuscular LPS injection. Data are mean ± SD for each experimental group of 4 mice 
per group, pooled from two different experiments 
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Figure 3.8 (A) Illustrative μCT of mouse right legs 10 days following SCI, LPS injection 
alone or LPS injection and crush injury from the height of 15cm (Impact1), p<0.01**; (B) 
Quantification of HO volumes by 3D μCT reconstitution following SCI, crush injury and 
intramuscular LPS injection. Data are mean ± SD for each experimental group of 6 mice 
per group. 
 
3.4 Discussion 
In this work, we are the first to establish a mouse model of NHO is genetically non-
modified wild-type mice. This latter point is essential as to-date, all mouse models of HO 
involve a genetic manipulation (e.g. introduction of a mutant gene or overexpression of a 
gene involved in BMP signaling), which is not clinically relevant to model NHO which 
affects a relatively high proportion of humans suffering SCI (20-25%). Our mouse model of 
NHO displays similar features to NHO in human patients. In particular, mouse and human 
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NHO share similar growth patterns with development of separate HO that merge into 
larger ossified mass over time. In this respect, our mouse model clearly establishes that 
SCI alone is not sufficient to induce NHO and requires additional local muscular 
inflammation caused by CDTX injection. Importantly, whilst CDTX-induced muscle 
inflammation alone was not sufficient to elicit HO, it was necessary to induce HO in 
response to SCI. This suggest that SCI could prime mesenchymal or muscle progenitor 
cells towards osteogenic differentiation, similar to ACVR1 mutations in FOP patients, 
whilst inflammation triggers and drives osteogenic differentiation that leads to HO. 
It must be noted that SCI-induced HO and FOP are likely caused by different mechanisms. 
Indeed while FOP is always caused by activating mutations in the ACVR1 gene that 
encodes a BMP receptor, ACVR1 is normal in victims of SCI-NHO. Single nucleotide 
polymorphism (SNP) analysis in SCI-HO patients has revealed three genes that alter the 
risk of developing NHO [134]. Mutation in ADRB2 gene (β2-adrenergic receptor) that is 
part of adrenergic system was shown to increase the incidence of NHO, while 
polymorphisms in toll-like receptor4 (TLR4) and complement factor H (CFH), involved in 
immune signaling and inflammation were associated with decreased risk of NHO formation 
[134]. 
It has been published in numerous articles that both acute and chronic SCI is associated 
with bone cortex loss, bone density and bone mass reduction and osteoporosis [135]. We 
have unintentionally confirmed these findings in mice following SCI resection by 
performing μCT. Furthermore this loss of bone cortex occurs in mice even without 
intramuscular inflammation. In their article McCarthy et al. [136] have also pointed out fast 
decreasing in porosity of the tibia bones after SCI and the presence of partially mineralised 
osteons. It can explain degradation pits we noticed in mice after SCI, that were 
independent to CDTX injection. 
To date there is no information whether NHO is formed by intramembranous or 
endochondral bone formation. Sections of mouse right hind limbs injected with CDTX were 
harvested 7, 14, 21 days and 6 weeks after SCI and stained by Toluidine Blue or Safranin 
O by our collaborator (Fig.3.9). Toluidine Blue staining did not reveal acidic proteoglycans 
7 days, 14 days and 6 weeks after SCI with CDTX-induced inflammation. Safranin O 
staining also did not detect any cartilage glycosaminoglycans at day 14 and 21. Thus our 
data suggest that NHO formation after SCI is not via endochondral bone formation and 
most likely is formed by intramembranouse pathway as occurs in POH patients [137]. 
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Figure 3.9 Immunohistochemistry of mouse right hind limbs harvested from mice with SCI 
and CDTX-induced inflammation. Top row: Toluidine Blue stain for acidic proteoglycans at 
1 week(A), 2 weeks (B), 6 weeks (C) and positive control – femur epiphyseal cartilage (D) 
from same tissue section as in (A). Bottom row: Safranin O stain for cartilage 
glycosaminoglycan at 2 weeks (E), 3 weeks (F) and positive control – femur epiphyseal 
cartilage (G) from the section F. Purple colour indicated hematoxylin counterstain of nuclei, 
light blue – fast green stain. White bars 100μm. 
 
It has been published that degree of severity of NHO depends on the completeness of SCI 
[132, 133]. Our data confirmed these findings. SC compression that did not lead to 
permanent immobility in mice in our experiment was insufficient to cause NHO even in the 
presence of CDTX injection. On top of that we have also found that the size of NHO is 
directly dependent of the severity of concomitant trauma impact in increasing manner 
(Fig.3.7B). 
In conclusion, we have established the first model of NHO following SCI on wild-type non-
genetically modified animals. We find out model shares many clinical and histological 
features of NHO in patients suffering of SCI or TBI. This model suggests that NHO are 
caused by the combination of neurological damage and muscular inflammation. To make 
our model even more physiologically similar to NHO that develops in patients following 
battle-field injury, I successfully altered our model to combine trauma with components of 
bacterial inflammation. This more physiological model will help in the discovery of true 
mechanisms of NHO. Establishment of this model in the mouse will enable to use powerful 
genetic tools to further understand the molecular mechanisms that lead to NHO, and 
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provide a clinically relevant pre-clinical model in genetically unmanipulated animal, to test 
drugs for their ability to reduce or prevent NHO in patients with SCI or TBI. 
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Chapter 4: Role of Macrophages in Heterotopic Bone Formation after Spinal Cord 
Injury 
4.1 Introduction 
The severity of neurotrauma increases the prevalence of HO formation in patients [29, 
138]. Incidence of NHO is known to be higher in patients with severe trauma and 
concomitant infection [139]. In the late 80s Michelsson et al. demonstrated a positive 
correlation between HO formation and traumatic and inflammatory component on a rabbit 
model of HO, where bone was formed in immobilised limb [140, 141]. 
It has been shown previously that inflammation in the CNS involves different cell types and 
mechanisms compared to inflammation in peripheral tissues [142, 143]. In injuries of the 
CNS there is lower leukocyte recruitment in comparison with an equivalent peripheral 
injury. However contusion-type injuries of the spinal cord still result in rapid microglial cell 
activation and neutrophil infiltration. This inflammatory response after CNS injury can lead 
to damage of other tissues and organs. For example it can indirectly damage liver via 
acute phase protein production causing hepatic injury [142]. SCI induces cellular and 
molecular inflammatory cascade which promotes systemic cytokines release that 
subsequently may trigger chronic pathology [144]. Moreover it has been recently 
discovered and published that SCI can cause aseptic systemic inflammatory response 
syndrome and lead to immune system depression including splenic involution [142, 145]. 
Patients with SCI have been shown to be prone to development of pulmonary and urinary 
infections [146].  
Considering that macrophages play a central role in any inflammatory process we decided 
to have a closer look on these cells. Dr Pettit has shown that a population of residential 
macrophages is present in the mouse and human osteal tissue and was required for 
normal function and efficient mineralization of osteoblasts [114, 120]. These macrophages, 
called osteomacs were also required for in vitro expansion of osteoblasts, promoted 
intramembranous healing of bone in mouse tibia injury model and were shown to increase 
collagen deposition and enhance mineralization at the site of injury [147]. Macrophages 
have also been shown to produce BMP-2 to contribute to oteogenesis during bone healing 
[148]. 
4.1.1 Aims and Objectives 
With the results from the previous chapter that NHO requires a combination of SCI and 
muscle inflammation further investigation on the role of inflammation was performed.  
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Firstly the aim of this chapter is to find out whether inflammatory macrophages are 
invlolved in the NHO pathogenesis. To explore this we  
 tested the effect of macrophage depletion on our mouse model using clodronate-
loaded liposomes, which deplete phagocytic cells; 
 As osteoclasts can also be depleted by clodronate-loaded liposomes, zoledronate 
treatment which specifically depletes osteoclasts alone was then tested.  
Secondly, our aim was to investigate inflammation that promote heterotopic bone 
formation in affected limbs. 
This was assessed by  
 causing muscle inflammation in SCI-operated mice then administering different 
types of inflammatory and anti-inflammatory agents or by 
  performing surgery on mice with specific knockout genes, in which immune 
response was altered. 
Finally in this chapter I attempted to reveal the origin of inflammatory cells that may prime 
osteogenic differentiation of muscle mesenchymal progenitor cells (MPCs).  
The source of inflammatory cells was tested by  
 performing surgery in CCR-2 knockout mice; 
 combining SCI with inflammation together with splenectomy as mobilisable pool of 
monocytes resides in spleen [149]. 
Also RNA expression was tested via qRT-PCR on whole muscle tissue from the hind limbs 
of SCI and SHAM operated mice with and without muscle inflammation on wild-type and 
CCR-2 knockout mice.  
4.2 Methods specific for this chapter 
4.2.2 SCI surgery and mouse strains used in this chapter 
SCI surgery was performed as described in Chapter 2, section 2.2.  
Strains used in experiments include: 
 CCR2 knockout mice: B6.129S4-Ccr2tm1Ifc/J were purchased from Jackson 
Laboratory and bred as homozygous; 
 E-selectin knockout: B6.129S2-Seletm2Hyn/J were obtained as homozygous from 
Paul Frenette and maintained at the TRI animal facilities  
 Conditional deletion of Hif-1 in LysM-Cre mice: LysMCre/WT:Hif1afl/fl. The strain was 
bred as B6.129P2-Lyz2tm1(cre)Ifo/J x B6.129-Hif1atm3Rsjo/J (control for this strain was - 
LysMCre/WT:Hif1aWT/WT) and  
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 C57BL/6J as a wild-type control.  
All mice were euthanized for analysis 10-14 days after surgery. 
4.2.3 Splenectomy technique and sham surgery 
Splenectomy was performed as described earlier [150]. Briefly mice were anaesthetized; 
fur was sprayed with 70% ethanol. After skin incision peritoneal cavity was opened and 
spleen was gently pulled to the surface. Both vessel bundles were ligated twice with silk 6-
0 thread, followed by gentle severing the blood vessels between the sutures. Peritoneal 
cavity and skin were closed by silk sutures 6-0. Recovery period care was performed as 
described in SCI surgery section, Chapter 2. For the SHAM splenectomy surgery was 
performed in the same way, however sutures were not placed on the blood vessels, that 
remained intact and spleen was not removed. 
4.2.4 Treatment options 
4.2.4.1 Clodronate-loaded liposomes 
Clodronate-loaded liposomes were purchased from VU medisch centrum (product code 
283539, Amsterdam, The Netherlands)  [151]. Empty liposomes were prepared in the 
same conditions in PBS without clodronate. Phagocytic macrophages were depleted in 
vivo by retro-orbitally injecting 100µL/20g body weight clodronate-loaded liposome 
suspension immediately after surgery and injection of CDTX and then every second day 
for 2 weeks. Control mice were injected with an equivalent volume of saline or PBS-loaded 
liposomes prepared in the same conditions but without clodronate. 
4.2.4.2 Zoledronate 
Zoledronate (Zometa, Novartis Pharmaceuticals Australia, North Ryde, Australia) was 
injected intraperitoneally at 50 µg/kg daily for the first five days after surgery and then at 
100µg/kg every third day from day 6 to day 12. 
4.2.4.3 G-CSF 
G-CSF (filgrastim (G-CSF) 6mg/0.6mL syringe, Neulasta) was injected subsutaneously 
twice daily at a dose of 125µg/kg. Treatment was started upon recovery after surgery and 
anaesthesia and was continued for the whole period of experiment (10-14 days). 
4.2.4.4 Meloxicam 
Meloxicam (Enzo Life Science, BML-EI292-0100) was injected subsutaneously twice daily 
at 6mg/kg starting when mice recovered after surgery and anaesthesia and was continued 
for the whole period of experiment (10-14 days). 
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4.2.4.5 Harvest of inflammatory peritoneal macrophages 
Inflammatory macrophages were produced by naïve C57BL/6J mice. Lipopolysacharides 
(LPS) from Escherichia coli 0111:B4 (L4391-10x1MG, Sigma-Aldrich) was injected 
intraperitoneally in a dose of 2.5mg/kg. Mice were sacrificed 48 hours later by cervical 
dislocation and peritoneal cavity was lavaged with 10mL of saline. All liquid was collected 
into 50mL Falcon tubes and centrifuged at 4°C for 5 min at 340g. Supernatant was 
discarded and cells were counted and resuspended in saline 1million cells per 100μL. Cell 
suspension was then injected into hamstring muscles of SCI operated mice. Saline was 
injected as a negative control. 
4.2.5 G-CSF quantification in mouse plasma 
G-CSF was quantified in mouse plasma harvested from SCI and SHAM-operated mice 
using R&D Mouse G-CSF Quantikine ELISA Kit (MCS00, R&D Systems). Mouse plasma 
was diluted with Assay Diluent RD1-54 in proportion 1:2. ELISA procedure was performed 
as per manufacturer’s instructions and generation of standard curve and assessment was 
performed using GraphPad Prism 5 software (GraphPad Sofwares, La Jolla, CA). 
4.3 Results 
4.3.1 Macrophage depletion considerably reduces NHO in mice  
We have already shown that muscular inflammation is necessary for NHO formation 
following SCI in our mouse model (Chapter 3, section 3.3.1). To further investigate the 
importance of macrophages, mice with SCI and intramuscular CDTX injection were 
administered intravenously with clodronate-loaded liposomes in order to deplete 
phagocytic macrophages [147, 152]. Control mice underwent SCI and intramuscular 
injection of CDTX but received PBS-loaded liposomes instead. Clodronate-loaded 
liposomes reduced the volume of HOs and in 3 out of 11 mice (~28%) prevented their 
development entirely (Fig.4.1). On average, the heterotopic bone volume was 11-fold 
lower in the clodronate liposome-treated group compared to the control PBS-liposome 
group (p-value: 0.0003*** by Mann-Whitney test) (Fig.4.1). 
Previously it was found that clodronate-loaded liposomes can deplete both 
macrophages and osteoclasts [153] , therefore we tested the effect of osteoclast depletion 
alone by injecting zoledronate in combination with SCI and CDTX as this treatment 
reportedly eradicates osteoclasts in the mouse. Efficacy of this zoledronate regimen was 
confirmed by the absence of bone resorption pits on iliac crest and vertebras of mice with 
SCI. Interestingly we found that zoledronate administration actually increased the average 
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bone volume of NHO 3-fold compared to SCI+CDTX mice injected with saline when 
measured at Day14 (Fig 4.2). Thus osteoclast ablation by zoledronate has an opposite 
effect to combined macrophages and osteoclast depletion. Collectively, these results 
suggest that phagocytic macrophages, not osteoclasts, recruited in the inflamed muscle 
trigger the development of NHO subsequent to SCI. 
 
Figure 4.1 Effect of macrophage depletion on NHO. (A) Illustrative μCT of right hind limbs 
after SCI with injection of CDTX and treatment with clodronate-loaded liposomes or 
vehicle; (B) Quantification of HO volumes by 3D μCT reconstitution following SCI, with 
injection of CDTX and treatment with clodronate-loaded liposomes or vehicle; bars and 
error bars represent mean ± SD of 4 mice per group pooled from two different experiments  
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Figure 4.2 Effect of osteoclast inactivation on NHO. (A) Illustrative μCT of right hind limbs 
after SCI with injection of CDTX and treatment with zoledronate; (B) Quantification of HO 
volumes by 3D μCT reconstitution following SCI with injection of CDTX and treatment with 
zoledronate, clodronate-loaded liposomes or vehicle; bars and error bars represent mean 
± SD of 5 mice per group. 
 
4.3.2 Effect of G-CSF on NHO 
To further test role of macrophages in SCI-induced NHO, mice that had undergone SCI 
and intramuscular injection of CDTX, were injected twice daily with G-CSF (125µg/kg) with 
and without meloxicam or vehicle alone from immediately after SCI surgery and CDTX 
injection. It was reported previously that G-CSF treatment enhances recovery of blood 
monocytes and increases numbers of macrophage and granulocyte-macrophage 
progenitors [154]. Also our group has previously shown that G-CSF treatment can lead to 
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the depletion of osteoblast and alter endosteal bone formation [120]. The NSAID 
meloxicam was used in this experiment as clinical application of NSAIDs show modest 
efficacy has been shown in treatment of patients with HO [155-157]. Mice were sacrificed 
14 days after surgery, and microCT was performed. Surprisingly mice injected with G-CSF 
developed significantly larger bone masses in hind-limb muscles in comparison with 
saline-injected mice (p-value: 0.0051** by Mann-Whitney test). In our mice meloxicam 
alone had no effect on HO formation, however when G-CSF was injected together with 
Meloxicam there was no significant increase of heterotopic bone volume compared to 
vehicle injected mice (Fig.4.3), showing that Meloxicam successfully negates the G-CSF-
mediated boost in NHO. 
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Figure 4.3 (A) Illustrative μCT of right hind limbs 14 days after SCI with injection of CDTX 
and treatment with G-CSF/Meloxicam; Quantification of HO volumes (B) and density (C) 
by 3D μCT reconstitution following SCI, intramuscular CDTX injection and treatment with 
G-CSF/Meloxicam; bars and error bars represent mean ± SD of 6 mice per group pooled 
from two different experiments. 
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As G-CSF enhanced HO in our mouse model we next tested whether administration of G-
CSF together with LPS to mimick bacterial infection could cause HO in our mouse model.  
For that purpose mice that had undergone SCI and intramuscular injection of LPS on day 
0, 2 and 4, were injected twice daily with G-CSF (125µg/kg) or saline from the day of 
surgery. The other control group received saline as intramuscular injection into right hind 
limb and G-CSF treatment as described above. We did not observe any NHO formed in 
any of the groups 14 days after surgery (Fig.4.4). 
 
Figure 4.4 (A) Illustrative μCT of right hind limbs 10 days after SCI with injection of LPS 
and treatment with G-CSF; (B) Quantification of HO volumes by 3D μCT reconstitution 
following SCI, intramuscular LPS injection and treatment with G-CSF; bars and error bars 
represent mean ± SD of 4 mice per group. 
 
G-CSF was also measured in plasma of wild-type C57BL/6 mice with SCI and 
inflammation induced by CDTX injection to identify whether mice that develop NHO have 
an increase in plasma concentration of G-CSF that could drive abnormal bone formation. It 
was compared with concentration of G-CSF in plasma harvested from SHAM operated 
mice with and without inflammation and plasma harvested from mice with SCI alone at 
different time points. Time points included day 1, 3 and 7 after surgery. 
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Plasma standard curve and equation are presented on Fig.4.5A.  
In all 4 groups we noticed significant increase in the G-CSF concentration in plasma at 
Day1 post-surgery (Fig.4.5B,C,D,E). Interestingly although major decrease in G-CSF 
concentration was observed in SCI and SHAM groups by Day3, it remained high in group 
of SHAM-operated mice injected with CDTX (p-value <0.01**, Two-way ANOVA with 
Bonferroni posttest). This increase however was not observed in SCI+CDTX group where 
SCI-associated immune system changes might lead to slightly dampened inflammatory 
response. However subsequent decrease of G-CSF concentration was observed in all four 
groups by the day 7 including the CDTX group (Fig.4.5F). 
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Figure 4.5 Quantification of G-CSF in mouse plasma harvested from mice with and 
without NHO 
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Taken results together from these findings can be drawn 2 conclusions: 
1) G-CSF worsens NHO and 
2) We observe increased concentration of G-CSF in the blood plasma of all mice after 
surgery, whether it is SHAM or SCI. 
4.3.3 Inflammatory peritoneal macrophages do not induce HO after SCI in mice 
To test inflammatory macrophages involvement into NHO after SCI we injected 
inflammatory peritoneal macrophages suspension into right hind limb of SCI-operated 
mice. Macrophages were harvested from C57BL6/J mice treated with LPS 2 days prior 
harvest as described in Methods. Control group was injected with the same volume of 
PBS. At 14 days we did not observe any heterotopic bone formation in either group of 
operated mice (p-value: 0.68ns by Mann-Whitney test). 
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Figure 4.6 (A) Illustrative μCT of right hind limbs harvested 10 days after SCI with injection 
of inflammatory macrophages; (B) Quantification of HO volumes by 3D μCT reconstitution 
following SCI and intramuscular injection of inflammatory macrophages; bars and error 
bars represent mean ± SD of 4 mice per group. 
4.3.4 Local muscle macrophages may play an important role on NHO 
To test whether monocytes are recruited from remote reservoirs (e.g. bone marrow and 
spleen), we performed SCI following by CDTX injection on CCR2-knock-out mice with wild 
type C57BL6/J as a negative control. Mice lacking CCR2 chemokine receptor are known 
to have impaired monocyte/macrophage infiltration in response to inflammation and in 
general decreased inflammatory response. After 10 days mice were sacrificed and 
microCT analysis showed significant increase in bone volume in CCR2 deficient mice (p-
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value: <0.0001*** by Mann-Whitney test). This shows that CCR2 is not necessary for 
macrophages to invade inflamed muscle and promote NHO development. 
 
 
Figure 4.7 (A) Illustrative μCT of right hind limbs harvested 10 days after SCI with injection 
of CDTX in CCR-2ko mice; (B) Quantification of HO volumes by 3D μCT reconstitution 
following SCI and intramuscular CDTX injection in CCR-2ko mice; bars and error bars 
represent mean ± SD of 4 mice per group (experiment 1) and 8 mice per group 
(experiment 2)  pooled from two different experiments. 
 
To further investigate the differences in CCR2 knockout mice vs wild type control qRT-
PCR for osteogenic and inflammatory markers was performed on mRNA extracted from 
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hind limb muscle at Day2 after SCI and CDTX injection. Interestingly M2 (anti-
inflammatory macrophage) markers such as Arg-1, Chi3l3 and Mrc1 were significantly 
downregulated in CCR-2 knock-out mice (Fig.4.8A,B,C). However CCR-2 knockout mice 
expressed higher level of IL1β and CSF-1RNAs, however the difference was not 
statistically significant (Fig.4.8D,E).  
 
 
Figure 4.8 Quantification of macrophage markers in hind limb muscles of CCR-2 knockout 
and wild type mice. Quantification of (A) Arginase 1, (B)Chitinase 3l3, (C)Mrc1, (D)CSF1, 
(E)IL-1β mRNA by qRT-PCR on from whole hamstring muscle group harvested from wild-
type C57BL/6 mice or CCR-2 knockout. All expression levels were relative to the 
housekeeper gene β-actin. Each dot represents hind limb muscle mRNA from a separate 
mouse (4 mice per group). 
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4.3.5 Splenectomy does not affect NHO after SCI in mice 
To further test the origin of macrophages that are involved in NHO formation we performed 
a series of experiments to identify whether splenic monocyte population could be involved. 
We performed splenectomy immediately before SCI injury and CDTX injection on a cohort 
of mice. Control group underwent SCI surgery, CDTX injection and sham operation where 
peritoneal cavity was opened but spleen remained untouched. MicroCT analysis 
performed at Day 10 after surgery did not show any difference in bone formation between 
two groups of mice (p-value: 0.84 ns by Mann-Whitney test) (Fig4.9). Furhtermore when 
we performed splenectomy/SHAM surgery on CCR2-knock-out mice with SCI and CDTX 
injection the results were the same (p-value: 0.53 ns by Mann-Whitney test) (Fig.4.10). 
Therefore macrophages responsible for NHO are not recruited from a splenic reservoir via 
CCR2. 
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Figure 4.9 Effect of splenectomy on NHO. (A) Illustrative μCT of right hind limbs harvested 
10 days after SCI with injection of CDTX and splenectomy; (B) Quantification of HO 
volumes by 3D μCT reconstitution following SCI, intramuscular CDTX injection and 
splenectomy; bars and error bars represent mean ± SD of 8 mice per group. 
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Figure 4.10 Effect of splenectomy on NHO in CCR-2 knockout mice. (A) Illustrative μCT of 
right hind limbs harvested 10 days after SCI with injection of CDTX and splenectomy in 
CCR2-ko mice; (B) Quantification of HO volumes by 3D μCT reconstitution following SCI, 
intramuscular CDTX injection and splenectomy in CCR2-ko mice; bars and error bars 
represent mean ± SD of 4 mice per group pooled from two different experiments. 
4.3.6 E-selectin influence on NHO in mice 
As E-selectin is utilised by circulating monocytes to roll and arrest an inflamed vasculature 
and extravasate into inflamed tissue, we reasoned that macrophages homing to damaged 
muscles may be reduced in E-selectin knockout mice. We compared effect of SCI and 
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CDTX injection in E-selectin knockout and wild type mice. MicroCT analysis performed at 
Day10 after surgery showed a trend towards reduction in bone volume in E-selectin knock-
out mice compared to wild type mice (p-value: 0.06 ns by Mann-Whitney test) (Fig4.11). 
Interestingly the absence of E-selectin resulted in a significant decrease in density of 
newly formed heterotopic bone in E-selectin knock-out mice in comparison with control 
group (p-value: 0.0002*** by Mann-Whitney test) (Fig.4.11). This result supports our 
hypothesis that lessening the number of monocytes recruited to the site  of muscle injury 
may lead to reduced amount of NHO after SCI. 
 
 
Figure 4.11 Role of E-selectin in NHO. (A) Illustrative μCT of right hind limbs harvested 10 
days after SCI with injection of CDTX in E-selectin-ko and wild-type mice; Quantification of 
HO volumes (B) and density (C) by 3D μCT reconstitution following SCI, intramuscular 
CDTX injection in E-selectin-ko mice and and wild-type mice; bars and error bars 
represent mean ± SD of 5 mice per group pooled from two different experiments. 
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4.3.7 Myeloid cell-derived Hif enhanced NHO after SCI 
To determine whether macrophages responsible for NHO are of M1 type polarized we 
used mice with conditional deletion of the Hif1α gene in myeloid cells (LysMCre/WT/Hif1αfl/fl). 
LysMCre/WTxHif1αWT/WT mice were used as a control cohort. Indeed it has been reported 
that Hif1α expression is a cardinal feature of M1 polarized macrophages [158]. MicroCT 
analysis performed at Day10 after surgery showed tendency towards increase in bone 
volume in mice with inactivated Hif1α, although statistically not significant (p-value: 0.09 ns 
by Mann-Whitney test). We also observed significant increase in density of newly formed 
bone in myeloid-specific Hif1α inactivated mice in comparison with control group (p-value: 
0.04* by Mann-Whitney test) (Fig.4.12). This result shows that absence of M1 and possible 
switch of polarization to M2 macrophages increase density of NHO after SCI. To increase 
statistical power this experiment needs to be repeated with larger cohorts of mice. 
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Figure 4.12 Role of M1 macrophages in NHO. (A) Illustrative μCT of right hind limbs 
harvested 10 days after SCI with injection of CDTX in LysMCre/WT/Hif1αfl/fl and control 
groups of mice; Quantification of HO volumes (B) and density (C) by 3D μCT reconstitution 
following SCI, intramuscular CDTX injection in LysMCre/WT/Hif1αfl/fl and control groups of 
mice; bars and error bars represent mean ± SD of 4 mice per group pooled from 2 different 
experiments. 
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4.4 Discussion 
As muscular inflammation is necessary to NHO following SCI, we further investigated the 
importance of macrophages. To deplete all phagocytic cells mice with SCI and 
intramuscular CDTX injection were treated with clodronate-loaded liposomes immediately 
after surgery and then every 2nd day for 8 days [120, 147]. The control mice underwent 
SCI and intramuscular injection of CDTX but received PBS-loaded liposomes instead. We 
found that macrophage depletion significantly reduced the volume of HOs and in ~28% of 
mice prevented development of HO. On average, the heterotopic bone volume was 11-fold 
lower in the clodronate liposome-treated group compared to the control group without 
clodronate liposomes. Clodronate is a first generation bisphosphonate that is unable to 
cross cell plasma membranes to kill osteoclasts effectively. However when packaged into 
liposomes, it is uptaken by phagocytes such as macrophages, antigen-presenting cells 
and osteoclasts and rapidly kills these cells once digested [147, 152, 159]. To confirm this 
effect was via macrophage and not the osteoclast depletion we repeated this experiment 
with zoledronate, which specifically depletes osteoclasts. At day 14, zoledronate increased 
the average bone volume of NHO up to 3 folds compared to SCI+CDTX controls injected 
with saline. This effect was opposite to that of clodronate-loaded liposomes. Collectively, 
these results suggest that phagocytic macrophages, not osteoclasts, recruited in the 
inflamed muscle trigger the development of NHO subsequent to SCI. 
  
The role of inflammation and macrophages in our mouse model of NHO is also consistent 
with the two types of observations. Firstly SCI and TBI patients that develop NHO are 
those which suffering most violent impacts with bruising, additional bone fractures, or 
infections [5]. Furthermore, the incidence of NHO in war casualties where infections, 
inflammation and multitrauma are presumably more prevalent, is much higher than in 
accidents involving civilians [35, 160]. Secondly, ossification can be reduced by NSAID in 
NHO patients [49, 52, 53]. Our hypothesis that macrophages infiltrating inflamed muscles 
are critical to NHO is also consistent with our previous observation that specific subsets of 
macrophages are critical to the maturation of osteoblasts and bone formation in skeletal 
bones [114, 120]. In long skeletal bones, macrophage depletion induces a rapid loss of 
mature osteoblasts on bone surface, arrests bone formation and mineralization in adult 
mice [114, 120], and impairs bone repair following fracture [147], yet the mechanisms by 
which these specific macrophages induce osteoblast maturation and bone formation 
remain unknown. 
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Interestingly NSAIDs treatment in our experiment did not cause reduction of NHO bone 
volume. This could potentially be due to the excessively strong inflammatory stimuli CDTX 
caused in the muscles. This potential limitation can be addressed in future by performing 
next series of experiments in our new more physiological model of NHO (developed in 
Chapter 3) where we combined muscle crush-injury with LPS intramuscular injection to 
mimic bacterial infection. 
 
G-CSF 
Hara et al. [161] have shown that G-CSF is required for myocyte proliferation during 
muscle regeneration after injury. In addition our laboratory has shown that G-CSF 
administration depletes osteoblasts at the endosteum but not at the periosteum of skeletal 
bones resulting in a transient arrest in endosteal bone formation whereas periosteal bone 
formation is not perturbed [120]. Indeed our model of SCI-NHO, G-CSF administration 
significantly increased bone formation in the muscles after CTDX induced injury. It is 
possible that following G-CSF administration enhanced muscle regeneration when 
combined with SCI could help force proliferating muscle progenitor cells to differentiate 
more along the osteogenic lineage. An alternative explanation is that increased activation 
or homing of neutrophils or monocytes to the damaged muscle in mice administered G-
CSF (G-CSF stimulates neutrophil progenitors proliferation and neutrophil production) 
could exacerbate the proosteogenic effect. Interestingly that while the anti-inflammatory 
meloxicam on its own did not reduce bone formation, it diminished the exacerbated NHO 
caused by G-CSF treatment.  
However despite exacerbating the effect of NHO in SCI-operated mice with CDTX 
injection, G-CSF was insufficient to cause NHO on its own or even in combination with 
mimicked bacterial infection. 
We also observed an increase of G-CSF concentration in plasma of SCI- and SHAM-
operated mice at day 1. This is most likely explained as part of the immune response to 
inflammation. Indeed systemic G-CSF levels were greater in mice treated with CDTX. 
 
CCR2 and splenectomy 
In attempt to determine whether monocytes reside locally in the muscles or are recruited 
from a remote location such as from spleen to the damaged muscles. Rationale for these 
experiments is that CCR2 is a chemokine receptor used by inflammatory monocytes to 
home to the sites of injury. While the spleen is the primary source of mobilisable 
monocytes we performed a few sets of experiments:  
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 SCI-injury in CCR-2 knockout mice (Fig,4,7) 
 SCI-injury in CCR-2 knockout and wild type mice with and without splenectomy 
(Fig.4.9, 4.10). 
Mader et al. [162] have shown that CCR2 knockout mice were less prone to bone loss 
after denervation or hormonal changes due to impaired osteoclast maturation and function, 
that was also reported earlier [163]. Despite a decrease in function of osteoclasts, bone 
formation at the fracture healing site was delayed in CCR-2 knockout mice at day 14, 
however the volume of bone 3 weeks after injury was higher than in wild-type mice. 
Muscle regeneration after CDTX induced injury was also impaired in CCR knockout mice 
due to defective monocyte recruitment [164]. Warren et al. [165] have also noticed worse 
regeneration of freeze-injured muscle, however they have also noticed calcifications in the 
muscles of CCR2 knockout mice at day 21 after injury. In our experiments NHO bone 
volume was increased in CCR2 knockout mice with and without splenectomy in 
comparison with wild type control, which is consistent with bone volume increase data 
from previous research. However we found increase in bone mass earlier than 21 days 
after injury, which might be explained by the enhancing effect of SCI. Splenectomy on its 
own, did not change the bone volume of newly formed ossifications suggesting that splenic 
monocytes most likely would not be involved in NHO after SCI or can easily be replaced 
by monocytes from other depots. 
 
E-selectins 
The endothelial selectins are cell adhesion molecules that are involved in normal leukocyte 
function and their homing and activation [166]. E-selectin deficient mice are more 
susceptible to infections and inflammatory changes due to defective leucocyte homing. 
Mice deficient in E- and P-selectins have shown increased bone destruction following 
infection in comparison with wild type control along with increase in bone resorptive 
cytokine, IL-1α [167]. E-selectin has been shown to be involved in homing of endothelial 
progenitor cells [168, 169] and its deletion impaired inflammation response. E-selectin has 
also been shown to accelerate haematopoietic progenitors differentiation towards 
granulocyte and monocyte lineages in vitro, and increase HSC proliferation in vivo [170, 
171]. During inflammation leukocyte adhesion molecule E-selectin becomes up-regulated 
on endothelial cells and guides migration of pro-inflammatory cells to the site of injury 
[172]. We found a reduction of the bone volume of NHO after SCI in our E-selectin 
knockout mice. This is possibly due to a dampened inflammatory response with a 
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reduction in number or activation of monocytes recruited to the site of CDTX-induced 
injury. 
Macrophages are pleotropic cells with many different functions and can be skewed 
towards particular roles by the factor in their local environment.  
It is still not clear whether macrophage skewing could play the main role in NHO. However 
we found quite a few publications on the role of macrophages in muscle regeneration, 
such as seen in our mouse model with CDTX-induced muscle injury. Saclier et al. [173] 
have shown that M2-skewed macrophages increased myogenic differentiation when co-
cultured with human myogenic progenitor cells. These authors have also shown that in 
vivo regenerating muscles contain both inflammatory M1 and M2 polarised macrophages, 
and M2 macrophages were located in the same sites as differentiating myogenic 
progenitors. However despite of obvious role of M2 macrophages, authors specifically 
assessed effect of TNFα amongst other factors stimulating myogenic proliferation, and 
confirmed its role in myogenic differentiation. This confirms that both M1 and M2 skewed 
macrophages are required for adequate muscle regeneration after injury. Arnold et al. 
[174] have also published that monocytes recruited to the site of muscle inflammation 
caused by notexin injection are also a mixture of both M1 and M2 subsets in affected 
muscle. These authors also suggested that pro- inflammatory cells initiate growth of 
myoprogenitors while anti-inflammatory macrophages promote myogenic differentiation 
and muscle fibre growth. Another group of researchers have later also confirmed that in 
mice with altered M2 macrophage skewing as a result of genetic absence of IL-4, muscle 
regeneration was very delayed [175]. Wang et al. [176] have recently provided similar 
results inducing muscle injury by CDTX injection in CD11b-diphtheria toxin receptor 
transgenic mice that have shown delayed regeneration in impaired muscles in absence of 
anti-inflammatory macrophages. Thus it appears that both M1 (inflammatory) and M2 
macrophages play a role in muscle regeneration. 
Again it’s hard to say whether M2 play a crucial role in our mouse model as the major 
altering factor is SCI that on its own affects immune system response.  
Macrophages have also been shown to stimulate collagen production by fibroblasts in co-
culture experiments following by phagocyting of apoptotic cells [177] that was driven by 
up-regulation in TGF-β. This is important as collagen type I deposition guides bone matrix 
formation in the sites of injury [178, 179]. Chen et al. have also shown that with the 
induction of the osteoconductive biomaterial β-tricalcium phosphate that is used in clinical 
bone regeneration most macrophages expressed M2 markers [180]. 
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Both Hif1α and iNOS have been shown to be important in M1 polarization of macrophages 
[181]. Our microCT results from mice with Hif1α inactivated in myeloid cells showed 
increased NHO, suggesting M1 skewed inflammatory macrophages may play a role in 
dampening NHO. This is the opposite of what we predicted. A possible explanation for this 
unexpected result is that following deletion of Hif1α gene inflammatory macrophages can 
not undergo M1 polarization and by default polarize to an M2 function instead. This 
suggests that M2 polarized macrophages may be more likely to be involved in abnormal 
bone formation after SCI. In the next Chapter 5 I show by microarray on damaged muscles 
in mice following SCI with/without CDTX injection that this may indeed be the case. 
An alternative explanation for the increased NHO observed in mice with Hif1α depleted 
myeloid cells is that Hif1α affects M1 macrophage skewing. Recently Colegio et al. [182] 
have published that transcription factor Hif1α is also involved in M2 polarization. As lactic 
acid accumulated during tumour homeostasis this promotes expression of M2 specific 
markers such as Arg1, Fizz1 and Mgl2 via Hif1α. Therefore our studies need to be 
confirmed by examining whether conditional depletion of Hif1α in macrophages alters 
distribution and function of M1 and M2 macrophages accumulating in the muscles 
developing NHO. 
This chapter results were combined into the Table 4.1: 
Table 4.1 Effect of G-CSF, E-selectin, CCR2 and splenectomy on NHO after SCI. 
 Bone volume Bone density 
G-CSF ↑ ↑ 
E-selectin knock-out mice ↓* ↓ 
CCR2 knock-out mice ↑ ns 
Splenectomy ns ns 
LysMCreHif1α mice ↑* ↑ 
* The difference between control and treated groups is not significant, but there is a trend 
towards increase/decrease (↑/↓); ns: not significant 
 
Our results suggest that NHO after SCI requires recruitment of macrophages, 
granulocytes or both via the vascular cell adhesion molecule E-selectin, which is critically 
involved in leucocyte recruitment to inflamed vasculature. Granulocytes contribution via G-
CSF is an interesting possibility and is to be further investigated in G-CSF receptor knock-
out mice. Data from CCR2 knock-out mice and mice with splenectomy are surprising. It 
suggests a role of tissue resident muscle macrophages in NHO development with a 
dampening effect of spleen and marrow macrophages recruited via CCR2 in case of 
altered migration of monocytes from bone marrow or spleen. 
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Chapter 5: The comparison of gene expression profiles of operated mice and local 
changes in damaged muscles 
5.1 Introduction 
My data from previous experiments show that SCI alone is not sufficient to induce NHO 
and that macrophages in the inflamed muscle are involved in NHO development after SCI. 
However, a muscular inflammation alone is not sufficient to promote HO either, therefore it 
appears to be the combination of the two insults, SCI and muscular inflammation which 
causes NHO. I hypothesize that in the context of a SCI, macrophages infiltrating the 
inflamed muscles are activated differently to what they would be in the absence of SCI. 
Since my findings are novel, there is no prior knowledge of how SCI could alter 
macrophage activation in an inflamed muscle.  In order to gain insights into possible 
mechanisms and test whether macrophage activation is altered following SCI, I have 
performed the transcriptome profile of muscles following SCI and/or CDTX-mediated 
muscle injury. These experiments were performed to test my hypothesis that the 
transcriptome of muscle cells and macrophage would be different in mice with muscular 
injury mediated by CDTX alone versus mice with muscle injury and SCI. 
5.1.1 Aims and Objectives 
In the experiments described in this chapter, I performed gene expression microarray 
analyses on RNA extracted from whole hind limb muscles from mice in four experimental 
conditions  as follows: 1) SHAM-operated, 2) SCI alone, 3) intramuscular CDTX alone, 4) 
SCI together with intramuscular CDTX. Muscles were harvested at day 2 following 
surgery, an early time point in NHO development.  To validate microarray results RNA 
expression was tested via qRT-PCR on whole muscle tissue from the hind limbs of mice 
from the same experimental groups. I also used some inhibitors of inflammatory cytokines 
found to be overexpressed in mice undergoing both SCI and intramuscular CDTX injury to 
test their potential inhibitory effect on NHO. Finally, I have performed qRT-PCR for some 
genes of the BMP signalling pathway in order to compare my NHO model with FOP, a 
condition where muscles similarly become ossified caused by mutatious and abnormal 
signalling of BMP pathway.  
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5.2 Methods specific for this chapter 
5.2.1 Processing and analysis of microarray data 
Processing and analysis of Illumina microarray is described in Chapter 2, section 2.12 in 
details. Total RNA was extracted from hamstring muscles from four cohorts of mice at Day 
2 after surgery. Cohorts included: 
 SCI surgery + CDTX injection 
 SCI alone 
 CDTX injection + SHAM operation and 
 SHAM operation 
RNA was cleaned-up, concentrated and amplified as described in 2.12.1, Chapter 2. 
Analysis was performed using BRB ArrayTools software. 
5.2.2 SCI surgery and mouse strains used in this chapter 
SCI surgery was performed as described in Chapter 2, section 2.2. All experiments for this 
chapter were performed on C57BL/6J. All mice were euthanized for microCT analysis 10-
14 days after surgery and at 2 days after surgery for microarray assay. 
5.2.3 Treatment options 
5.2.3.1 Kineret 
Kineret (Anakinra 100mg, catalogue number EU/1/02/203/002, Swedish Orphan Biovitrum, 
Sweden) is recombinant human IL-1 receptor antagonist and competitively inhibits the 
binding of IL-1 to its cognate receptor. It was administered by intraperitoneal injection as 
described previously [183] at two doses: 25mg/kg and 10mg/kg body weight immediately 
after surgery and injection of CDTX and then once daily for 10 days. Control mice were 
injected with an equivalent volume of saline. To inject 25mg/kg:  50μl of commercial stock 
from the syringe (100 mg/0.67 mL) was diluted in 1.45mL of saline. For 10mg/kg 20μl of 
stock from the syringe was diluted in 1.48mL of saline. 
5.2.3.2 Etanercept 
Etanercept (Enbrel 25mg, Pfizer New Zealand Ltd. Catalogue number R90456) is a fusion 
protein between the extracellular domain of human TNF-α receptor 2 and human IgG1 Fc 
fragment. It works by binding directly to human or mouse TNF-α and prevents the binding 
of the human/mouse TNF-α to their cellular receptors. It was administered by 
intraperitoneal injection in a dose of 10mg/kg and 20mg/kg of body weight immediately 
after surgery and injection of CDTX and then daily for 10 days, doses previously shown to 
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be effective in mice [184, 185]. Control mice were injected with an equivalent volume of 
saline (100 μl). Etanercept powder (25mg) was diluted with 1 mL of water for injections as 
per manufacturer’s instructions. To inject 20mg/kg: 336μl of stock was diluted in 1.76mL of 
water for injections. To inject 10mg/kg 168μl of 20mg/kg solution was diluted in 1.76mL of 
water for injections. 
5.2.3.3 GW2580 (CSF1R kinase inhibitor) 
To make vehicle for oral gavage of GW2580, 10μl of Tween20 was diluted in 10mL of 
water for injections, then 50mg of hydroxypropyl methylcellulose (USP grade H3785, 
Sigma Aldrich) powder was added as described previously [186, 187]. The mixture was 
rotated on rotating wheel until powder was fully dissolved at room temperature. This 
mixture was stored in -80°C for 10 days. To make fresh stock 3.2mg of GW2580 
(orb61037, Byorbyt) was diluted in 100μL of vehicle by gently mixing with syringe mounted 
with a 23G needle until the suspension was homogenous. Mice were gavaged with 
GW2580 160mg/kg (100 μL) or vehicle at the day of surgery after recovery and then daily 
for 10 days.  
5.2.4 qRT-PCR analysis 
For qRT-PCR analysis expression was determined relative to β-actin. For myogenic 
markers RNA extracted from whole hamstring group of muscle was used. RNA was 
extracted from whole hind limb muscle as described in Materials and Methods section 2.8, 
Chapter 2. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and 
analysis the relative to housekeeping gene expression as determined by ΔCt was 
compared between the groups as described in Chapter 2, section 2.10. 
Primers used in this chapter are outlined in the Table 5.1. 
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Table 5.1 Primers used for qRT-PCR 
Primer Sequence Product size (bp)/ 
Amplicon length* 
Acvr1* Mm01331069_m1 65* 
Arg1 Mm00475988_m1 65* 
β2M 75’f  CTGGTCTTTCTGGTGCTTGTC 
181’b GTATGTTCGGCTTCCCATTC 
106 
 
β-actin f’ AGC ACT GTG TTG GCA TAG AGG TC 
b’ CTT CTT GGG TAT GGA ATC CTG TG 
168 
BMP2* Mm01340178_m1 58* 
BMP4* Mm00432087_m1 61* 
BMP5* Mm00432091_m1 60* 
BMP7* Mm00432102_m1 65* 
Ccl2* Mm00441242_m1 74* 
Chi3l3* Mm00657889_mH 90* 
Collagen1 4060’f GATGGATTCCCGTTCGAGTA 
4225’b CCTTCTTGAGGTTGCCAGTC 
165 
Csf1* Mm00432686_m1 70* 
F4/80 ’f TGCCACAACACTCTCGGAAGCTAT 
’b AAGGTGGGACCACAGAGAGTTGAA 
149 
IL-1β 560f ACAAGGAGAACCAAGCAACG 
803b CTCTGCTTGTGAGGTGCTGA 
243 
Lgals3 Mm00446190_m1 78* 
Mrc1 Mm00485148_m1 76* 
MyoD* Mm01203489_g1 103* 
Nog* Mm01297833_s1 72* 
Osteocalcin 32’f TTCTGCTCACTCTGCTGACCCT 
137’b CCCTCCTGCTTGGACATGAA 
Probe 86’f CAAGCCCAGCGGCCCTGAGTCT  
105 
Osterix* Mm04209856_m1 88* 
Pax7* Mm01354484_m1 68* 
Runx2 904’f CCAAGAAGGCACAGACAGAA 
995’b ATACTGGGATGAGGAATGCG 
Probe949’b CCCTAAATCACTGAGGCGATCAGAGAA 
91 
Tnf alpha Mm00443258_m1 81* 
*for TaqMan Gene Expression Array Mix 
5.3 Results 
Sixteen RNA samples harvested from whole hind limb muscle 48 hours after surgery were 
used in this study coming from four mice per experimental groups. The four experimental 
groups were:  
 SCI surgery + CDTX injection 
 SCI alone 
 CDTX injection + SHAM operation and 
 SHAM operation. 
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The IlluminaBeadChip array was used as described in 2.12, Chapter 2 and the data set 
was filtered and normalised using the Lumi package developed by the North-western 
University. All subsequent analyses were performed with BRB Microarray software on the 
normalised data set and were performed using SOURCE annotations for the pathway 
analysis. The gene sets were defined based on Gene Ontology and Lymphoid signatures 
2.12.3, Chapter 2. 
5.3.1 Mouse groups with NHO, SCI only or inflammation only display a unique 
transcriptomic profiles 
Principal component analysis was performed on RNA from whole muscle from the 4 
experimental groups to determine whether samples clustered according to the mouse 
treatment. All four groups of mice were compared on a two dimensional plane, principal 
component 1 and principal component 2 as shown in Figure 5.1. Figure 5.1A represents 
raw data, while in Figure 5.1B normalised data are presented. Black arrow indicates the 
only mouse sample that did not cluster with other samples from the same group and was 
considered outliers. Therefore, this sample was removed from the subsequent analysis of 
differentially expressed sets of genes. However it was left for statistical analysis of genes 
that expression was validated by qRT-PCR. Figure 5.1B displays four distinct clusters that 
match the mouse treatment groups. Interestingly, following data normalisation, the 4 
treatment groups clustered at the 4 different corners of the principal component 2 D plot 
suggesting that SCI and CDTX-mediated injury have very distinct effect of cellular 
transcriptome in the muscle.  
Hierarchical clustering was also performed to determine if the surgical groups were 
clustering as a pure or homogeneous population according to the type of surgery and 
injection, or to determine if there was heterogeneity between these groups of mice. In this 
analysis, hierarchical clustering resulted in relatively stable groupings. It can be seen in 
Figure 5.2 that there were 4 main groups, according to the type of surgery performed. All 
samples in each group are clustering together and groups appear to be small and 
homogeneous clusters of 4 samples except for one outlier sample from SCI+CDTX group 
that was clustered with CDTX group. In the hierarchy of this clustering CDTX mediated 
injury split the experimental groups upstream of the SCI showing that the effect of CDTX 
induced injury is dominant over the SCI on the muscle transcriptome. This is not too 
surprising as CDTX injection causes major destruction of the muscle and infiltration of 
macrophages whereas the effect of SCI is due to the result of the paralysis, a more subtle 
effect probably to do to reduced muscle activity and metabolism. 
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Figure 5.1 Principle component analysis and whole muscle gene expression arrays in 
mice that underwent SCI and or CDTX-mediated muscular inflammation. (A) The original 
data set containing all samples from SCI and SHAM-operated mice. (B) The normalised 
data set. This is the final data set used for all subsequent analyses. The black arrow 
indicate mouse sample from SCI+CDTX group that did not cluster with other samples from 
the same surgical group-outlier. Dotted line – SCI+CDTX, Compound line – SCI, Long 
dash dot line – CDTX, Dash line – SHAM 
 
Figure 5.2 Hierarchical clustering of mouse surgery groups based on their differentially 
expressed genes. This is the final normalised data set contained all mouse samples used 
for all subsequent analyses. 1.1-1.4 – SCI+CDTX, 2.1-2.2 – SCI surgery, 3.1-3.4 – 
CDTX+SHAM, 4.1-4.4 – SHAM surgery 
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5.3.2 Ingenuity pathway analysis confirms expression molecules of inflammation and 
cellular response signalling pathways  
BRB ArrayTool Gene Ontology and BioCarta Pathway databases were used to identify the 
major biological gene sets that were significantly differentially expressed between the four 
surgical groups. Gene Ontology database identified 5518 total investigated gene sets, 
BioCarta Pathway identified 264 total gene sets. I first evaluated the effect of SCI on whole 
muscle transcriptome by comparing SCI mice to SHAM-operated mice. In SCI vs SHAM 
analysis, 497 out of 5518 investigated gene sets passed the 0.005 significance threshold 
based on Two-sample T-test. LS/KS permutation test that finds gene sets which have 
more genes differentially expressed among the phenotype classes than expected by 
chance found 270 significant gene sets. In SCI+CDTX vs CDTX analysis 570 out of 5518 
investigated gene sets passed the 0.005 significance threshold based on Two-sample T-
test. LS/KS permutation test that finds gene sets which have more genes differentially 
expressed among the phenotype classes than expected by chance found 277 significant 
gene sets.   
According to BioCarta Pathway database analysis of SCI vs SHAM showed that 29 out of 
264 investigated gene sets passed the 0.005 significance threshold. Analysis of 
SCI+CDTX vs CDTX showed that 34 out of 264 investigated gene sets passed the 0.005 
significance threshold. These differentially expressed pathways are represented in Table 
5.2 and 5.3. All gene sets could be classified as biological process, cellular component 
and molecular function. 
 
Table 5.2 Pathway analysis of gene sets differentially expressed between SCI and SHAM 
groups. 
Pathway 
description 
Number and list of genes 
included in pathway Type of 
pathway 
LS 
permutat
ion p-
value 
KS 
permutat
ion p-
value 
Effects of 
calcineurin in 
Keratinocyte 
Differentiation 
Cdkn1a, Prkca, Ppp3ca, 
Nfatc1, Nfatc4, Ppp3cb, 
Calm3, Marcks, Sp1, Ppp3cc, 
Sp3, Nfatc3, Calm1, Nfatc2, 
Gnaq, Plcg1, Prkcb 
cell 
proliferation 
and 
metabolism 0.00001 0.01875 
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Control of 
skeletal 
myogenesis by 
HDAC & 
calcium/calmo
dulin-
dependent 
kinase (CaMK) 
Map2k6, Myod1, Ppp3ca, 
Camk2a, Nfatc1, Ppp3cb, 
Calm3, Mapk14, Hdac5, 
Ywhah, Ins, Igf1r, Igf1, Avp, 
Ppp3cc, Mapk7, Pik3r1, 
Calm1, Nfatc2, Pik3ca, 
Pik3cg, Insr, Akt1 
cell 
proliferation 
and 
metabolism 0.00001 0.0123 
p53 Signaling 
Pathway 
Cdkn1a, Gadd45a, Pcna, 
Rb1, Bax, Trp53, Mdm2, 
Ccnd1, Ccne1, Apaf1, Cdk2, 
Bcl2, Timp3, E2f1 
cell 
proliferation 
metabolism 
and apoptosis 0.00001 0.03482 
fMLP induced 
chemokine 
gene 
expression in 
HMC-1 cells 
Map2k6, Map2k1, Ppp3ca, 
Nfatc1, Nfatc4, Camk2a, 
Ppp3cb, Calm3, Hras1, 
Map2k2, Nfkbia, Mapk14, 
Fpr1, Pak1, Pik3c2g, Ppp3cc, 
Nfatc3, Ncf2, Raf1, Calm1, 
Nfatc2, Map3k1, Mapk1, 
Nfkb1, D830050J10Rik, 
Mapk3, Rela, Ncf1, Gna15, 
Plcb1, Map2k3 inflammation 0.00002 0.00755 
Shuttle for 
transfer of 
acetyl groups 
from 
mitochondria to 
the cytosol 
Slc25a11, Cs, Acly, Pdha1, 
Mdh1, Slc25a1, Pcx 
cell 
proliferation 
and 
metabolism 0.00011 0.01175 
Regulation of 
PGC-1a 
Ppp3ca, Camk2a, Esrra, 
Ppp3cb, Calm3, Slc2a4, 
Ppargc1a, Hdac5, Ywhah, 
Camk4, Ppp3cc, Ppara, 
Hdac5, Calm1 
cell 
proliferation 
and 
metabolism 0.00012 0.00004 
p38 MAPK 
Signaling 
Pathway 
Daxx, Tgfb2, Creb1, Cdc42, 
Grb2, Hmgn1, Map3k1, 
Hspb2, Myc, Shc1, Max, Atf2, 
Tgfbr1 
cell 
differentiation 0.00012 0.00924 
Erythropoietin 
mediated 
neuroprotectio
n through NF-
kB 
Cdkn1a, Jak2, Arnt, Nfkbia, 
Sod2, Arnt, Grin1, Epor, 
Grin1, Nfkb1, Epo, Hif1a, 
Rela 
cell 
proliferation 
and 
metabolism 0.00015 0.01822 
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TNF/Stress 
Related 
Signaling 
Map2k6, Tgfbr, Cdc42, 
Tgfbr1, Ddit3,  Mapkapk2, 
Hspb1, Map2k4, Stat1, 
Hras1, Creb1, Map3k7, Atf2, 
Traf2, Mapk14, Ripk1, Shc1, 
Tgfb1, Myc, Tgfb3, Mknk1, 
Jun, Map3k14, Tnfrsf1a, 
Tank, Nfkbia, Map4k2, Ripk1, 
Ikbkg, Casp2, Ikbkb, Atf1, 
Map3k1, Nfkb1, Mapk8, Rela, 
Tnf, Chuk, Cradd, Map2k3 inflammation 0.00016 0.00049 
Toll-Like 
Receptor 
Pathway 
Map2k6, Ecsit, Jun, 
Map3k14, Irak1, Map2k4, 
Traf6, Map3k7, Nfkbia, 
Mapk14, Ikbkg, Eif2ak2, 
Ikbkb, Fos, Ppara, Myd88, 
Map3k1, Nfkb1, Mapk8, Rela, 
Chuk, Pglyrp1, Map2k3 inflammation 0.00033 0.00904 
Cell Cycle: 
G2/M 
Checkpoint 
Cdkn1a, Gadd45a, Trp53, 
Mdm2, Cdc25c, Ywhah, 
Rps6ka1, Prkdc, Wee1, Myt1, 
Cdkn2d, Cdc34, Cdc25a, 
Cdc25b, Ep300, Brca1, 
Chek1, Ccnb1, Plk1 
cell 
proliferation 0.00037 0.16096 
NFkB 
activation by 
Nontypeable 
Hemophilus 
influenzae 
Map2k6, Tgfbr1, Dusp1, 
Map3k14, Map3k7, Nfkbia, 
Mapk14, Mapk11, Crebbp, 
Tgfbr2, Smad3, Ikbkb, Il1b, 
Myd88, Nfkb1, Nr3c1, Ep300, 
Rela, Tnf, Chuk, Map2k3 inflammation 0.00037 0.00532 
Signal 
Dependent 
Regulation of 
Myogenesis by 
Corepressor 
MITR 
Myod1, Camk2a, Ywhah, 
Hdac9 
cell 
proliferation 
and 
metabolism 0.00052 0.04036 
Role of 
nicotinic 
acetylcholine 
receptors in 
the regulation 
of apoptosis 
Musk, Chrnb1, Rapsn, Chrng, 
Fasl, Ywhah, Bad, Ptk2b, 
Pik3r1, Pik3ca, Foxo3, 
Pik3cg, Tert, Akt1 
programmed 
cell death and 
apoptosis 0.00054 0.00594 
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Malate-
aspartate 
shuttle 
Slc25a11, Mdh1 
cell 
proliferation 
and 
metabolism 0.00088 0.08255 
TNFR1 
Signaling 
Pathway 
Casp8, Mapk8, Tnf, Fadd, 
Lmnb1, Dffb, Cradd, Arhgdib, 
Prkdc inflammation 0.0009 0.00008 
ATM Signaling 
Pathway 
Lmna, Rb1, Jun, Tnfrsf1a, 
Map2k4, Arhgdib, Map3k7, 
Parp1, Traf2, Dffa, Ripk1, 
Prkdc, Lmnb2, Casp2, 
Casp3, Pak1, Bag4, Fadd, 
Map3k1, Cdkn1a, Gadd45a, 
Rpa1, Trp53, Mdm2, Nfkbia, 
Mre11a, Chek2, Rad50, 
Rad51, Chek1, Trp73, Nfkb1, 
Abl1, Mapk8, Nbn, Rela, 
Brca1 
cell 
proliferation 
metabolism 
and apoptosis 0.00099 0.3424 
The role of 
FYVE-finger 
proteins in 
vesicle 
transport 
Tfrc, Hgs, Egfr, Trf 
cell 
proliferation 
and 
metabolism 0.0012 0.01193 
Agrin in 
Postsynaptic 
Differentiation  
Chrna1, Musk, Arhgef6, 
Rapsn, Cdc42, Jun, Agrn, 
Cttn, Utrn, Lama2, Dag1, 
Git2, Itga1, Pak3, Egfr, 
Mapk1, Pak1, Sp1, Dmd, 
Dvl1, Nrg3, Lama1, Pak4, 
Mapk8, Mapk3, Chrm1, 
Lama4, Acta1, Itgb1 
muscle 
specific cell 
proliferation 
and 
metabolism  0.00123 0.12024 
Keratinocyte 
Differentiation  
Map2k6, Prkca, Ets1, 
Map2k1, Jun, Map3k14, 
Tnfrsf1a, Map2k4, Ppp2ca, 
Hras1, Map2k7, Fasl, Nfkbia, 
Traf2, Mapk14, Prkch, Prkcq, 
Ripk1, Fas, Egfr, Ikbkb, 
Mapk1, Fos, Sp1, Egf, Daxx, 
Noxa7, Raf1, Mapk13, Bcl2, 
Map3k1, Tnfrsf1b, Nfkb1, 
D830050J10Rik, Mapk8, 
Ets2, Mapk3, Rela, Prkce, 
Prkcb, Tnf, Chuk, Cebpa, 
Prkcd, Map2k3 
cell 
proliferation 
and 
metabolism 0.00154 0.06435 
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Role of MEF2D 
in T-cell 
Apoptosis  
Prkca, Ppp3ca, Ppp3cb, 
Calm3, Nfatc1, 
A430107P09Rik, Capns1, 
Hdac2, Ppp3cc, Mef2d, 
Calm1, Nfatc2, Ep300, 
Capn2, Prkcb inflammation 0.00326 0.08504 
Signaling 
Pathway from 
G-Protein 
Families  
Prkca, Map2k1, Ppp3ca, 
Nfatc1, Nfatc4, Jun, Ppp3cb, 
Calm3, Prkar2a, Hras1, 
Creb1, Prkar1b, Fos, 
Prkar2b, Rps6ka3, Ppp3cc, 
Nfatc3, Raf1, Calm1, Nfatc2, 
Gnaq, Prkar1a, Plcg1, Gnaq, 
Prkacb, Adcy1, 
D830050J10Rik, Mapk3, 
Prkcb, Nfatc1 
cell 
proliferation 
and 
metabolism 0.00351 0.181 
BCR Signaling 
Pathway  
Prkca, Map2k1, Ppp3ca, 
Nfatc1, Nfatc4, Jun, Ppp3cb, 
Calm3, Hras1, Mapk14, 
Shc1, Fos, Ppp3cc, Nfatc3, 
Sos1, Raf1, Calm1, Grb2, 
Nfatc2, Btk, Cd79b, Map3k1, 
Plcg1, D830050J10Rik, 
Mapk8, Mapk3, Vav1, Syk, 
Prkcb, Cd79b 
inflammation 0.00783 0.22291 
Polyadenylatio
n of mRNA  
Papola, Cstf3, Cstf1, Cpsf3, 
Cpsf1, Pabpn1 
cell 
proliferation 
and 
metabolism 0.00862 0.00057 
Signal 
transduction 
through IL1R  
Map2k6, Irak2, Ecsit, Jun, 
Map3k14, Irak1, Traf6, 
Map3k7, Nfkbia, Mapk14, 
Ikbkb, Tgfb1, Il1rap, Tgfb3, 
Il1b, Irak3, Il6, Tgfb2, Myd88, 
Ifna1, Il1rn, Map3k1, Nfkb1, 
Ifnb1, Mapk8, Il1a, Rela, Tnf, 
Chuk, Il1r1, Map2k3 inflammation 0.01239 0.29512 
Human 
Cytomegalovir
us and Map 
Kinase 
Pathways  
Map2k6, Map2k1, Rb1, 
Map2k2, Creb1, Mapk14, 
Mapk1, Sp1, Pik3r1, Pik3ca, 
Map3k1, Nfkb1, Pik3cg, 
Mapk3, Rela, Akt1, Map2k3 proliferation 0.01255 0.28157 
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Cell Cycle: 
G1/S Check 
Point  
Cdkn1a, Rb1, Trp53, Tfdp1, 
Cdkn2b, Ccna1, Ccnd1, 
Smad3, Tgfb1, Cdkn1b, 
Tgfb3, Cdkn2a, Abl1, Dhfr, 
Ccne1, Tgfb2, Cdk2, Cdc25a, 
Cdk6, Skp2, Gsk3b, E2f1 
cell 
proliferation 
and 
metabolism 0.01275 0.11727 
Y branching of 
actin filaments  
Psma7, Wasf1, Nckap1, 
Wasf2, Wasl, Wasf3, Nck1, 
Pira1, Abi2, Acta1 
cytoskeleton 
structure 0.02186 0.30535 
Influence of 
Ras and Rho 
proteins on G1 
to S Transition 
Cdkn1a, Rb1, Hras1, Tfdp1, 
Nfkbia, Ccnd1, Ikbkg, Ikbkb, 
Mapk1, Pak1, Cdkn1b, 
Ccne1, Pik3r1. Raf1, Cdk2, 
Pik3ca, Nfkb1, Rhoa, 
D830050J10Rik, Cdk6, 
Mapk3, Rela, Chuk, E2f1, 
Akt1 
cell 
proliferation 
and 
metabolism 0.04878 0.43207 
 
This table clearly shows that majority of differentially expressed pathways between SCI- 
and SHAM-operated groups are related to muscle biology and repair, cell metabolism, and 
cell proliferation with only a few related to inflammation. In majority of differentially 
expressed pathways up- and down-regulated genes are spread equally in both groups, 
However all genes in Polyadenylation of mRNA, p53 signaling pathway and role of 
nicotinic acetylcholine receptors in the regulation of apoptosis are up-regulated in SCI 
alone group. Indeed all three pathways are involved in apoptosis and as we mentioned 
earlier that could be associated with 21-28% loss of muscle mass in the limbs of mice with 
SCI [188]. Interestingly all genes were down-regulated in SCI group in the following 
pathways:  
 Regulation of PGC-1a, which is involved in muscle specific cell proliferation;  
 shuttle for transfer of acetyl groups from mitochondria to the cytosol, involved in 
glucose metabolism and as a result in the muscle function; and  
 malate-aspartate shuttle, also specific for skeletal muscle tissue. 
This down-regulation can possibly be explained by muscle paralysis and slower rates of 
muscle cells metabolism. 
The pathway analysis of gene sets differentially expressed between SCI+CDTX and CDTX 
groups however presented a very different picture with the most of these pathways related 
to inflammation (Table 5.3).  
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Table 5.3 Pathway analysis of gene sets differentially expressed between SCI+CDTX and 
CDTX groups. 
Pathway 
description 
List of genes included in a 
pathway Type of 
pathway 
LS 
permutat
ion p-
value 
KS 
permutat
ion p-
value 
mTOR 
Signaling 
Pathway 
Tsc2, Mknk1, Eif4a2, Eif3a, 
Ppp2ca, Eif4ebp1, Eif4a1, 
Pdk2,  Rheb, Pik3r1, Pten, 
Pdpk1, Eif4e, Eif3a, Pik3ca, 
Rps6kb1, Akt1, Tsc1 
cell 
proliferation 0.00001 0.01188 
TNF/Stress 
Related 
Signaling 
Map2k6, Map2k4, Rela, 
Map3k1, Jun, Tank, Traf2, 
Nfkb1, Casp2, Tnfrsf1a, 
Nfkbia, Map3k14, Mapk14, 
Ripk1, Tnf, Chuk, Ikbkg, 
Tank, Ikbkb, Map4k2, Cradd, 
Atf1, Mapk8, Map2k3 inflammation 0.00004 0.00007 
Toll-Like 
Receptor 
Pathway 
Pglyrp1, Map2k6, Map2k4, 
Rela, Map3k1, Jun, Nfkb1, 
Myd88, Traf6, Nfkbia, 
Map3k14, Mapk14, Chuk, 
Ecsit, Ikbkg, Ikbkb, Eif2ak2, 
Ppara, Fos, Map3k7, Irak1, 
Mapk8, Map2k3 inflammation 0.00014 0.00195 
NFkB 
activation by 
Nontypeable 
Hemophilus 
influenzae 
Map2k6, Rela, Ep300, 
Mapk11, Nfkb1, Myd88, 
Smad3, Tgfbr1, Nfkbia, 
Map3k14, Mapk14, 
Il1b, Tnf, Chuk, Tgfbr2, 
Nr3c1, Dusp1, Ikbkb, Crebbp, 
Map3k7, Map2k3 inflammation 0.00026 0.00011 
Keratinocyte 
Differentiation 
Ets2, Map2k6, Map2k4, 
Ppp2ca, Rela, Map3k1, Jun, 
Raf1, Traf2, Nfkb1, Tnfrsf1a, 
Daxx, Prkcq, Prkca, Nfkbia, 
Hras1, Map3k14, Mapk14, 
Fas, Ripk1, Tnf, Chuk, 
Map2k7, Mapk1, Bcl2, 
Hoxa7, Egf, Map2k1, Ets1, 
Sp1, Cebpa, Mapk3, Ikbkb, 
Prkcb, D830050J10Rik, 
Tnfrsf1b, Egfr, Map2k7, 
Prkce, Fas, Prkcd, Fos, 
cell 
proliferation 
and 
metabolism 0.00044 0.00493 
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Mapk13, Fasl, Prkch, Mapk8, 
Map2k3 
Acetylation and 
Deacetylation 
of RelA in The 
Nucleus 
Rela, Ep300, Fadd, Nfkb1, 
Nfkbia, Ripk1, Tnf, Chuk, 
Fadd, Ikbkg, Tnfrsf1a, Ikbkb, 
Tnfrsf1b, Crebbp, Traf6, 
Ikbkg 
cell 
proliferation 
and 
metabolism 0.00058 0.00064 
TACI and 
BCMA 
stimulation of B 
cell immune 
responses. 
Rela, Tnfrsf13c, Traf2, Nfkb1, 
Traf6, Map3k14, Mapk14, 
Chuk, Tnfrsf17, Tnfsf13b, 
Tnfrsf13b, Traf3, Mapk8 
inflammation 0.00062 0.00015 
TNFR2 
Signaling 
Pathway 
Rela, Traf3, Map3k1, Tnfaip3, 
Tank, Traf2, Nfkb1, Nfkbia, 
Map3k14, Ripk1, Chuk, 
Ikbkap, Ikbkg, Dusp1, Ikbkb, 
Tnfrsf1b, Traf1, Ikbkg inflammation 0.0008 0.00343 
Internal 
Ribosome 
entry pathway 
Eif4a2, Eif3a, Eif4a1, Ptbp1, 
Eif4e 
cell 
proliferation 
and 
metabolism 0.00081 0.00433 
NF-kB 
Signaling 
Pathway 
Fadd, Rela, Map3k1, Tnfaip3, 
Nfkb1, Myd88, Tnfrsf1a, 
Traf6, Nfkbia, Map3k14, 
Ripk1, Tnf, Chuk, Ikbkg, 
Ikbkb, Tnfrsf1b, Il1r1, Il1a, 
Map3k7, Irak1 inflammation 0.00086 0.00125 
Chromatin 
Remodeling by 
hSWI/SNF 
ATP-
dependent 
Complexes 
Actb, Smarca4, Smarce1, 
Smarcc1, Nr3c1, Nf1, Tbp, 
Smarcb1, Smarcd1, Arid1a 
cell 
proliferation 
and 
metabolism 0.00096 0.00933 
Ceramide 
Signaling 
Pathway 
Fadd, Map2k4, Rela, 
Map3k1, Cycs, Raf1, Traf2, 
Nfkb1, Tnfrsf1a, Ripk1, Cycs, 
Aifm1, Tnfrsf1, Smpd1, 
Mapk1, Bcl2, Map2k1, 
Mapk3, Casp8, 
D830050J10Rik, Bax, Nsmaf, 
Bad, Mapk8 
programmed 
cell death and 
apoptosis, 
inflammation 0.00137 0.00076 
SODD/TNFR1 
Signaling 
Pathway 
Fadd, Birc2, Traf2, Bag4, 
Tnfrsf1a, Ripk1, Tnf, Casp8, 
Tnfrsf1b inflammation 0.00175 0.00496 
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Free Radical 
Induced 
Apoptosis 
Rela, Sod1, Xdh, Gss, Nfkb1, 
Tnf, Gpx1 
programmed 
cell death and 
apoptosis 0.00243 0.00548 
fMLP induced 
chemokine 
gene 
expression in 
HMC-1 cells 
Ppp3ca, Map2k6, Rela, 
Map3k1, Camk2a, Nfatc1, 
Raf1, Pik3c2g, Nfkb1, 
Map2k2, Nfkbia, Nfatc4, 
Hras1, Mapk14, Ncf1, 
Ppp3cb, Mapk1, Fpr1, 
Nfatc1, Map2k1, Ppp3cc, 
Nfatc2, Mapk3, 
D830050J10Rik, Calm3, 
Nfatc3, Pak1, Gna15, Ncf2, 
Plcb1, Ncf2, Map2k3, Calm1, 
Pik3c2g inflammation 0.0028 0.00458 
Induction of 
apoptosis 
through DR3 
and DR4/5 
Death 
Receptors 
Lmna, Fadd, Rela, Birc2, 
Cycs, Traf2, Nfkb1, 
Tnfrsf10b, Nfkbia, Map3k14, 
Ripk1, Chuk, Casp9, Apaf1, 
Bid, Casp6, Bid, Bcl2, 
Tnfrsf25, Cflar, Casp3, 
Casp8,  Casp7, Dffa, Tnfsf12, 
Dffb, Tnfsf10, Gas2 
programmed 
cell death and 
apoptosis 0.003 0.00205 
HIV-I Nef: 
negative 
effector of Fas 
and TNF 
Lmna, Fadd, Rela, Map3k1, 
Birc2, Cycs, Rasa1,Traf2, 
Nfkb1, Bag4, Casp2, 
Tnfrsf1a, Daxx, Mdm2, 
Nfkbia, Map3k14, Fas, 
Mdm2, Ripk1, Tnf, Chuk, 
Map2k7, Rb1, Casp9, Apaf1, 
Bid, Casp6, Psen1, Bcl2, 
Cflar, Arhgdib, Casp3, 
Casp8, Tnfrsf1b, Map2k7, 
Lmnb2, Parp1, Traf1, Casp7, 
Psen1, Psen2, Prkcd, Dffa, 
Lmnb1, Gsn, Fas, Dffb, 
Cradd, Map2k7, Fasl, Prkdc, 
Mapk8 inflammation 0.0034 0.00221 
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p38 MAPK 
Signaling 
Pathway 
Mknk1, Hspb1, Map2k6, 
Map2k4, Map3k1, Atf2, 
Tgfb2, Traf2, Daxx,Tgfbr1, 
Hras1, Mapk14, Mapkapk2, 
Hmgn1, Shc1, Ripk1, Myc, 
Cdc42, Stat1, Myc, 
Tgfbr1,Ddit3, Creb1, Max, 
Hspb2, Grb2, Map3k7, Tgfb3 
cell 
differentiation 0.00353 0.03044 
CXCR4 
Signaling 
Pathway 
Cxcr4, Crk, Rela, Gnaq, 
Raf1, Cxcl12, Pik3c2g, 
Nfkb1, Prkca, Bcar1, Hras1, 
Ptk2b, Pik3r1, Mapk1, 
Map2k1, Crk, Mapk3, Pik3ca, 
Prkcb, D830050J10Rik, 
Gnaq, Plcg1 inflammation 0.00398 0.00875 
T Cell 
Receptor 
Signaling 
Pathway 
Lat, Ppp3ca, Map2k4, Rela, 
Map3k1, Jun, Zap70, Rasa1, 
Nfatc1, Raf1, Cd3d, Nfkb1, 
Cd3g, Prkca, Nfkbia, Nfatc4, 
Hras1, Vav1, Shc1, Cd3e, 
Ppp3cb, Pik3r1, Lck, 
Map2k1, Ppp3cc, Fyn, 
Nfatc2, Mapk3, Pik3ca, 
Prkcb, D830050J10Rik, 
Calm3, Cd247,  Nfatc3, Fos, 
Sos1, Pik3cg, Grb2, Zap70, 
Mapk8, Plcg1, Calm1, 
A430107P09Rik inflammation 0.00608 0.10654 
Control of 
Gene 
Expression by 
Vitamin D 
Receptor 
Tsc2, Smarca4, Smarce1, 
Ep300, Smarcc1, Vdr, 
Carm1, Rpgrip1, Actl6a, 
Baz1b, Top2b, Ncor1, Snw1, 
Med1, Rxra, Crebbp, 
Smarcd1, Ncoa3, Arid1a, 
Kat2b, Chaf1a 
cell 
proliferation 
and 
metabolism 0.00665 0.01182 
Endocytotic 
role of NDK, 
Phosphins and 
Dynamin 
Ppp3ca, Ap2a1, Epn1, 
Eps15, Ppp3cb, Synj2, 
Dnm1, Ppp3cc, Calm3, 
Nme2, Nme1 
cell 
proliferation 
and 
metabolism 0.00789 0.11027 
Polyadenylatio
n of mRNA 
Cstf1, Cstf3, Pabpn1, Cpsf3, 
Cpsf1, Papola 
cell 
proliferation 
and 
metabolism 0.00892 0.0917 
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Cadmium 
induces DNA 
synthesis and 
proliferation in 
macrophages 
Rela, Jun, Raf1, Nfkb1, 
Prkca, Nfkbia, Hras1, Tnf, 
Myc, Mapk1, Myc, Map2k1, 
Mapk3, Prkcb, 
D830050J10Rik, Fos, Plcb1 
cell 
proliferation 0.00907 0.00681 
The 
information-
processing 
pathway at the 
IFN-beta 
enhancer 
Irf3, Rela, Jun, Atf2, Irf1, 
Nfkb1, Crebbp, Kat2b, 
Hmgb1 
inflammation 0.01224 0.16993 
Msp/Ron 
Receptor 
Signaling 
Pathway 
Mst1r, Csf1, Il1b, Ccl2, Tnf, 
Mst1 
inflammation 0.01693 0.00371 
Role of Ran in 
mitotic spindle 
regulation 
Kpnb1, Rangap1, Tpx2, 
Rcc1, Kpna2, Ranbp1, Kif15, 
Aurka, Ran 
cell growth and 
proliferation 0.0263 0.00187 
Deregulation of 
CDK5 in 
Alzheimers 
Disease 
Ppp2ca, Capn1, Capns1, 
Cdk5r1, Cdk5, Gsk3b 
cell 
proliferation 
and apoptosis 0.04224 0.05334 
NFAT and 
Hypertrophy of 
the heart 
(Transcription 
in the broken 
heart) 
Calr, Ppp3ca, Prkar1a, Myh2, 
Camk2a, Nfatc1, Raf1, 
Mef2c, Ctf1, Nkx2-5, Nfatc4, 
Hras1, Mapk14, Hbegf, Agt, 
Ppp3cb, Pik3r1, Mapk1, 
Prkar2a, Map2k1, Ppp3cc, 
Csnk1a1, Pik3r1, Nfatc2, 
Mapk3, Fgf2, Igf1, 
D830050J10Rik, Calm3, 
Rps6kb1, Acta1, Camk4,  
Akt1, Crebbp, F2, Nfatc3, 
Gsk3b, Edn1, Hand1, Pik3cg, 
Nppa, Prkar2b, Prkar1b, 
Prkacb, Gata4,  Hand2, 
Mapk8, Calm1 
cell 
proliferation 0.0719 0.08844 
IL-6 signaling 
pathway 
Csnk2a2, Jun, Raf1, Cebpb, 
Hras1, Ptpn11, Il6st, Shc1, 
Stat3, Il6, Il6ra, Srf, Map2k1, 
Jak2, Ptpn11, Mapk3, Jak3, 
D830050J10Rik, Csnk2a1, 
Fos, Sos1, Jak1, Grb2 inflammation 0.09595 0.19796 
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Regulation of 
transcriptional 
activity by PML 
Tnfrsf1a, Daxx, Sumo1, 
Hras1, Sirt1, Fas, Sp100, Tnf, 
Sae1, Rb1, Uba2, Trp53, 
Rara, Pml, Tnfrsf1b, Sae1, 
Crebbp, Pax3, Fasl 
cell 
proliferation 
and apoptosis 0.09798 0.00234 
Basic 
Mechanisms of 
SUMOylation 
Sumo1, Sumo2, Sae1, Uba2, 
Sumo3, Ube2i 
cell 
proliferation 0.13223 0.00409 
Pelp1 
Modulation of 
Estrogen 
Receptor 
Activity 
Esr1, Ep300, Mapk1, Mapk3, 
Crebbp 
cell 
proliferation 
and 
metabolism 0.14531 0.27464 
EPO Signaling 
Pathway 
Csnk2a2, Jun, Raf1, Stat5a, 
Ptpn6, Hras1, Epor, Shc1, 
Map2k1, Jak2, Mapk3, 
D830050J10Rik, Csnk2a1, 
Fos, Stat5b, Sos1, Grb2, 
Epo, Mapk8, Plcg1 
cell 
proliferation 
and 
metabolism 0.15511 0.60358 
 
Among all differentially expressed gene sets changes in Msp/Ron Receptor Signaling 
Pathway between SCI+CDTX and CDTX alone groups were of a high interest. It was the 
only differentially expressed pathway where all genes included in this pathway were highly 
up-regulated in SCI+CDTX group. All genes included in this pathway are inflammatory 
cytokines and the pathway includes macrophage stimulating protein (Fig.5.3). 
 
Figure 5.3 Clustered heatmap of significantly differentially expressed genes included in 
Msp/Ron Receptor Signaling Pathway that were up-regulated in SCI+CDTX group 
 
MSP/RON signaling plays a role in inflammation and the response to tissue injury. It has 
been implicated in the functional regulation of mononuclear phagocytes [189]. Not much is 
known about this signalling pathway role in muscles, however Chanda et al. have 
published that MSP/RON signaling may regulate hepatic glucose metabolism [190], but 
what is more important MSP has also been shown to stimulate bone resorbing activity of 
osteoclasts [191].  
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5.3.3 Differentially expressed genes 
After removing outlier sample 1.2 (SCI+CDTX group) cluster analysis of all groups was 
performed with set p-value of univariate test with p value below 0.005. I have got a number 
of genes significant at 0.005 level of the univariate test: 7548. Since SCI+CDTX and CDTX 
alone groups were clustered closer on the hierarchical cluster map, cluster analysis was 
then performed between these two groups with set p-value of univariate test 0.005.  The 
number of genes significant at this level was 2851. I then sorted these genes on the fold 
change based on up-regulated genes (2 fold and more) and downregulated genes (0.5 fold 
and less) in SCI+CDTX group. Analysis revealed 135 up-regulated and 145 down-
regulated genes. 
Then new cluster analysis of all groups was performed with selected up-regulated and 
down-regulated gene subsets. Heatmaps are represented on Figure.5.4. 
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Figure 5.4 Clustered heatmap of significantly differentially expressed genes that were (A) 
down-regulated in SCI+CDTX group and (B) up-regulated in SCI+CDTX group. 
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Upregulated osteoblast and macrophage markers 
My previous data from Chapter 4 show that macrophages play a crucial role in NHO after 
SCI. Numerous genes related to inflammation or macrophages were similarly highly up-
regulated in SCI+CDTX group – the only group where NHO develops compared to 
muscles from mice with SCI injury alone (Fig 5.4 and table 5.4). Indeed some genes up-
regulated in SCI+CDTX group are exclusive to osteoblasts or activated macrophages.  
Also numerous inflammatory markers are upregulated in SCI+CDTX group. Interestingly 
these markers were significantly higher in group, where CDTX-induced inflammation was 
coupled with SCI, suggesting that SCI may enhance muscular inflammation. 
 
Table 5.4 Osteoblasts and macrophages expressed markers which are differentially 
expressed among classes and up-regulated in SCI+CDTX group compared to all groups 
Gene 
symbol 
Gene name Function Expression pattern 
Cd163 CD163 antigen scavenger receptor for 
the hemoglobin-
haptoglobin complex, 
M2 marker; acute-phase 
response, inflammatory 
response 
bone, bone marrow 
Slpi secretory leukocyte 
peptidase inhibitor 
secreted inhibitor which 
protects epithelial 
tissues from serine 
proteases released by 
granulocytes 
strongly induced in 
macrophages 
activated by LPS or 
thioglycollate  
Cd14 CD14 antigen LPS binding, lipoteichoic 
acid binding; immune 
system process, 
inflammatory response, 
response to molecule of 
bacterial origin, 
response to tumor 
necrosis factor 
LPS activated 
macrophages  
Trap1 TNF receptor-associated 
protein 1 
negative regulation of 
cellular respiration, 
negative regulation of 
oxidative stress-induced 
intrinsic apoptotic 
signaling pathway, 
protein folding, response 
to stress 
Highly expressed in 
liver, kidney, brown 
adipose tissue 
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Irf3 interferon regulatory factor 
3 
cellular response to 
LPS, immune system 
process, immune 
response, positive 
regulation of interferon-
alpha and beta 
production 
B-cells, live and 
spleen 
Glycam1 glycosylation dependent 
cell adhesion molecule 1 
Involved in cell 
adhesion, regulation of 
immune response 
highly expressed in 
lymph nodes and 
mammary gland  
Chi3l3 chitinase 3-like 3 Inflammatory response, 
M2 marker 
Granulocytes; bone 
and bone marrow 
 
Itgb5 integrin beta 5 part of VLA-5, the 
integrin receptor for 
fibronectin and VCAM-1 
osteoblasts, LPS 
activated 
macrophages 
Cxcl14 chemokine (C-X-C motif) 
ligand 14 
platelet factor 4, immune 
response, 
chemoattractant and 
activator of monocytes, 
NK, dendritic cells 
Brain tissue and 
cortex 
Socs3 suppressor of cytokine 
signaling 3 
inhibits the signal from 
the G-CSF receptor and 
IL6 receptor family 
LPS activated bone 
marrow macrophages 
P2ry6 pyrimidinergic receptor 
P2Y, G-protein coupled, 6 
Regulator of immune 
response 
macrophages, 
dendritic cells and 
microglia 
Saa3 serum amyloid A 3 Acute inflammatory 
phase protein, 
recruitment of immune 
cells to the site of 
inflammation 
LPS activated 
macrophages and 
microglia 
Mfge8 milk fat globule-EGF factor 
8 protein 
Stimulates 
angiogenesis, 
chemotherapy 
resistance to cancer 
cells 
LPS activated 
macrophages, 
spleen, lymph nodes 
Plod3 procollagen-lysine, 2-
oxoglutarate 5-
dioxygenase 3 
synthesis of collagens, 
deficiency causes 
Ehlers–Danlos 
syndrome 
Macrophages and 
osteoblasts 
Ier3 immediate early response 
3 
Involved in apoptosis 
and specific immune 
response 
mast cells, T-cells, 
macrophages and 
osteoblasts 
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Srgn serglycin Mediator of apoptosis, 
mast cell and T-cell 
secretory granule 
organization 
mast cellsfollicular B-
cells, LPS activated 
macrophages 
Hp haptoglobin acute-phase response, 
immune response to 
bacterial infection 
macrophages,  
osteoblasts, bone, 
bone marrow, liver 
Hyal2 hyaluronoglucosaminidase 
2 
Monocyte activation, 
response to viruses 
LPS activated 
macrophages, 
osteoclasts and 
osteoblasts 
Col18a1 collagen, type XVIII, alpha 
1 
Angiogenesis LPS activated 
macrophages, 
osteoblasts, mast 
cells 
Timp1 tissue inhibitor of 
metalloproteinase 1 
inhibitor of many matrix 
metalloproteinases 
released by 
granulocytes/monocytes, 
tissues in repair, inhibits 
collagenase 
Osteoblasts 
Sema3f sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3F 
role in vascularisation 
together with VEGF, 
immunoglobulin 
secretion  
osteoblasts, 
osteoclasts, mast 
cells, macrophages 
Txndc5 thioredoxin domain 
containing 5 
expressed in response 
to hypoxia 
Osteoblasts, follicular 
B-cells, bone marrow 
macrophages 
Kcnab2 potassium voltage-gated 
channel, shaker-related 
subfamily, beta member 2 
hematopoietic progenitor 
cell differentiation 
LPS activated 
macrophages, NK-
cells, osteoclasts, 
neuroglia 
Igfbp7 insulin-like growth factor 
binding protein 7 
Invlolved in 
neurogenesis 
Osteoblasts, 
spleen,kidney, lymph 
nodes 
 
Downregulated osteoblast and macrophage markers 
Surprisingly, some inflammatory markers were also down-regulated in SCI+CDTX group 
(Table 5.5). Surprisingly macrophage inflammatory type activation was reduced in the 
CDTX+SCI group compared to CDTX, which may be effect of SCI. 
Interestingly a few muscle specific genes like Eno3, Tpm2, Actc1, Myoz1, Vgll2, Myom1, 
2310042D19Ryk (Perm1), Fh1 and Adipor1 were down-regulated in SCI+CDTX group 
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exclusively. It may suggest that muscle affected by CDTX has worse regeneration abilities 
in the presence of SCI. 
 
Table 5.5 Osteoblasts and macrophages expressed markers which are differentially 
expressed among classes and downregulated in SCI+CDTX group compared to all groups 
Gene 
symbol 
Gene name Function Expression pattern 
Itm2b integral membrane 
protein 2B 
mutation is associated 
with familial dementia, 
T-cell development 
and functioning, 
repressed by CSF-1 
mast cells, osteoblasts, 
LPS  activated 
macrophages, spinal 
cord, cerebellum 
Mlf1 myeloid leukemia factor 
1 
myeloid progenitor cell 
differentiation 
Skeletal muscle 
Ifit3 interferon-induced 
protein with 
tetratricopeptide repeats 
3 
anti-viral immunity  LPS activated 
macrophages  
Ifit2 interferon-induced 
protein with 
tetratricopeptide repeats 
apoptotic process, 
cellular response to 
interferon-alpha, anti-
viral immunity  
  LPS activated 
macrophages 
Clec4a1 C-type lectin domain 
family 4, member a1 
regulate leukocyte 
reactivity 
B-cells, dendritic cells 
and macrophages 
express C-type lectin 
receptors 
Lgals9 lectin, galactose 
binding, soluble 9 
T-cell immunoglobulin, 
overexpressed in 
Hodgkin’s disease, 
knock-out mice have 
increased susceptibility 
to collagen induced 
arthritis 
LPS activated 
macrophages, 
osteoclasts 
Ctsa cathepsin A degradation of 
glycosaminoglycans, 
proteoglycans, and 
glycoproteins 
LPS activated 
macrophages, 
osteoclasts, microglia 
Calr calreticulin regulates NF-Kb 
signalling, regulation of 
monocyte/macrophage 
compartment 
LPS activated 
macrophages, 
osteoclasts, osteoblasts 
Gbp3 guanylate binding 
protein 3 
Anti-viral immunity, 
cellular response to 
interferon-beta 
LPS thioglycollate 
activated  macrophages 
Lgals3bp lectin, galactoside-
binding, soluble, 3 
binding protein 
Macrophage 
scavenger receptor 
(M1 and M2), immune 
response associated 
with NK 
LPS thioglycollate 
activated  macrophages, 
osteoblasts, osteoclasts 
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Gns glucosamine (N-acetyl)-
6-sulfatase 
Mutation causes 
mucopolysaccharidosi
s 
LPS thioglycollate 
activated  macrophages, 
osteoclasts, mast cells, 
B-cells 
Gnai2 guanine nucleotide 
binding protein (G 
protein), alpha inhibiting 
2 
acetylcholine receptor 
signaling pathway, cell 
cylce 
LPS thioglycollate 
activated  macrophages, 
osteoclasts, mast cells, 
follicular B-cells 
 
5.3.4 Validation of macrophage and inflammation associated markers differentially 
expressed among the groups by qRT-PCR 
Considering that previous experiments described in Chapter 4 confirmed that 
macrophages are required for NHO. Two main types of macrophages have been identified 
previously: inflammatory (M-1-like) and tissue regenerative (M-2-like) [192], however their 
actaul roles are complicated, especially taking into consideration phenotype skewing 
process when M2 replaces M1 phenotype in the site of inflammation. In this chapter I took 
the opportunity to utilise the microarray data to determine whether specific macrophage 
biases (either M-1 or M-2) I have compared expression of M1- and M2- related markers 
between the groups of operated mice. I discovered that M2 inflammatory macrophage 
markers Arg-1, Mrc1, Chi3l3, Ccl2, Lgals wereall up-regulated in SCI+CDTX group 
compared to all other groups by the microarray results (Fig.5.5). 
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Figure 5.5 Differentially expressed genes of anti-inflammatory macrophage markers in 
muscle of SCI and SHAM operated mice with and without CDTX induced inflammation at 
Day 2 after surgery – microarray results. (A) Ccl2, (B)Chi3l3, (C)Arg1, (D)Lgals3, (E) Mrc1 
mRNA from hind limb muscle from operated mice. Data are represented as mean ± SD. 
Data were analyzed by One-way ANOVA with Bonferroni’s multiple comparison test. Each 
dot represents hind limb muscle mRNA from a separate mouse (4 mice per group) 
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Inflammatory cytokines IL-6, IL-1β, TNFα and Csf1 were also highly upregulated in 
SCI+CDTX group in comparison with three other groups including one with combination of 
SHAM surgery and CDTX-induced inflammation (Fig.5.6). 
 
Figure 5.6 Differentially expressed genes of inflammatory cytokines in muscle of SCI and 
SHAM operated mice with and without CDTX induced inflammation at Day 2 after surgery 
– microarray results. (A) IL-1β, (B) Csf1, (C) Tnfα, (D) IL-6. Data are represented as mean 
± SD. Data were analyzed by One-way ANOVA with Bonferroni’s multiple comparison test. 
Each dot represents hind limb muscle mRNA from a separate mouse (4 mice per group). 
 
Microarray results were validated on the mRNA isolated from hind limb muscles of SCI- 
and SHAM-operated mice with and without CDTX injection. Endosteal and central bone 
marrow (CBM) mRNA was used as a reference control and were not used in statistical 
analysis. Ccl2 was expressed significantly higher in SCI+CDTX group in comparison with 
SHAM operated mice, however the difference was not statistically significant between 
other groups of operated mice (Fig.5.7 A). Same tendency was observed for Lgals3 and 
IL1β (Fig5.7D). Arginase 1 was upregulated in both groups with CDTX induced 
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inflammation, however the difference between groups with and without CDTX induced 
inflammation was not statistically significant (Fig.5.7C). Despite the differentially 
expressed Mrc1 accordingly to microarray results, qRT-PCR failed to show the difference 
between the groups (Fig.5.7 F). Difference in cytokines Csf1 and Tnfα expression 
(Fig.5.7G,H)  also did not match microarray results, as Csf1 was significantly upregulated 
in SCI alone group, while Tnfα was not significantly differently expressed in all four groups 
of mice according to the qRT-PRC results, however in gene microarray results both Csf-1 
and Tnfα were significantly upregulated in SCI+CDTX group. 
Comparative analysis of inflammatory markers expression at Day 2 and Day 4 after 
surgery has shown reduction in all markers throughout all groups by the Day 4 
(Fig.5.8A,B,C,D,E). Interestingly that Csf1 and Tnfα remained up-regulated in SCI alone 
group by Day 4 (Fig.5.8F,G). 
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Figure 5.7 Inflammatory mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 after surgery – qRT-PCR results. 
Quantification of (A) Ccl2, (B)Chi3l3, (C)Arg1, (D)Lgals3, (E)IL-1β, (F)Mrc1, (G)Csf1, 
(H)Tnfα mRNA by qRT-PCR on hind limb muscle from operated mice. Endosteal and 
central bone marrow mRNA from untreated naïve mice was used as a control. All 
expression was compared to the housekeeper gene β-actin. Data are represented as 
mean ± SD. Combined time course for all four experimental groups of animals. Data 
analysed by One-way ANOVA with Kruskall-wallis test. Each dot represents hind limb 
muscle mRNA from a separate mouse (4 mice per group). 
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Figure 5.8 Inflammatory mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 (pale grey bars) and Day 4 (dark 
grey bars) after surgery – qRT-PCR results. 
Quantification of (A) Ccl2, (B)Chi3l3, (C)Arg1, (D)Lgals3, (E)IL-1β, (F)Csf1, (G)Tnfα mRNA 
by qRT-PCR on hind limb muscle from operated mice. Endosteal and central bone marrow 
mRNA from untreated naïve mice was used as a control. All expression was compared to 
the housekeeper gene β-actin. Data are represented as mean ± SD. Combined time 
course for all four experimental groups of animals. Data analysed by Two-way ANOVA 
with Bonferroni post-test. 
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In the next section, I utilized the microarray data to identify specific inflammatory agents for 
intervention with the aim of finding potential treatments that alleviate NHO following SCI. 
Mice were administered with drugs that inhibit cytokines involved in inflammation: 
 IL-1  
 TNF-α 
as well as monocyte/macrophage development and M2 activation: 
 CSF1R  
5.3.5 IL-1 receptor antagonist does not improve NHO  
Inflammatory cytokine IL-1β was found to be increased locally in the muscles of SCI-
operated mice with CDTX injection by microarray and qRT-PCR (Fig.5.5). 
To inhibit IL-1 in vivo, we performed treatment of operated mice with Kineret at doses of 
10mg/kg or 20mg/kg daily from immediately after the surgery. Mice in control group were 
injected with the same volume of saline. At 10 days we did not observe any changes in 
NHO volumes or density between the groups of operated mice (p-value: 0.2303ns by 
Mann-Whitney test for Kineret dose 20mg/kg and, 0.5273ns for Kineret dose 10mg/kg). 
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Figure 5.9 Effect of IL-1 receptor antagonist on NHO. (A) Illustrative μCT of right hind 
limbs after SCI with injection of CDTX and treatment with IL-1 receptor antagonist Kineret; 
Quantification of HO volumes (B) and density (C) by 3D μCT reconstitution following SCI 
with injection of CDTX and treatment with IL-1 receptor antagonist Kineret; bars and error 
bars represent mean ± SD of 6 mice per group. 
 
5.3.6 Combination of IL-1 receptor antagonist and TNF-α inhibitor reduced bone formation 
in NHO 
As TNF-α expression was also found to be up-regulated in muscle from mice with 
SCI+CDTX (Fig.5.5). We also inhibited TNF-α in vivo by administering Etanercept. 
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In mice that underwent SCI and intramuscular CDTX injection I administered TNFα 
inhibitor Etanercept alone or in combination with IL-1 receptor antagonist Kineret. Control 
group was injected with the same volume of saline - 100μL. Treatment groups included: 
 Control group (saline) 
 Kineret 10mg/kg 
 Kineret 20mg/kg 
 Etanercept 20mg/kg and 
 Etanercept 10mg/kg + Kineret 10mg/kg. 
At 10 days we observed a significant reduction of NHO volumes in group of mice injected 
with Etanercept 20mg/kg and combination of Etanercept and Kineret (10mg/kg each) (p-
value: 0.0424* by Mann-Whitney test), but there was no difference between Etanercept 
alone group and Etanercept plus Kineret group. Of note, although the reduction of NHO 
volume by etanercept treatment was significant, NHO were still large. 
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Figure 5.10 Effect of IL-1 receptor antagonist and TNF-α inhibitor on NHO. (A) Illustrative 
μCT of right hind limbs after SCI with injection of CDTX and treatment with IL-1 receptor 
antagonist Kineret and TNF-α inhibitor Etanercept; (B) Quantification of HO volumes by 3D 
μCT reconstitution following SCI with injection of CDTX and treatment with IL-1 receptor 
antagonist Kineret and TNF-α inhibitor Etanercept; bars and error bars represent mean ± 
SD of 4 mice per group, data pooled from two experiments. 
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5.3.7 CSF1R kinase antagonist reduced the bone density but not the volume of NHO 
My microarray analysis revealed that a macrophage stimulatory factor CSF1 was 
increased locally in the muscles of SCI-operated mice with CDTX injection. To test the 
effect of CSF1 inhibition we performed treatment with CSF1R kinase small antagonist 
GW2580. Mice with SCI and CDTX-induced inflammation were gavaged with GW2580 
160mg/kg or vehicle at the day of surgery after recovery and then daily for 10 days. At 10 
days we did not observe any changes in NHO volumes between the groups of operated 
mice (p-value: 0.9551 ns by Mann-Whitney test), however bone density was significantly 
reduced after treatment with CSF1 kinase antagonist (p-value: 0.0098**, One way Anova, 
Bonferroni’s multiple comparison test; p-value: 0.0428*, Mann-Whitney test) (Fig.5.11) 
 
Figure 5.11 Effect of CSF1R kinase inhibitor on NHO. (A) Illustrative μCT of right hind 
limbs after SCI with injection of CDTX and treatment with CSF1R kinase inhibitor; 
Quantification of HO volumes (B) and density (C) by 3D μCT reconstitution following SCI 
with injection of CDTX and treatment with CSF1R kinase inhibitor; bars and error bars 
represent mean ± SD of 4 mice per group pooled from two different experiments; p-value: 
**0.01-0.0001 
100 
 
 
5.3.8 BMP signalling and osteogenic mRNA expression in muscle of mice with and without  
NHO 
RNA was extracted from hamstring muscle of 4 groups of mice, 4 mice in each group. The 
groups included: 
 SCI+CDTX 
 SCI alone 
 CDTX + SHAM operation 
 SHAM-operated mice 
 Central bone marrow and endosteal RNA were also extracted from naïve mice in 
steady state to see how they compared to RNA extracted from muscles. The 
rationale for these 2 control tissues was to evaluate RNA abundance relative to a 
well-known site of bone formation (femoral endosteum) and a site with little bone 
formation despite the abundance of mesenchymal progenitor cells and 
haematopoietic cells (central bone marrow). 
It has been documented that in FOP BMP signalling is abnormally activated due to 
activating mutations of the Acvr1 receptor [48]. I investigated a possible role of BMP 
signalling molecules in SCI-induced NHO by assessing mRNA expression of BMP family 
members in muscle of mice with SCI or SHAM with and without muscular inflammation. 
Interestingly at day2 after surgery Acvr1 mRNA was upregulated in mice with SCI alone in 
comparison with other groups of mice and CBM reference (Fig.5.12A). This upregulation 
remained consistent in this group at day4 after surgery, while Acvr1 mRNA from mice with 
CDTX injection remained the same by day4 (Fig.5.13A). This is interesting as Acvr1 (a 
part of BMP signaling pathway) is the most common driving mutation observed in patients 
with FOP [193]. BMP2, 4, 5 and 7 were slightly upregulated in SCI alone group and by 
day4 after surgery BMP2 has got increasingly upregulated in SCI alone group (Fig.5.12B). 
BMP4, 5 and 7 expression did not change markedly during the same time course in the 
SCI group (Fig.5.12 C,D,E) and were slightly downregulated in the other three groups by 
the day 4, however the decrease was not statistically significant (Fig.5.13 B,C,D,E). 
Interestingly Noggin, the BMP receptor antagonist was also upregulated in SCI group at 
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day 2, however it reduced to the level of other 4 groups of mice by the day 4 (Fig.5.12F, 
5.13F). Muscle harvested from SCI operated mice have also expressed higher levels of 
markers for early osteogenic development, such as Runx2 and osterix/Sp7 at day 2 
(Fig.5.12 G,H), however both of these markers decreased in SCI group by day 4 (Fig.5.13 
G,H). Interestingly osterix mRNA significantly increased in CDTX and SCI +CDTX groups 
by the day4, while Runx2 decreased to the same level in all 4 groups by the day 4 after 
surgery. 
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Figure 5.12 Osteogenic mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 after surgery – qRT-PCR results. 
Quantification of (A) Acvr1, (B)BMP-2, (C)BMP-4, (D)BMP-5, (E)BMP-7, (F)Nog, 
(G)Runx2, (H)Osterix/Sp7 mRNA by qRT-PCR on hind limb muscle from operated mice. 
Endosteal and central bone marrow mRNA from untreated naïve mice was used as a 
control. All expression was compared to the housekeeper gene β-actin. Each dot 
represents one sample of mRNA, harvested from one mouse. Data analysed by One-way 
ANOVA with Kruskall-Wallis test  
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Figure 5.13 Osteogenic mRNA expression in muscle of SCI and SHAM operated mice 
with and without CDTX induced inflammation at Day 2 (pale grey bars) and Day 4 (dark 
grey bars) after surgery – qRT-PCR results. 
Quantification of (A) Acvr1, (B)BMP-2, (C)BMP-4, (D)BMP-5, (E)BMP-7, (F)Nog, 
(G)Runx2, (H)Osterix/Sp7 mRNA by qRT-PCR on hind limb muscle from operated mice. 
Endosteal and central bone marrow mRNA from untreated naïve mice was used as a 
control. All expression was compared to the housekeeper gene β-actin. Data are mean are 
mean ± SD. Combined time course for all four experimental groups of animals. Data 
analysed by Two-way ANOVA with Bonferroni post-test. 
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We then evaluated changes in TGF-β family in our microarray results (Fig.5.14). 
Interestingly, BMP4 and BMP-5 were significantly down-regulated in SCI+CDTX group 
(Fig.5.14C,D) while other markers did not differ much between the groups. 
 
Figure 5.14 Differentially expressed genes of osteogenic markers in muscle of SCI and 
SHAM operated mice with and without CDTX induced inflammation at Day 2 after surgery 
– microarray results. (A) Acvr1, (B)BMP2, (C)BMP4, (D)BMP5, (E)BMP7, (F)Nog mRNA 
by qRT-PCR on hind limb muscle from operated mice. Data are represented as mean ± 
SD. Each dot represents hind limb muscle mRNA from a separate mouse (4 mice per 
group). Data were analyzed by One-way ANOVA with Bonferroni’s multiple comparison 
test. *0.05-0.01; **0.01-0.0001;  ***<0.0001 
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5.4 Discussion 
The importance of osteogenic factors including bone morphogenetic proteins in bone 
regeneration and formation is well known. However it is important to remember that 
inflammatory cytokines were also shown to be involved in bone tissue regeneration 
process [194]. As specified in previous Chapter 4, specific tissue residential macrophages 
osteomacs support osteoblast survival differentiation and function in vivo in steady-state 
as well as in bone fracture models [114, 147].   
Chapter 5 microarray results show that a lot of genes which are macrophage specific or 
involved in macrophage activation and response to interferons were differentially regulated 
in inflamed muscles depending whether there was SCI or not. Therefore SCI changes 
macrophage activation profile in the inflamed muscle. Interestingly M2 related genes 
Cd163 and Chi3l3 were significantly up-regulated only in SCI+CDTX group, suggesting M2 
involvement in the bone formation strongly supporting our results in Chapter 4. Amongst 
down-regulated genes in the same group a lot of them are markers and cytokines 
associated with LPS-activated macrophages, which predominantly are M1 polarised 
macrophages: Itm2b, Ifit3, Ifit2, Gnai2 [192] and Lgals3bp, that was described as M1 and 
M2 marker [195]. Thus the data suggest that while CDTX promotes an inflammatory 
response in muscle, when CDTX is administered after spinal cord injury this inflammatory 
response is skewed more towards M2 phenotype. Based on those data we chose factors 
to investigate which are detailed below. 
 
CCL2 
Moreno et al. [196] have shown induction of CCL2 and axon loss in a multiple sclerosis 
model within months after CNS injury. Deletion of CCL2 chemokine by Spiegelmer-based 
inhibitor mNOX-E36 was shown to decrease CNS accumulation of M1 macrophages and 
M1 markers expression [197]. It is interesting, as we have found that mostly M2 markers 
are increased in the SCI+CDTX group together with CCL2 up-regulation. It supports our 
results from Chapter 4 about the possible role of M2 macrophages in NHO formation after 
SCI. 
 
TNFα, IL-6 and IL-1 
TNFα, IL-1 and IL-6 have been shown to play crucial role in bone regeneration and healing 
after fractures [198]. TNFα and IL-1β were shown to increase within the acute phase of 
inflammation after fracture – within the first 24 hours – which associated with intensive 
infiltration of injury site by inflammatory cells. The second peak in TNFα was observed 
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after 21-28 days, suggesting that during this period the cytokine is expressed by newly 
formed chondrocytes and osteoblasts [198, 199]. IL-1β knockout mice were shown to have 
increased bone volume and density associated with decreased osteoclast formation and 
maturation [199] while IL-1RI-deficient mice have decreased bone mass and increased 
number of osteoclasts [200]. Indeed TNFα, IL-1 and IL-6 were found to be significantly 
upregulated in SCI+CDTX group at Day 2 after surgery. However qRT-PCR results did not 
show significant difference in TNFα between SCI and SCI+CDTX groups which could be 
explained by bone damage during laminectomy to perform SCI surgery. 
IL-1 was shown to be one of the most potent activators of osteoclastogenesis and also a 
dominant factor in osteoclast differentiation [201]. It has been shown to increase bone 
resorption in chronic arthritis, therefore IL1 blocking has been suggested as a potential 
treatment of RA. IL-1 receptor antagonist Kineret was developed for rheumatoid arthritis 
and Sjögren's syndrome treatment [202-205]. It has also been shown to reduce alcoholic 
liver injury [183]. Bresnihan et al. have shown that along with intiinflammatory effect 
Kineret markedly reduced bone erosions in patients with rheumatoid arthritis [205]. In our 
experiment Kineret treatment did not affect bone formation after SCI. Etanercept – TNFα 
inhibitor has been successfully used in treatment of patients with rheumatoid arthritis and 
ankylosing spondilitis [206-209]. Genovese et al. have demonstrated that treatment with 
etanercept significantly reduced neuroinflammation as soon as 24 hours after treatment 
initiation and even stimulated movements in affected limbs in mouse model of spinal cord 
compression 10 days after injury [185]. Authors have found significant decrease in 
neutrophil infiltration along with reduced expression of TNFα and IL-1β locally in the spinal 
cord of mice treated with etanercept together with reduced expression M1 marker iNOS. 
While it effectively reduced inflammatory markers mediators it has also increased specifiv 
bone resorption markers (c-telopeptide-1 and sclerostin) in blood of patients with 
rheumatoid arthritis treated with etanercept for 12 weeks [210]. It confirms our results of 
NHO reduction after treatment with high dose of Etanercept or combination of Etanercept 
and Kineret. Both treatments are associated with a number of potentially serious adverse 
effects. Etanercept can cause leukopenia with subsequent higher risks of bacterial and 
viral infection development that has been reported by several authors [211, 212]. 
Anakinra’s adverse effects include hepatotoxicity [213], neutropenia [214] and injection-
site reactions [215]. Therefore it is highly unlikely to use the combination of both in 
treatment of NHO in patients at this stage. 
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MSP/Ron signalling 
We observed dramatic changes in MSP/Ron signalling pathway, where all included genes 
were highly up-regulated in SCI+CDTX group of mice. MSP/Ron signalling pathway plays 
an important role in wound healing, tumour growth but what is more important to us - it is 
strongly associated with macrophage activation [216]. Our findings were very exciting as in 
the results presented in Chapter 4 we confirmed that macrophages play an important role 
in SCI-NHO. MSP/Ron signalling pathway plays an important role in wound healing, 
tumour growth Ron or receptor tyrosine kinase signalling knockout in vivo has been shown 
to be compatible with life, however inflammatory response in those mice was attenuated 
[217]. It has also been shown to modulate function of M1 and M2 macrophages by Sharda 
et al. [218]. The same group of scientists performed in vitro stimulation of macrophages 
with macrophage stimulating protein (MSP), the only known ligand for Ron, and found 
upregulation of M2 marker Arginase 1.  Interestingly that short exposure to MSP led to 
increase of both M1 markers, like IL-1β and IL-6, and M2 markers: Mrc1 and Arg1. It is 
consistent with our microarray results on muscle harvested from SCI-operated mice with 
CDTX-induced inflammation. It has been suggested that by changing RON activity it would 
be possible to shift the activation state of macrophages between acute and chronic 
inflammatory states, which has significant therapeutic potential [216, 219]. 
 
CSF1 
We then decided to test CSF1 kinase inhibitor to reduce NHO. It has previously been 
published that M-CSF1 up-regulated osteoclast differentiation as osteoclasts are derived 
from cells of monocyte lineage [220]. Considering our hypothesis of M2 macrophage 
involvement into NHO after SCI and previous publications that CSF-1 induces polarization 
towards M2 macrophages and that blocking CSF-1R depletes normal microglia and 
reduced and M2 polarization [221, 222] it was exciting to observe reduction in bone 
density of newly formed HO. However we found that CSF-1 inhibition did not change the 
bone volume suggesting that multiple stimuli are involved in NHO. 
Thus although our data from Chapters 4 and 5 strongly suggest a driving role for 
inflammation in NHO it appears that multiple inflammatory factors contribute towards bone 
formation after SCI and the pathways are redundant in function. 
 
The dosage of inhibitors and agonists was taken from the literature; however we have not 
tested the efficacy in our mouse model, which is a limitation. Alternative strategies to 
overcome it would be to use double knock-out mice for receptors to IL-1 and TFN-α. As for 
108 
 
the CSF-1 inhibitor, we have not tested it in the muscles, but our results showed that the 
same dosage, we took from literature, was sufficient to reduce monocytes and 
macrophages response to M-CSF stimulation and decrease their proliferation (Fig 5.15). 
 
Figure 5.15 Effect of CSF1R kinase inhibitor on bone marrow monocytes and 
macrophages in vivo. Mice were treated with saline (Sal) , M-CSF, CSF1R kinase inhibitor 
or combination of M-CSF and CSF1R kinase inhibitor (M+G). Data are mean±SD of 3 mice 
per group. (R Jacobsen, unpublished data) 
 
BMP signalling 
It has been documented that in FOP BMP signalling is abnormally activated due to 
activating mutations of the Acvr1 receptor [48]. Although genetically driven FOP 
mechanisms might be different from neurologically driven HO, it still does not exclude the 
possibility of changes in BMP family molecules in response to SCI in genetically normal 
animals. In order to gain insight into a possible role of BMP signalling molecules in SCI-
induced NHO, I followed the mRNA expression of BMP family members in muscle of mice 
with SCI or SHAM with and without muscular inflammation. TGF-β superfamily role in bone 
regeneration and formation was most extensively studied to date [223-225]. TGF-β was 
shown to play an important role in osteogenesis imperfecta – hereditary disease caused 
by mutation in collagen type I gene [226, 227]. TGF-β caused altered bone formation 
through inhibition of osteoblast apoptosis [228] and repressing Runx2 thus inhibiting 
osteoblast differentiation [229]. Inhibition of TGF-α has leaded to increased bone mass 
and improved bone strength [226]. 
TGF-β superfamily members like activin A receptor type 1 and BMPs were documented to 
play important role in osteoblast differentiation and bone formation [225]. As mentioned 
earlier Acvr1 mutation has a substantial priming effect on HO formation in genetic disease 
FOP [18, 19, 48]. According to our results Acvr1 was upregulated in mice with SCI in 
comparison with other groups, however by day 4 upregulation was also observed in group 
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SCI+CDTX, that usually shows NHO formation. Knock-out models of BMP-2, 4 ,7 have 
shown impaired osteogenesis and mutation in BMP receptor was also shown to increase 
bone mass and volume in mice [230]. BMP-2 was found to be elevated after muscle injury 
and released during bone injury [39, 40]. In our experiment BMP-2 and 4 were significantly 
upregulated by day 4 in mice with SCI, however BMP-4 and 7 expression in SCI group 
was comparable expression in the muscle of SHAM operated mice. Interestingly that BMP-
4, 5 and 7 were downregulated by day 4 in a group of mice that usually develops NHO. 
Despite reports of absent increase of BMPs in cerebrospinal fluid from TBI patients 
suggesting that BMPs are unlikely to be responsible for the osteogenic cell response that 
triggers HO [42] we have shown an immense and consistent increase of BMP-2, 4 and 7 in 
the muscle tissue harvested from mice with SCI, that could suggest association with 
subsequent bone formation. Genetically modified mice overexpressing BMP antagonist 
Noggin have been shown to cause osteopenia and fractures together with impaired 
osteoblastic function [231]. In our results Nog was significantly higher expressed in the 
muscle of SCI operated mice, however its expression markedly decreased by day 4, 
reaching the level of Nog expression in the other three groups of operated mice. 
Interestingly microarray analysis has shown that BMP-1 that does not belong to the TGF-β 
family but is involved in bone and cartilage development though collagen maturation [232, 
233] was highly increased exclusively in the SCI+CDTX group. BMP-1 is expressed in 
osteopblasts but not muscles or macrophages. 
As BMP signaling changes may not be reflected in transcriptional changes immediately 
after SCI with inflammation, it will be necessary to perform assessment of phosphorylation 
of Smad1, 5 and 8 proteins that are involved in BMP signaling cascade by 
immunohistochemistry or Western blot analysis. 
Early onset of Runx2 expression has been shown to induce mineralization in embryo 13.0. 
It was sufficient to direct MSCs to osteoblasts and lead to intramembranous bone 
formation during embryogenesis. Thus it is essential for skeletal development [234]. 
Interestingly it was substantially upregulated in mice with SCI alone on Day 2, however 
this effect was diminished to the level of the other three groups of operated mice by the 4th 
day after surgery. 
Increased expression of osteoblastic differentiation genes Runx-2, osterix and cathepsin-K 
has been reported in TBI patients [41]. Muscle from SCI operated mice expressed higher 
levels of markers for early osteogenic development: Runx2 as was described earlier and 
osterix/Sp7, however osterix expression was significantly downregulated in SCI alone 
group by day 4. This effect was opposite to the groups of mice with CDTX injection without 
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correlation to SCI as in both groups of mice with inflammation we have shown significant 
increase of osterix by day 4 after surgery. Among other markers, that are known to be 
associated with bone formation leptin has been shown to be expressed by human healthy 
osteoblasts in vitro during mineralization phase [235]. Later the same research group has 
published that leptin promotes osteoblast differentiation in vitro along with its function of 
mineralization and collagen deposition [38]. Although leptin is known to be a promoter of 
bone progenitors and osteoblasts activation and was found also to decrease osteoblastic 
activity by binding to hypothalamic neurons [29]. Osteocalcin is another biomarker of bone 
remodelling, which was found to be significantly lower in patients with TBI [45] along with 
collagen type I, that suggests that patients with neurotrauma are prone to HO 
development. We did not get convincing data in regards to these markers in our mice at 
early time points (days 2 and 4) following surgery. 
 
The main finding of this chapter is an increased production of inflammatory cytokines. 
They can be involved in NHO formation by polarizing macrophages, which instead of 
fulfilling their roles by dampening inflammation and repairing damaged muscles, can be 
pushed to contribute to the induction of osteogenic differentiation.  
Indeed in order to get the full picture of changes in the muscles of operated mice further 
analysis is required. Therefore we are planning to perform gene microarray on the muscle 
samples from the same groups of mice at later time points. In view of considerable 
changes in inflammatory markers and macrophages it is necessary to sort macrophages 
from muscles of SCI- and SHAM- operated mice to look at their gene expression profile as 
it may enlighten new potential candidates for target treatment. 
Furthermore experiments using mice knock-out for genes encoding these cytokine 
receptors will be designed to test their role in SCI-NHO. 
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Chapter 6: Characterisation of muscle and bone marrow progenitor cells prone to 
osteogenic differentiation 
6.1 Introduction 
Osteoblasts are required to form bone in damaged muscles. Osteoblasts are derived from 
mesenchymal progenitors that may constitutively reside in muscles in healthy individuals 
or be recruited to damaged muscles via the blood from remote reservoirs such as the bone 
marrow. Discovering the “cells of origin” of osteoblasts that accumulate in injured muscles 
following SCI has potential to improve  understanding of the physiopathology of NHO, 
increase prognostic information, enhance diagnostic abilities as well as provide treatment 
targets. In this chapter I experimentally evaluated the potential origins of osteoblasts 
during heterotopic ossification in mice. 
6.1.1 Aims and Objectives 
The potential cell source of osteoblast for bone formation in heterotopic ossifications are: 
three types of mesenchymal progenitor cells in muscle and two types of mesenchymal 
progenitor cells in bone marrow MSCs. The aim of this chapter was to isolate and culture 
an adult murine bone/bone marrow mesenchymal stromal cell and muscle mesenchymal 
progenitors cells populations and to define their osteogenic potential in vitro. Osteogenic 
differentiation potential was evaluated by measuring mineral calcium deposition by Alizarin 
Red staining, and mineral phosphate deposition by Von Kossa staining. RNA expression 
was tested via qRT-PCR on cells from the hind limb muscle and BM to identify the cell 
type that contributes to osteogenic differentiation in vitro.  
6.2 Methods 
6.2.1 Harvest sort and culture of muscle and bone marrow progenitors 
To identify which cells are responsible for making bones in muscles (are they derived from 
the muscle itself, or are they recruited from the skeleton and bone marrow via the blood) I 
used hind limb muscles. As control mesenchymal progenitor were isolated from the bone 
marrow of femurs and tibias from naïve untreated adult C57Bl/6 wild type mice. Sorting 
and culture methods are described in Chapter 2, section 2.3. In total 10 FACS sorts of 
muscle mesenchymal progenitor cells and 7 FACS sort for BM MSCs from 47 and 34 mice 
respectively were performed over the course of the project. 
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6.2.2 Osteogenic differentiation of muscle and bone marrow progenitors 
Methods for osteogenic differentiation are described in Chapter 2, section 2.4. 
6.2.3 qRT-PCR analysis 
For qRT-PCR analysis the expression was determined relative to β2-microglobulin (β2M). 
For myogenic markers RNA extracted from whole hamstring group of muscle was used. 
Level of significance was calculated using the Mann-Whitney test in GraphPad Prism 
v5.01 (San Diego, California, USA). 
Primers used in this chapter are outlined in the Table 6.1. 
Table 6.1 Primers used for qRT-PCR 
Primer Sequence Product size (bp)/ 
Amplicon length* 
β2M 75’f  CTGGTCTTTCTGGTGCTTGTC 
181’b GTATGTTCGGCTTCCCATTC 
106 
 
Collagen1 4060’f GATGGATTCCCGTTCGAGTA 
4225’b CCTTCTTGAGGTTGCCAGTC 
165 
MyoD* Mm01203489_g1 103* 
Osteocalcin 32’f TTCTGCTCACTCTGCTGACCCT 
137’b CCCTCCTGCTTGGACATGAA 
Probe 86’f CAAGCCCAGCGGCCCTGAGTCT  
105 
Osterix* Mm04209856_m1 88* 
Pax7* Mm01354484_m1 68* 
Prrx1* Mm00440932_m1 65* 
PW1* Mm01337379_m1 60* 
Runx2 904’f CCAAGAAGGCACAGACAGAA 
995’b ATACTGGGATGAGGAATGCG 
Probe949’b CCTAAATCACTGAGGCGATCAGAGAA 
91 
*for TaqMan Gene Expression Array Mix 
6.3 Results 
6.3.1 FACS-sorting of muscle and bone marrow mesenchymal progenitors 
I prepared single cell suspension from hamstring muscles from naïve C57BL/6 mice by 
digesting muscle fragments with Collagenase I and Dispase II. Then I sorted viable 
nucleated cells, defined as 7-AAD- (viable cells exclude this non-permeable DNA 
intercalating fluorochrome) and Hoechst+ (cell permeable DNA intercalating fluorochrome). 
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Erythrocytes were excluded  on Ter119 marker, endothelial and leukocytes were also 
excuded on the basis CD45 and CD31 markers. The resulting 7-AAD- Hoechst+ CD45- 
Ter119- CD31- cells were sorted and collected as follows: 
 muscle satellite cells (SC) as CD45- Ter119- CD31- Sca1- CD34+ cells; 
 muscle mesenchymal interstitial cells (IC) as CD45- Ter119- CD31- Sca1+ CD34+ 
cells as previously reported [100, 101] ; 
 CD45- Ter119- CD31- Sca1- CD34- progenitor cells; 
 and CD45- Ter119- CD31- Sca1+ CD34- progenitor cells (Figure 6.1). 
 
Figure 6.1 Phenotypic characterization of cell populations in mouse skeletal muscle and 
bone marrow of mice. 
This figure represents the sorting strategy to collect satellite cells and interstitial cells from 
mouse skeletal muscles (top row), and MSCs from mouse bone marrow stromal cells 
(bottom row). The left dot-plots show gating of viable (7AAD-negative) mononucleated 
(Hoechst33342+) cells. In the middle dot-plots, viable mononucleated cells are gated after 
exclusion of CD45+ leukocytes, Ter119+ erythroid cells and CD31+ endothelial cells. In the 
right dot-plots, non-hematopoietic non endothelial CD45- Ter119- CD31- cells are further 
gated as Sca1- CD34+ satellite cells, Sca1+ CD34+ interstitial cells or Sca1-CD34- 
progenitor cells. 
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Satellite cells and interstitial cells represented a frequency of 0.1-1% and 0.4-3% of all 
muscle sorted cells, respectively.  Sca1+ CD34- progenitors and Sca1- CD34- progenitors 
represented the smallest and the largest populations with a frequency of 0.1% and 7-15% 
of all muscle sorted cells, respectively. 
We performed the same sort on cell suspension harvested from mouse bone marrow 
(Fugire 6.1). Sca1+ CD34+ and Sca1+ CD34- bone marrow progenitors represented a 
frequency of 0.031-0.2% and 0.09-0.3% of all sorted bone marrow cells, Sca1- CD34+ 
bone marrow progenitors represented the smallest group of 0.01-0.08% and Sca1- CD34- 
progenitors represented the largest population with a frequency of 2-5% of all bone 
marrow sorted cells. Sorted cells were cultured until passage 2, and were used for 
mesodermal differentiation assay and RNA extraction. Part of cells was frozen in liquid 
nitrogen for future experiments.  
The morphology of IC, SC and Sca1+ BM MPCs populations was similar throughout the 
cultures. They were adherent, large elongated cells that exhibited a fibroblast-like 
morphology (Figure 6.2). Muscle Sca1- CD34- progenitors had similar morphology, 
however were larger in size. When plated at low densities, all cell populations formed 
colonies as would be expected of the typical clonal colony forming cell. Muscle Sca1+ 
CD34- progenitors and bone marrow Sca1- CD34+ progenitors represented the rarest 
groups, these cell populations showed poor growth and self-renewal abilities and survival 
and were not included in the next experiments. Mouse osteoblastic cell line MC-3T3 was a 
kind gift from Dr Allison Pettit’s group. These cells were elongated and smaller in size than 
previously described sorted cell populations, they formed colonies and looked similar to 
sorted bone marrow Sca1- CD34- progenitors. 
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Figure 6.2 Morphology of cell populations sorted from mouse bone marrow and skeletal 
muscle after exclusion of erythroid cells, endothelial cells and leucocytes. 
Adherent bone marrow (left column) and muscle (right column) cells with fibroblast-like 
morphology by light microscopy. The following populations were cultured until passage 2: 
Sca1+ CD34+ (first row), Sca1+ CD34-  (second row), Sca1- CD34+ (third row) and Sca1- 
CD34-  (fourth row). White bars 200µm. 
 
6.3.2 Osteogenic differentiation of muscle and bone marrow mesenchymal progenitors 
For osteogenic differentiation muscle IC, SC,  BM Sca1+ MPCs (further called BM MSC), 
BM and muscle Sca1- CD34- progenitors and cell line MC-3T3 was plated into 96 wells 
116 
 
plate in normal culture medium (DMEM supplemented with 20%FBS, 10% horse serum 
and antibiotics) as per Chapter 2, section 2.3. At confluence, expansion medium was 
replaced by a classic osteogenic medium containing phospho-ascorbic acid, β-
glycerophosphate and dexamethasone. Cells were cultured in osteogenic differentiation 
medium for three weeks; at the end of each week two plates were stained with Alizarin 
Red to detect mineral calcium deposits (Figure 6.4) and von Kossa to detect mineral 
phosphate deposits (Figure 6.3). By the end of the first week bmMPCs and muscle IC 
were capable of depositing mineralized matrix, stained both by von Kossa and Alizarin 
Red. By the end of second week Alizarin Red staining was positive also in sorted muscle 
satellite cells, while phosphate deposits were shown in all populations of cells. By the end 
of the third week all plated populations of cells show mineralized matrix, however muscle 
interstitial cells had the highest osteogenic potential over all other plated cell types 
including BM mesenchymal progenitor cells and osteoblastic cell line MC3T3 in vitro 
(Figure 6.5). This experiment suggests that resident progenitors from the muscle 
(interstitial cells and satellite cells) both have osteogenic potential and could possibly 
originate osteoblasts responsible for NHO, although muscle IC could differentiate and 
deposit a mineral matrix faster than satellite cells. 
I have shown that another type of resident muscle progenitor cells - Sca1-CD34- muscle 
cells – exhibits osteogenic potential similar to interstitial cells and bmMSCs in vitro. 
Therefore in the mouse, resident progenitors located within the muscle have osteogenic 
potential in vitro and could directly contribute to the bone formation after SCI, thus 
eliminating the need to recruit mesenchymal progenitors from the bone marrow via blood. 
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Figure 6.3 Von Kossa staining of mouse bone marrow and skeletal muscle cell 
populations. From top to the bottom: 1 week, 2 weeks, 3 weeks in culture. 
Columns of wells contained muscle interstitial cells (1), muscle satellite cells (2), Sca1-
CD34- muscle progenitor cells (3), Sca1+ bone marrow MPCs (4), bone marrow Sca1-
CD34- MPCs (5), and mouse osteoblastic cell line MC3T3 (6) cultured for 3 weeks in 
osteogenic medium or without osteogenic factor. The black staining shows mineralized 
phosphate deposited at the bottom of the wells. 
118 
 
 
Figure 6.4 Alizarin Red staining of mouse bone marrow and skeletal muscle cell 
populations. From top to the bottom: 1 week, 2 weeks, 3 weeks in culture. Columns of 
wells contained muscle interstitial cells (1), muscle satellite cells (2), Sca1-CD34- muscle 
progenitor cells (3), Sca1+ bone marrow MPCs (4), bone marrow Sca1-CD34- MPCs (5), 
and mouse osteoblastic cell line MC3T3 (6) cultured for 3 weeks in osteogenic medium or 
without osteogenic factor. The red staining shows mineralized calcium deposited at the 
bottom of the wells. 
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Figure 6.5 Quantification of osteogenic differentiation of mouse bone marrow and skeletal 
muscle cell populations by Alizarin Red staining. From the top to the bottom 1 week, 2 
weeks, 3 weeks in culture. 
The histograms show the quantification of the Alizarin Red staining by light absorbance at 
562nm of cells cultured in osteogenic conditions (grey bars) or in non-osteogenic 
expansion medium (empty bars). X axis: muscle interstitial cells (1), muscle satellite cells 
(2), Sca1-CD34- muscle progenitor cells (3), Sca1+ bone marrow MPCs (4), bone marrow 
Sca1-CD34- MPCs (5), and mouse osteoblastic cell line MC3T3 (6). Data are mean ± SD 
of four wells of a typical experiment out of 5 independent sorts and experiments.  
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6.3.3 Osteogenic and tissue specific mRNA expression in cultured muscle and bone 
marrow mesenchymal progenitors 
To further investigate the populations of mesenchymal progenitor cells from muscle and 
bone marrow, qRT-PCR was performed on mRNA extracted from cells at passage 2 for 
lineage-specific markers. I found that BM MPCs and osteoblastic cell line MC3T3 
expressed higher levels of markers for early osteogenic development, such as RUNX2 and 
osterix/Sp7, when compared to muscle IC and SC (Figure 6.7 A, B). In addition, BM MPCs 
and MC3T3 also expressed higher levels of osteocalcin (also known as bone gamma-
carboxyglutamate protein), a marker of mature – osteoblasts (Figure 6.7 C). Finally 
collagen 1 expression was increased in muscle IC and bmMPCs in comparison with 
muscle SC and MC3T3 cell line (Figure 6.7 D). Muscle specific marker MyoD, and the 
muscle satellite cell marker Pax7 were below detection in all four cell types, while highly 
expressed in whole murine hind limb muscle (Figure 6.7 E, F). Muscle interstitial cell 
marker PW1 [236] was highly expressed in muscle IC, SC and bone marrow MPCs, 
however was below detection in MC3T3 cell culture (Figure 6.7 G). Finally, the 
mesenchymal progenitor cell marker Prrx1 was well expressed in all cultured cell types 
with higher expression in bmMSCs and MC3T3, relative to cucltured in muscle progenitor 
cells (Figure 6.7 H). 
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Figure 6.6 Osteogenic myogenic and mesenchymal mRNA expression in muscle and 
bone marrow mesenchymal progenitors. 
Quantification of (A) Osterix, (B)Runx2, (C)Osteocalcin, (D)Collagen1, (E)MyoD, (F)Pax7, 
(G)PW1, (H)Prrx1 mRNA by qRT-PCR on muscle interstitial cells, satellite cells, bone 
marrow MSCs sorted from wild-type C57BL/6 mice and cell culture MC3T3. mRNA from 
whole hamstring muscle group was used as a positive control for myogenic markers 
MyoD(E) and Pax7(F). All expression was compared to the housekeeper gene β2M. Each 
dot represents one sample of mRNA, 4 samples of cells were harvested and sorted from 4 
different experiments. 
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6.4 Discussion 
It is well known that osteoblasts and osteocytes participate in normal bone formation, bone 
growth and regeneration in a fine balance with osteoclasts [237]. However the source of 
new bone in abnormal sites in the muscle after spinal cord injury remains a mistery. 
Potential sources of osteoblasts include mesenchymal progenitor cells, however it is 
unknown whether they are present locally in the damaged tissue or are recruited to the site 
of inflammation via blood from the most common source of MPCs – bone marrow. It is also 
a common knowledge that MPCs reside in different organs and tissues, such as heart 
muscle, kidney, skin, etc. [85]. A few groups of progenitor cells have been reported to be 
present in skeletal muscle [109, 238]. 
Muscle progenitor cells include interstitial cells and satellite cells. Satellite cells were 
discovered in 1961 my Dr.Mauro [239] and were reported to locate under basal lamina of 
the muscle fiber, able to self-renew and differentiate towards myogenic lineage in case of 
muscle damage. Fukada et al. generated monoclonal antibody SM/C-2.6 to simplify 
isolation of satellite cells [240]. Quiescent SC do not express MyoD, while during 
differentiation this marker is getting switched-on [240]. Previously SCs were isolated based 
on negative selection for Sca-1, CD31 and CD45 markers along with positive selection for 
CD34 and integrin α 7 [96, 241]. I used the same markers in my experiment except for 
integrin α 7. They’ve also been shown to express M-cadherin and Pax3 [101]. In my 
experiments qRT-PCR showed that Pax7 gene specific for SC [242] was highly expressed 
in whole fresh muscle. However it was below detection in all sorted cell populations 
including SC. This could be associated with changes in cells occurring during the  culture 
by passage 2 as Hashimoto et al. found that muscle MPCs can differentiate in culture and 
Pax7 was detected in human SC in early passage, but not during subsequent passages 
[107]. 
Besson et al. [236] studied PW1 marker (Peg3) for identification the other group of self-
renewing stem cells in adult tissues, so called interstitial cells due to their location in the 
interstitial space between muscle fibers. Previously the same marker was also reported by 
Mitchell et al. to be present in muscle interstitial cells [100]. According to the authors PW1+ 
cells were different from SC in terms of location in the muscle and other surface markers 
(Sca-1) however contributed toward muscle regeneration in vivo at levels comparable to 
SC. IC have also been reported to have the ability to self-renewand segregate SC 
population [100]. Surprisingly PW1 mRNA was well expressed in all sorted muscle MPC 
and BM Sca-1+ progenitors in my experiment which could again be associated with 
changes in cells in culture. 
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IC also have been shown to express mesenchymal marker PDGFRα while freshly isolated 
[111] and have adipogenic potential in vitro, which is consistent with my results of 
adipogenic differentiation. This cell population was Sca-1+ and part of them expressed 
CD34, similar to IC and BM Sca-1+ progenitors that were isolated in my project. 
Unlike SC, PDGFRα+ IC did not express MyoD and Pax7, unless they acquire a myogenic 
fate [100, 111]. These IC have also been reported to show multiple mesodermal 
differentiation potential (adipogenic, osteogenic and minimal myogenic capacity) [238, 
243]. Further to this PDGFRα+ IC in degenerative muscle also showed higher expression 
of collagen type 1a gene [244] which makes them possibly responsible for excessive 
fibrosis in muscular distrophy. Interestingly, in my experiments collagen type 1a was highly 
expressed in IC and BM Sca-1+ progenitors.  
Sorting of bone marrow Sca-1+ progenitors (BM MSCs) was similar to that published 
previously [123]. Sorted population negative for Sca-1 and CD34 markers in bone marrow 
could represent osteochondroprogenitors as have been suggested before [124, 245] and 
therefore it can be already prone to osteogenic fate which explains their high osteogenic 
differentiation rate and expression of Runx2, Osteocalcin and Osterix, similar to BM Sca-1+ 
progenitors and MC3T3 cell line population. 
MC3T3 cell line consists of mouse preosteoblasts, thus its osteogenic fate is predisposed. 
For this reason I included these cells in my experiments as a positive control. 
Prrx-1 is mesenchymal marker, essential for the normal osteogenesis and its depletion 
causes severe defects in skull, limbs, spinal column and inner ear [246]. It has been 
shown to be present on MC3T3 cells and primary mesenchymal stromal cells before [247] 
which is consistent with my qRT-PCR results. 
I have shown that all populations of cells differentiated towards osteoblasts by the third 
week of culture in osteogenic conditions in vitro. Previously aforementioned cell 
populations have been shown to differentiate towards this mesodermal lineage under 
different conditions: 
a) Muscle SC exhibited osteogenic potential following treatment with BMPs [109]. 
b) Human SC expressing Pax-7  also displayed osteoblastic properties in Duchenne 
muscular dystrophy patients [107]. In vitro these cells also expressed osteogenic 
lineage markers Runx2 and ALP without additional BMP-2 stimulation. 
c) CD44+Sca-1+ cells isolated from mouse muscles showed osteogenic potential [248] 
after 4 week culture in osteogenic conditions. 
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d) Muscle-derived progenitors (both Sca-1+ and Sca-1-) retrovirally transduced to 
express BMP-4 and non-transduced muscle-derived progenitors with prolonged 
exposure to BMP2 showed heterotopic ossification in vivo [249] as soon as 2 weeks 
after transplantation. 
These findings demonstrate that all the progenitor cell populations isolated from the naïve 
muscle can potentially differentiate towards one of the mesodermal lineage - osteogenic, 
and these differentiation capabilities can be further amplified by culture in lineage-specific 
induction conditions as they do express Osteocalcin, Runx2, collagen type 1a and Prrx1 
and can form mineralized matrix in vitro. 
We investigated a few populations of muscle progenitor cells along with bmMSCs and BM 
Sca1- CD34- progenitors and found that a few populations of cells in the muscle have 
osteogenic potential in vitro, moreover muscle interstitial cells are prone to deposit 
mineralized matrix required for the bone formation even earlier bone marrow MSCs. Thus 
we confirmed the possible source of HO locally in the damaged muscle. 
Further to confirm the source of osteoblasts in muscle during the HO formation we are 
planning to establish in vivo experiment where we would be able to track specific cells and 
test their role in bone formation after SCI. We are working on the mouse model for lineage 
tracking experiments. These include: B6.Cg-Pax7tm1(cre/ERT2)Gaka/J x B6.Cg-
Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J to track muscle progenitor cells and B6.Cg-Tg(Prrx1-
cre)1Cjt/J x B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze/J to track mesenchymal progenitor 
cells. 
Finally, our model suggests that the osteoblasts responsible for NHO in muscles are not 
necessarily derived from mesenchymal progenitor recruited from the bone marrow. 
Although this remains to be demonstrated genetically with lineage tracking experiments, 
muscle satellite cell, interstitial cells or MPCs sorted from the muscle of naïve mice, which 
all have the potential to regenerate myofibers in vivo following muscle injury [101], were all 
capable of osteogenic differentiation in vitro as previously reported in mouse [109] and 
human [250]. 
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Chapter 7: Evidence of Systemic Factors Driving NHO following SCI  
7.1 Introduction 
Our model of NHO after SCI clearly suggests that two factors are required in order to 
cause abnormal bone formation: spinal trauma and local muscle inflammation. While role 
of inflammation was extensively discussed in the previous chapters, in this chapter I focus 
on the neurogenic part of NHO. Our hypothesis is that systemic/endocrine factors are 
released in blood in response to SCI, which prime mesenchymal progenitor cells to 
osteogenic differentiation upon muscle injury. It is unknown what factors released after 
spinal cord disruption locally or systemically can stimulate osteogenic differentiation of 
progenitors in some patients that develop HO. Discovering the systemic or local factors 
released in response to major nerve disruption has a potential to improve understanding of 
the pathogenesis, increase prognostic information and diagnostic abilities as well as 
provide potential treatment targets. To date very little is known about release of 
osteoinductive biochemical factors and their influence on osteogenic differentiation of 
MPCs. It has been previously shown that SCI stimulates systemic release of biologically 
active factors and hormones in the plasma such as calcium, leptin and [38, 251, 252].  
It has been proposed that substance P might be one of systemic factors responsible for 
HO in mouse models of FOP [36, 126]. Salisbury et al. have shown that BMP-2 stimulation 
of  substance P and calcitonin gene related peptide increased concentration of substance 
P in muscle [36]. They suggested that substance P is released from the sensory neurons 
as they did not observe substance P concentration increase in animals lacking functional 
sensory neurons. Nerve fibres staining positive for substance P, a well-known nociceptive 
signalling molecule typically associated with sensory nerves, enter the bone in association 
with vessels innervating medullary tissued of bones [253], and then dissociate and 
terminate as free nerve endings. Salisbury et al. have also found decrease in HO 
formation in mice with altered sensory neurons. Kan et al. have also investigated role of 
substance P in their Nse-BMP4 transgenic mouse model of FOP [126]. They found 
increased concentration of substance P in bone masses from FOP patient and in mouse 
model after CDTX-induced injury. Also the authors observed less bone formation in NK-1 
knockout mice. 
Substance P is a neuropeptide mediating response to pain [254] and produced by 
neurons, osteoblasts and macrophages in injured and diseased tissues [36, 255]. Three 
types of SP receptors were previously identified, that are called neurokinin receptors type 
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1, 2 and 3 [256]. SP binds more strongly to the NK1 receptors however it binds with a 
lower affinity to NK2R and NK3R [257, 258]. Substance P has been shown to increase 
chondrocyte differentiation [259], osteoblast differentiation through upregulation of osterix 
expression [260], bone colony formation, and osteoblast cyclic AMP production. It 
stimulated osteoblasts specific markers production such as alkaline phosphatase, Runx2 
and osteocalcin in bone marrow mesenchymal progenitor cells in vitro [261], At least one 
of its receptors, neurokinin-1 is expressed by osteoclasts. Neurokinin-1 drives osteoclast 
resorbtion activity in vitro when osteoclasts are exposed to substance P [262]. A non-
peptide NK1-receptor antagonist RP67580 has been reported over a decade ago [263]. It 
was shown to be effective in reducing neurogenic inflammation and in antinociceptive test 
its efficacy was comparable to the effect of morphin with just 1.5 fold less [264]. Substance 
P has proinflammatory effects or augments inflammatory responses in the respiratory, 
gastrointestinal, and musculoskeletal systems [265]. Indeed substance P receptor 
antagonist RP67580 has been reported to reduce leucocyte, neutrophil and monocyte 
accumulation in the lungs of mice with delayed-type hypersensitivity, thus confirming its 
ability to decrease inflammatory response [266].  
Although substance P has been reported to promote HO in genetic mouse models of FOP 
induced by overexpression of BMP2/4, it is unknown whether substance P is involved in 
our model of NHO after SCI, where there is no genetically enforced expression of BMPs. 
7.1.1 Aims and Objectives 
This chapter is to test the hypothesis that factors are released in the circulation following 
SCI that prime the formation of HO in inflamed muscles. 
The aim of this chapter is to determine whether SCI causes the release of systemic factors 
that could affect the osteogenic differentiation of muscle progenitor cells in vitro and 
promote the development of HO in vivo. 
In the first part, I tested the hypothesis that endocrine factors are released in the 
circulation following SCI that prime the formation of HO in inflamed muscles by causing 
muscle inflammation in non-paralysed front limb above the level of SCI. In a second part, I 
tested whether the plasma of mice with SCI could promote mineralization of culture muscle 
progenitor cells in vitro. In a third part, I tested the effect of substance P in vitro in cultures 
of sorted adult murine bone/bone marrow mesenchymal stromal cells and muscle 
mesenchymal progenitor cells. Finally the effect of a substance P receptor antagonist on 
the development of NHO following SCI was tested in vivo. 
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7.2 Methods 
7.2.1 Mouse surgery and treatment 
Mouse spinal cord injury surgery was performed as described in Chapter 2, section 2.2. To 
assess the possible effect of spinal cord injury on NHO cardiotoxin was injected 
intramuscularly in the right front limbs of the mice in the usual dose 0.256mg/kg. 
To assess the substance P receptor antagonist effect we used our usual model of NHO 
with CDTX injected in the hind limb. RP67580, a selective antagonist of the substance P 
receptor NK1R [264], was injected intraperitoneally twice daily at a dose of 2 mg/kg in 2% 
ethanol diluted with saline. Control mice were injected in parallel with an equivalent volume 
of vehicle – 2% ethanol in saline.  
7.2.2 Harvest sort and culture of muscle and bone marrow progenitors 
To identify which cells within the muscle are capable of mineral deposition are responsible 
for making bones in muscles (are they derived from the muscle itself, or are they recruited 
from the skeleton and bone marrow via the blood) I used hind limb muscles from naïve 
adult C57BL/6 mice and I sorted by flow cytometry the following populations: 
 muscle satellite cells (SC) as CD45- Ter119- CD31- Sca1- CD34+ cells; 
 muscle mesenchymal interstitial cells (IC) as CD45- Ter119- CD31- Sca1+ CD34+ 
cells as previously reported [100, 101]; and 
 CD45- Ter119- CD31- Sca1- CD34- progenitor cells as per Chapter 6.  
As positive controls for osteogenic differentiation and mineral deposition, I sorted CD45- 
Ter119- CD31- Sca1+ mesenchymal progenitor cells from femurs and tibias from naïve 
adult C57Bl/6 wild type mice and CD45- Ter119- CD31- Sca1- CD34- bone marrow 
progenitor cells. Sorting and culture methods are described in Chapter 2, section 2.4.1 and 
Chapter 6, Methods. 
7.2.3 Osteogenic differentiation of muscle and bone marrow progenitors 
Methods for osteogenic differentiation and quantification of calcium and phosphate mineral 
deposition (Alizarin Red staining and von Kossa staining) are described in Chapter 2, 
section 2.5. Briefly sorted populations of cells were seeded in 96 wells plates at a density 
5000 cells/cm2. All cell populations were seeded into two columns of wells, so that there 
would be two replicates of each cell type for each concentration of substance P/substance 
P receptor antagonist/vehicle control. The tissue culture medium (1X high glucose DMEM 
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high glucose containing 20 % (v/v) FCS, 10% horse serum, 10 U penicillin/mL, 10ug/ml 
streptomycin and 2mM glutamine) was replaced by osteogenic differentiation media 48 
hours after. Osteogenic differentiation medium consisted of 1x -MEM supplemented with 
dexamethasone (0.2 μM), β-glycerol phosphate (10 mM), L-ascorbate-2-phosphate (200 
μM), calcium chloride (2 mM), 10% (v/v) FBS and 10U Pen/mL;10ug Strep/ml; 2mM Gln. 
Mouse osteoblastic cell line MC-3T3 (a kind gift from Allison Pettit group) was used as a 
positive control for mineral deposition. 
R67580, a selective antagonist of the substance P receptor NK1R (catalogue # 1635, 
TOCRIS) was diluted in 10% ethanol at a concentration 20mM (8.86mg/mL) and stored in 
-70°C. Substance P (1156, TOCRIS) was reconstituted from powder with water as per 
manufacturer’s instructions at a concentration 1mM and stored in -70°C. 
The outline of substance P and substance P receptor antagonist (RP67580) used in the 
cultures concentrations is presented in the Table 7.1. Substance P receptor antagonist 
concentration was used as described previously with a wider range of doses [265]. 
Table 7.1 Substance P, substance P receptor antagonist concentrations. 
Substance P concentration, μM Substance P receptor antagonist concentration, μM 
0 0 
0.5 0.5 
1 1 
2 3 
5 5 
10 10 
20 20 
50 50 
 10% ethanol was used as a negative control in the following concentrations: 0 μM, 1 μM, 
3 μM, 5 μM and 10 μM. 
7.2.4 Quantification of substance P in mouse plasma and muscle protein extract 
Plasma and muscle protein extract were collected and prepared as described in Chapter 
2, section 2.7.1, 2.11. Concentration of protein in muscle extracts was determined using 
Pierce™ BCA Protein Assay Kit (23227; Thermo Fisher Scientific) in μg/mL according to 
the manufacturer’s instructions. Briefly all samples were diluted 1/10 with calibration 
diluent, standard diluted bovine serum albumin standards (BSA) were prepared and 25μL 
of sample or standard dilution were transferred into 96-wells plates. Working solution was 
added next (50 parts of reagent A and 1 part of reagent B from the kit) and the plate was 
covered and incubated on the shaker for 30 min at 37°C. Absorbance was then measured 
at 562nm on a plate reader and results were calculated and adjusted to the calibration 
curve with BSA. 
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To quantify substance P concentration we used the Substance P Parameter Assay Kit 
(KGE007; R&D Systems, Inc., Minneapolis, MN, USA). This assay is a competitive 
enzyme immunoassay in which an antibody specific for substance P is bound to a plastic 
plate. Then sample containing unlabelled substance P is combined with substance P 
linked horse radish peroxidase for binding to the unmobilised antibody. Therefore, a 
decreasing signal indicates higher concentrations of substance P present in the sample to 
test. This assay was performed with a change to the kit instructions as the plate is coated 
with a goat anti-mouse polyclonal antibody and could be blocked by mouse IgG contained 
in the mouse plasma samples. To overcome this: 50μL of Primary Antibody Solution 
(mouse monoclonal antibody for Substance P) was added to the plate first and incubated 
overnight at 4°C. Calibrator Diluent RD5-45 was added to the first 2 wells (non-specific 
binding wells). The next morning 50 μL of samples were mixed with Calibrator Diluent 
RD5-45 in proportion 1:2. Standard concentrations of 2500, 1250, 625, 312, 156, 78 and 
39pg/mL were prepared. Diluted samples or standard dilutions were then mixed with 
Substance P Conjugate in proportion 1:1 before adding to the plate. 100μL of sample or 
standard dilution mix was then added to the wells coated with the mouse anti-substance P 
antibody and incubated for 3 hours at room temperature on a shaker. Each well was then 
aspirated and washed four times with Wash buffer from the kit. The rest of the protocol 
was followed as per manufacturer’s instructions. Briefly 200μL of substrate solution were 
added into each well and the plate was covered and incubated at the room temperature for 
30 min. Then 50μL of Stop Solution from the kit was added into each well and the plate 
was scanned at 450nm on a plate-reader. 
The calibration of the assay was performed using GraphPad Prism 5 software (GraphPad 
Sofwares, La Jolla, CA) by plotting standard dilution concentrations in log10 value versus 
optical density. The best curve fit model employed was a non-linear regression with the 
equation of dose-response – inhibition fit. The equation for the standard curve is 
represented below: 
OD=OD ͚ + (OD0-OD ͚)/(1+Slope*10^(LogIC50-[SP])), where OD is optic density; OD ͚ is 
optic density of highest concentration of substance P, OD0 is optic density of lowest 
concentration of substance P; [SP] is concentration of substance P. 
Interpolated x-values that represent log-values of concentration were calculated, converted 
to numbers and corrected according to dilution factor. The substance P concentration for 
plasma and muscle protein extract was then calculated from this best fit as ng/mL of 
plasma or and pg/μg of muscle protein, respectively. 
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7.3 Results 
7.3.1 Limb paralysis is not necessary for NHO development 
To test whether the paralysis of the limb was necessary to NHO development after SCI, 
cardiotoxin was injected intramuscularly in the front limb muscles of mice that underwent 
spinal cord injury between T7 and T8. Front legs remain functional and active in these 
mice as the spinal cord transection between these two vertebrae results in the paralysis of 
the bottom part of the body (both hind limbs and bladder) without affecting motor or 
sensitive innervation of the upper part of the body. Micro CT scans at day 10 after SCI and 
CDTX injection showed the presence of heterotopic ossification in the CDTX injected 
mobile front limb (Figure 7.1A). HO developed in the CDTX-injected front limb whereas 
there was no HO in the non-injected limbs (front or back) (p-value: 0.008** by Mann-
Whitney test) (Figure 7.1B). However the amount of bone formed above the level of spinal 
cord injury was significantly less in comparison with mice where inflammation was induced 
below the level of injury (hind limb muscles) (1-3mm3 vs 20-30mm3) (p-value: 0.0012** by 
Mann-Whitney test).  The smaller volume of HO in the front limb is however to be 
considered relative to the muscle mass of the mouse front limb, which is much smaller 
than the hamstring muscle of the hind limb. 
 
Figure 7.1 Evidence of systemic factors contributing to NHO. (A) Illustrative μCT of right 
front limbs after SCI with injection of CDTX; (B) Quantification of HO volumes by 3D μCT 
reconstitution following SCI and intramuscular CDTX injection into front limb. Data 
presented as mean±SD of 5 mice per group. 
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From these findings we conclude that limb paralysis is not necessary to support NHO 
following SCI. An additional muscle inflammation is sufficient provided that the mouse has 
a spinal cord injury. 
Further to explain this phenomenon, we hypothesized that systemic factors may be 
released into the blood in response to SCI and these systemic factors may prime muscle 
cells to form an HO following muscle inflammation as CDTX-mediated muscle 
inflammation alone is not sufficient to induce HO development. This is explored with 
following experiments. 
7.3.2 Plasma harvested from mice with HO promotes osteogenic differentiation of muscle 
progenitor cells 
To further test the 2nd conclusion above (that is whether systemic osteogenic factors are 
released in the blood following SCI), muscle interstitial cells, satellite cells and bone 
marrow Sca-1+ mesenchymal progenitor cells were isolated form hamstring muscles of 
naïve untreated wild-type C57BL/6 mice and sorted by flow cytometry based on the CD45- 
Ter119- CD31- Sca-1+ CD34+/- phenotype (as described in Chapter 6). They were then 
expanded in culture until confluent and then cultured for three weeks in the presence of 
10% blood plasma from SCI or SHAM-operated mice, without addition of any osteogenic 
factor. Cells were then fixed, washed and stained with Alizarin red to quantify mineral 
calcium deposition (Fig.7.2A).  I had 2 mice in each treatment group and plasma from 
each mouse was tested individually and in separate well. Thus all the data are from two 
different biological replicates per treatment group. Plasma from mice with SCI alone did 
not cause mineralized matrix formation in all population of cells: muscle IC, muscle SC and 
bone marrow Sca-1+ mesenchymal progenitor cells, relative to control wells cultured with 
10% plasma from SHAM-operated mice or with wells without mouse plasma. However 
plasma from mice with combination of SCI and intramuscular injection of CDTX 
significantly enhanced mineral deposition by muscle interstitial cells (p-value <0.05*, one-
way ANOVA with Bonferroni’s multiple comparison test) (Fig 7.2B,C). Experiment was 
repeated three times with similar results. 
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Figure 7.2 Effect of plasma from SCI and SHAM-operated mice on osteogenic 
differentiation of interstitial cells, satellite cells and bone marrow MPCs. (A) Alizarin Red 
staining of mouse bone marrow and skeletal muscle cell populations. Rows of wells 
contained muscle interstitial cells (top), muscle satellite cells (middle), Sca1+ bone marrow 
progenitor cells (bottom) cultured for 3 weeks in tissue culture medium supplemented with 
plasma harvested from mice with SHAM surgery, SCI with saline injection and SCI with 
CDTX injection. The red staining shows mineralized calcium deposited at the bottom of the 
wells. 
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(B) Quantification of mouse plasma effect on osteogenic differentiation of mouse bone 
marrow and skeletal muscle cell populations by Alizarin Red staining for each cell 
population. The histograms show the quantification of the Alizarin Red staining by light 
absorbance at 562nm of cells cultured in tissue culture media supplemented with mouse 
plasma. Data are mean ± SD of four wells of a typical experiment. 
(C) Quantification of mouse plasma effect on osteogenic differentiation of mouse bone 
marrow and skeletal muscle cell populations by Alizarin Red staining for each condition for 
plasma harvest. Grey bars – muscle interstitial cells, dotted bars – muscle satellite cells, 
bars with diagonal lines - Sca1+ bone marrow progenitor cells. Data are mean ± SD of four 
wells of a typical experiment. 
As the volume of plasma collected per mouse was limiting factor I repeated this 
experiment with 8 plasma samples from 8 mice per group only on muscle mesenchymal 
progenitor cells – interstitial cells as they mineralised the best and satellite cells as internal 
muscle control (Fig.7.3).  
 
Figure 7.3 Effect of plasma from SCI and SHAM-operated mice on osteogenic 
differentiation of interstitial and satellite cells. (A) Alizarin Red staining of mouse bone 
marrow and skeletal muscle cell populations. Rows of wells contained muscle interstitial 
cells (top), muscle satellite cells (bottom) cultured for 3 weeks in tissue culture medium 
supplemented with plasma harvested from mice with SHAM surgery and SCI with CDTX 
injection. The red staining shows mineralized calcium deposited at the bottom of the wells. 
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(B) Quantification of mouse plasma effect on osteogenic differentiation of mouse bone 
marrow and skeletal muscle cell populations by Alizarin Red staining for each cell 
population. The histograms show the quantification of the Alizarin Red staining by light 
absorbance at 562nm of cells cultured in tissue culture media supplemented with mouse 
plasma. Data are mean ± SD of eight wells of a typical experiment. Plasma used in each 
well was harvested from different mice. *** p<0.001 
 
This result suggests that systemic factors that may promote mineral deposition by muscle 
derived progenitor cells are released in the circulation following SCI and intramuscular 
inflammation. 
7.3.3 Substance P enhances osteogenic differentiation of muscle and bone marrow 
mesenchymal progenitors 
One of the possible endocrine factors released in response to spinal cord injury is 
substance P, an 11 amino acid residues peptide (Arg Pro Lys Pro Gln Gln Phe Phe Gly 
Leu Met). It is known as neuromediator of nociception and physiological and immune 
responses to pain. Substance P is produced by neurons and macrophages in injured and 
diseased tissues [255]. Three types of SP receptors were previously identified, that are 
called neurokinin receptors type 1, 2 and 3 [256]. SP binds more strongly to the NK1 
receptors however it binds with a lower affinity to NK2R and NK3R [258]. 
It has been previously reported that the highly selective  NK1R antagonist RP67580 [267] 
or the deletion of the NK1r gene encoding substance P precursor significantly reduces HO 
in transgenic Nse-BMP4mouse model of FOP [126]. 
To determine whether substance P could also be involved in HO development following 
SCI, we performed in vitro experiments with muscle mesenchymal progenitors and bone 
marrow MPCs, where we added substance P and Substance P receptor antagonist 
(RP67580) in culture media together with osteogenic factors to assess their effect on 
mineral deposition. Cell groups were sorted from hamstring muscles and bone marrow of 
naïve C57BL/6 mice as described in methods. Sorted cells were cultured until passage 2, 
and then were used for osteogenic differentiation assay. Mouse osteoblastic cell line MC-
3T3 was used as a positive control for mineral deposition. Formation of calcium matrix was 
induced by substance P in a dose-dependent manner in all cell populations tested (Fig. 
7.4A, 7.5A). 
As substance P receptor antagonist was diluted in 10% ethanol, control wells were 
incubated with ethanol concentrations matching those substance P receptor antagonist 
135 
 
dilutions. As shown in Fig. 7.4C, ethanol did not affect calcium matrix formation stained by 
Alizarin Red. Substance P receptor antagonist decreased mineral deposition at 
concentrations between 1 and 5μM in a dose dependent manner (Fig. 7.4B, 7.5B). This 
effect was more profound with muscle interstitial cells, which have also shown the highest 
potential of mineral deposition in medium supplemented with mouse plasma. However 
increasing concentrations of RP67580 added to the osteogenic differentiation media 
caused an increase of calcium matrix formation in all cell populations. 
 
Figure 7.4 Effect of substance P and substance P receptor antagonist on osteogenic 
differentiation of muscle and bone marrow mesenchymal progenitor cells. Alizarin Red 
staining of muscle interstitial cells (1), muscle satellite cells (2), Sca1-CD34- muscle 
progenitor cells (3), Sca1+ bone marrow MPCs (4), bone marrow Sca1-CD34- MPCs (5), 
and mouse osteoblastic cell line MC3T3 (6) cultured for 3 weeks in osteogenic medium 
supplemented with substance P (A), substance P receptor antagonist (B) or vehicle control 
(C). The red staining shows mineralized calcium deposited at the bottom of the wells. This 
experiment was performed twice on different batches of cells and showed similar results. 
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Figure 7.5 Quantification of osteogenic differentiation of murine bone marrow and skeletal 
muscle cell populations supplemented with substance P or substance P receptor 
antagonist by Alizarin Red staining. 
The histograms show the quantification of the Alizarin Red staining by light absorbance at 
562nm of cells cultured for 3 weeks in osteogenic medium supplemented with substance P 
(A), substance P receptor antagonist (B). Data are mean ± SD of four wells of a typical 
experiment out of 5 independent sorts and experiments. X axis: muscle interstitial cells (1), 
muscle satellite cells (2), Sca1-CD34- muscle progenitor cells (3), Sca1+ bone marrow 
MPCs (4), bone marrow Sca1-CD34- MPCs (5), and mouse osteoblastic cell line MC3T3(6) 
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7.3.4 Substance P receptor antagonist RP67580 reduced SCI-HO in vivo 
To test substance P involvement in SCI-induced NHO, mice that had undergone SCI and 
intramuscular injection of CDTX, were injected twice daily with the selective substance P 
receptor NK1R antagonist RP67580 at 2mg/kg per dose or vehicle alone from immediately 
after SCI surgery and CDTX injection. Mice were sacrificed 10 days after surgery, and 
microCT was performed. The heterotopic bone mass was moderately but significantly 
reduced by 27.6% in the group where treatment was performed (p-value: 0.0418*, Mann-
Whitney test) (Fig.7.6). The bone density did not differ between the groups. 
 
Figure 7.6 Effect of substance P receptor antagonist on NHO. (A) Illustrative μCT of right 
hind limbs after SCI with injection of CDT and treatment with Substance P receptor 
antagonist; Quantification of HO volume (B) and density (C)  by 3D μCT reconstitution 
following SCI, intramuscular CDT injection and treatment with Substance P receptor 
antagonist. Data are mean±SD of 6 mice per group pooled from two different experiments. 
 
138 
 
7.3.5 Spinal cord injury and inflammation do not affect plasma and muscle concentration of 
substance P 
Substance P was measured in plasma of wild-type C57BL/6 mice with SCI and 
inflammation induced by CDTX injection and compared with plasma harvested from SHAM 
operated mice with and without inflammation and plasma harvested from mice with SCI 
alone. The measurements were also performed on protein extracted from the hind limbs of 
the same groups of mice. Time points included day 1, 2, 3 and 4 after surgery. 
Plasma and muscle protein standard curves and equation are presented on Fig.7.7 A,B.  
 
Figure 7.7 Standard curves for plasma (A) and muscle extracted protein (B) for the 
substance P quantification assay. 
 
Upon plasma analysis we noticed significant decrease in the substance P concentration at 
Day 2 time point in all 4 groups (Fig.7.8E). However by the day 3 subsequent increase of 
substance P concentration was found in groups of mice where local inflammation was 
caused by CDTX injection which then plateaus between Day3 and 4 (Fig.7.8A,B,D). 
Surprisingly this increase was also seen in SHAM operated mice. Substance P 
concentration in plasma harvested from mice with SCI did not change drastically within 
first 4 days after surgery apart from the aforementioned decrease at the day 2 (Fg.7.8C). 
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Figure 7.8 Substance P quantification in plasma harvested from mice with SCI+CDT (A), 
CDT alone (B), SCI alone (C) and SHAM-operated mice (D). Each dot represent single 
animal. Data are mean ± SD. Combined time course for all four experimental groups of 
animals (E); p- value: <0.05*; 0.01-0.001**, <0.001*** Two-way ANOVA with Bonferroni 
posttest. 
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Interestingly, substance P concentration in mouse protein extract showed similar drop to 
plasma substance P concentration (Fig.7.9E) at Day 2. However this drop was followed by 
an increase by the Day 3, similarly to plasma concentration amount of substance P in the 
muscle extract drastically decreased by the Day 4 time point in all four groups, reaching 
the same values. The decrease at Day 2 also was not as significant between the groups 
as we have seen in plasma substance P concentration (Fig.7.9A,B,C,D). Substance P 
concentration in muscles from SCI-operated mice has shown minimal changes throughout 
the first 4 days (Fig,7,8C) in comparison with the other three groups of operated mice. No 
significant differences between the groups were found at any particular time points (Day1, 
Day2, Day3 and Day4). 
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Figure 7.9 Substance P quantification in protein extracted from hind limb muscles in pg/μg 
of protein, harvested from  mice with SCI+CDT (A), CDT alone (B), SCI alone (C) and 
SHAM-operated mice (D). Each dot represent single animal. Data are mean ± SD. 
Combined time course for all four experimental groups of animals (E); p- value: <0.05*; 
0.01-0.001**, <0.001*** Two-way ANOVA with Bonferroni posttest. 
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However despite of minor differences in concentration of substance P both in muscle 
protein extract and plasma, in all groups substance P concentration was below mouse 
normal range (60.6±2.1ng/mL [268]). 
7.4 Discussion 
Our observation that muscular inflammation in the front limb, above the SCI, still promotes 
NHO suggests that factors priming resident muscle progenitor cells to osteogenic fate 
could be either released in the circulation or locally induced by a feed-back mechanism 
from the injured central nervous system. These data in our mouse model are consistent 
with similar occurrence of NHO in non-paralyzed shoulder or elbow in NHO patients [5]. 
However the NHO volume in the non-paralyzed front limb was considerably smaller than in 
the hind limb injected with CDTX. In a normal mouse hind limb/front limb ratio is 6/1. 
However there is a reduction in muscle volume of the hind and front limbs after SCI [188]. 
By the end of second week the hind limb muscle volume is reduced by 28% and the front 
limb muscle volume is reduced by 21%, thus decreasing the hind limb/front limb ratio to 
3/1. Interestingly the NHO volumes ratio between hind and front limbs is around 10/1, 
which is not compatible with the amount of muscles. This suggests that despite that SCI 
stimulates release of systemic factors contributing to NHO, the biggest effect is seen in the 
immobilized limbs.  
The fact that the blood plasma of mice that underwent both SCI and CDTX intramuscular 
injury accelerated mineralization of cultured muscle interstitial cells supports the 
hypothesis that osteogenic factors may be released after SCI and muscular inflammation 
which prime NHO formation from muscle progenitors. Consistent with this, blood serum 
from TBI patients has been reported to enhance proliferation and induce expression of 
osteoblast markers: osterix in cultures of primary skeletal muscle cells [269], and osterix, 
Runx2 and alkaline phosphatase in the human osteoblastic cell line FOB1.19 [41]. It has 
been also published earlier that plasma from rodents with severe burns also induced 
osteogenic differentiation of muscle MPCs [270]. This is an interesting fact, as severe 
burns also have a potential to cause HO formation in patients [271].  
Considering that substance P is expressed by neurons and macrophages [254] and 
stimulates osteoblast differentiation in mice and human osteoblastic cell line [260, 261, 
272] and that NK1R antagonists or deletion of the NK1r gene encoding substance P 
precursor significantly reduces HO in transgenic Nse-BMP4 mouse models of FOP [126], 
we decided to investigate first whether substance P could be one of the priming factors 
released in response to SCI. We found that substance P concentration was below the 
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normal mouse range in plasma (60.6±2.1ng/mL [268]) of all operated mice, despite 
differences between the groups. This could be due to the differences in methods of 
quantification of substance P. At Day 2 post-surgery we have noticed significant decrease 
in the substance P concentration both in plasma and muscle protein, which is consistent 
with results described by Salisbury et al. in their model of FOP in which HO are caused by 
injection of mouse fibroblasts transduced with an adenovirus carrying BMP-2 [36].  
Administration of RP67580, a selective antagonist of the substance P receptor NK1R 
reduced NHO by approximately 30% in our mouse model. Although this effect was 
statistically significant, this reduction was more modest than that observed in mouse 
genetic models of FOP  where transgenic Nse-BMP4 mice were injected with CDTX, 
which was around 70% [126]. RP67580 has been shown to be highly selective for NK1 
receptors (with Ki value of 4.16±0.59nM) which are the main receptors for Substance P 
binding and did not show any affinity to other neuropeptide receptors [273]. RP67580 was 
not active on NK2 and NK3 receptors as seen in binding assays and in isolated 
preparations on rabbit and rat tissues [264, 273]. It has also shown poor affinity for 
dopamine, serotonin, adrenergic and a variety of peptide receptors. However while 
RP67580 does not interact with other two types of neurokinin receptors, substance P still 
has low affinity to these receptors, and may still activate them which was a limitation of our 
experiment and could be associated with partial block of NHO formation [263, 264]. An 
alternative explanation is that substance P is only one of several pro-osteogenic factors 
released in the circulation in response to SCI and muscular inflammation. Proteomics 
studies comparing protein content of plasma from mice that underwent SCI alone or SCI 
plus intramuscular CDTX may provide additional clues to this question. It is unknown at 
this stage whether NHO reduction after RP67580 treatment was associated with 
dampened neuroinflammation or decrease in local monocyte infiltration in the muscles or 
delay in osteoblast differentiation as substance P has been reported to be involved in all of 
aforementioned processes. 
Several markers were found in human serum from patients with central nervous system 
injury, such as C-reactive protein, erythrocyte sedimentation rate, Interleukin-6, 
Parathyroid hormone, Alkaline Phosphatase, tumour necrosis factor-alpha (TNF-α), each 
of them could be a potential biomarker for HO [38].  
Obviously it is still unclear from the literature which factors are released in the blood as a 
result of SCI or as the result on the combination of neurodamage and muscular 
inflammation that both are required for the heterotopic bone formation. More work is 
required to identify these factors and establish firm mechanistic connections between 
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plasma markers and osteogenic differentiation of muscle mesenchymal progenitors to 
develop NHO. 
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Chapter 8: General Conclusion 
The etiopathology of NHO is poorly understood for two reasons. Firstly, most research in 
patients is retrospective, no studies on the earliest stages of NHO have occurred to aid 
identification of the initiating cellular and molecular events underlying HO in muscles and 
joints. Secondly, there is no clinically-relevant animal model of NHO after central nervous 
system (CNS) lesions [125]. The only existing animal models of HO are genetically 
modified mouse models of progressive osseous heteroplasia [127], and FOP [18, 46, 48, 
125]. Development of a non-genetically modified animal model of NHO would allow 
investigation of the mechanism linking the original neurological lesion to HO, and 
ultimately provide a model for pre-clinical testing of treatments to prevent or reduce NHO.  
I have addressed a number of questions in this project – 1) what is the source of the 
muscle osteoblasts responsible for making bones in muscles (are they derived from the 
muscle itself, or are they recruited from the skeleton and bone marrow via the blood); 2) 
which factors are produced in response to spine disruption that predispose bone formation 
in muscles; 3) whether inflammation in the muscle is the event triggering this abnormal 
ossification; 4) is there another agent other than cardiotoxin that can instigate heterotopic 
ossification in murine model of spinal cord injury? These questions were answered to 
some extent during the course of my PhD.  
Overall there are five key findings of my project: 
 SCI-NHO requires a combination of spinal cord injury and local muscle 
inflammation, which is induced by cardiotoxin in our mouse model; 
 Inflammatory macrophages play an important role in bone formation in our model 
of SCI-NHO; 
 In the presence of SCI macrophages are activated differently in comparison with 
mice that have got CDTX-induced inflammation combined with SHAM surgery; 
 SCI promotes release of systemic factors that prime osteogenic differentiation of 
mesenchymal progenitor cells; 
 Mesenchymal progenitor cells which are capable of osteogenic differentiation are 
presented locally in the muscles. 
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While transgenic mouse models of HO in which BMP signaling is increased by means of 
introduction of transgenes or constitutively active mutants of BMP receptors are 
physiologically relevant models of FOP (a very rare genetic disease involving activating 
mutations of ACVR1) they are irrelevant to model NHO in otherwise genetically normal 
patients.  
Therefore we have developed a clinically-relevant mouse model of NHO following SCI 
which displays the pathophysiology seen in patients with NHO. In most cases we are 
assessing NHO by bone volume and bone density by microCT. NHO in our mouse model 
and patients have the same pattern of growing where NHO forms as small foci of 
ossifications that grow with time merging into a big mass. The involvement of local 
inflammation and macrophages is also common to our model and NHO in patients. Our 
mouse model clearly demonstrates that it is the combination of SCI and local muscle 
inflammation that is the underlying mechanism in NHO development with either insult 
alone being insufficient. This suggests that SCI could prime mesenchymal or muscle 
progenitor cells towards osteogenic differentiation, by releasing factors such as substance 
P, whilst local macrophage-dependent inflammation triggers and drives site-specific 
osteogenic differentiation leading to heterotopic ossification. Our mouse model is highly 
consistent with the clinical observations as SCI and TBI patients that develop NHO as the 
incidence of NHO in patients is higher in cases of concomitant infection or severe trauma 
[5], including much higher incidence in war casualties who are more likely to have these 
co-morbidities than civilians [35]. 
Our model is consistent with the clinical observation that ossification can be reduced by 
NSAID in NHO patients [49, 52, 53], and with our previous observations that specific 
subsets of resident macrophages are critical to the maturation of osteoblasts and bone 
formation in skeletal bones [114, 120]. In long bones, macrophage depletion induces a 
rapid loss of mature osteoblasts on bone surface, arrests bone formation and 
mineralization in adult mice [114, 120], and impairs bone repair following fracture [147]. 
Emerging data also suggest that inflammatory macrophages can promote osteoblast and 
bone formation [274]. We have excluded potential involvement of splenic population of 
monocytes into NHO formation after SCI by performing a set of experiments with 
splenectomised mice. The results of experiments on CCR-2 knockout mice suggest that 
local muscle tissue macrophages are involved in the process of heterotopic bone 
formation. Alternatively macrophages could be recruited from distant sited independently 
of CCR-2. Whether macrophages directly or indirectly support ossification in NHO, their 
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potential molecular mediators and which population of macrophages is driving NHO are 
subjects of ongoing research. 
The finding that muscular inflammation in the front limb, above the SCI, also promoted 
NHO, suggests that factors priming resident muscle progenitor cells to osteogenic fate 
could be released in the circulation or induced locally by a feed-back mechanism from the 
injured CNS. The ability of plasma from mice with SCI to facilitate mineralization of 
cultured muscle interstitial cells supports the former hypothesis but does not exclude the 
latter. Consistent with this, blood serum from TBI patients induces expression of osterix in 
primary skeletal muscle cells [269], and osterix, Runx2 and alkaline phosphatase in the 
human osteoblastic cell line FOB1.19 [41]. We have performed gene microarray analysis 
that revealed up-regulation of inflammatory cytokines IL-1β, TNF-α, IL-6 and CSF-1 
together with up-regulation of M2 macrophage markers in SCI-operated mice with CDTX-
induced inflammation – the only group that develops NHO. Along with these results, we 
compared mice with CDTX-induced inflammation with and without SCI. Despite that both 
groups of mice were injected with CDTX they had differences in inflammatory signaling 
process that were up-regulated in SCI+CDTX group. Interestingly the group of mice with 
SCI alone had increased up-regulation of inflammatory markers in comparison with SHAM-
operated mice confirming previously published results about SCI-mediated inflammatory 
response [142, 143, 275]. 
In our mouse model, development of NHO was accompanied by an osteoporotic 
phenotype with degradation of skeletal bones, similar to osteoporosis in NHO patients 
[276, 277] suggesting that hyperphosphatemia and hyperparathyroidism could fuel 
developing HO. However, phosphatemia and blood PTH concentrations remained within 
the normal range in our mice developing HO following SCI and CDTX injection. We finally 
found that substance P is a possible candidate as one of the osteogenic priming factors 
released in response to SCI. Together with osteogenic potential substance P has been 
reported to reduce neuroinflammation after injury. By blocking substance P signaling we 
managed to partially but significantly reduce NHO in our model by 30%. The incomplete 
reduction in NHO after NK1R antagonism might be associated with low affinity of 
substance P to NK2R and NK3R and suggests that substance P may play a mediatory role 
and that alternative systemic mediators of NHO which remain to be identified, will 
represent more effective pharmacologic targets. 
Finally, our model suggests that the osteoblasts responsible for NHO in muscles are not 
necessarily derived from mesenchymal progenitors recruited from the bone marrow. Two 
types of mesenchymal progenitor cells were found locally in the muscles: satellite cells and 
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interstitial cells [100]. In the series of experiment we have shown that muscle interstitial 
cells are prone to mineralization and osteogenic differentiation in vitro in shorter time 
frames in comparison with SC and bone marrow mesenchymal progenitor cells. Also 
interstitial cells have readily formed mineralized matrix upon culture in media 
supplemented with plasma from mice developing NHO. Although this remains to be 
demonstrated genetically with lineage tracking experiments, muscle satellite cells, 
interstitial cells or MPCs sorted from the muscle of naïve mice, which all have the potential 
to regenerate myofibers in vivo following muscle injury [100, 278], were all capable of 
osteogenic differentiation in vitro as previously reported in mouse [109] and human [250]. 
In conclusion, a significant advantage of our model over the only other existing HO models 
[18, 26, 46, 48] is that it occurs in non-genetically modified mice. We have developed the 
first pre-clinical model of NHO that reliably reproduces disease pathophysiology without 
the necessity of creating genetic susceptibilities (e.g. introduction of a mutant gene or 
overexpression of a gene involved in BMP signaling) that are not clinically relevant to a 
large proportion of patients that suffer from NHO. This unique model could be used to 
understand the mechanisms causing this complication and test treatments that could 
prevent it. Importantly it provides a clinically relevant animal model to test drugs for their 
ability to reduce or prevent NHO in patients that include a high proportion of injured 
soldiers, with SCI. Finally the ramifications of our findings to basic stem cell biology are 
important as it illustrates how the cross regulation between CNS and innate immunity can 
lead to pathological osteogenic differentiation of muscle cells instead of myogenic repair. 
 
I have also improved our mouse model during the course of my PhD. Considering the 
CDTX affects muscle tissue very intensively causing massive necrosis of the underlying 
tissues, these stimuli may be different to what happens clinically. I found that combination 
of SCI with crush-injury and LPS-mimicking bacterial infection may be more adequate 
model to test drug efficacy and will be used in further testing of potential treatment options. 
Thus our future directions include testing Etanercept and Substance P receptor antagonist 
that have shown partial benefit in SCI+CDTX model on our new physiological mouse 
model of NHO after SCI. We consider this new model more adequate and close to what 
happens clinically as it has been reported earlier that NHO develops more often in patients 
with severe concomitant trauma or opportunistic infection. Therefore a combination of both 
together with SCI-injury should reveal mechanisms that are involved in this debilitating 
process. 
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Summarizing all the findings together, our model suggests that NHO requires SCI that 
stimulates the release of factors that sensitize muscle mesenchymal progenitor cells to 
abnormal osteogenic differentiation in muscles, however this process doesn’t happen 
without inflammatory macrophages accumulating in inflamed muscles then triggering 
abnormal osteogenic differentiation of muscle MPC. The potential impact of the project is 
four-fold: scientific, medical, social and financial. Scientifically the novelty of this project 
lies in the generation of new mouse model of heterotopic ossification after spinal cord 
injury and the enlightening of mechanisms leading to that. Insights gained from this project 
could lead to new research with the aim to supress new bone formation in damaged 
muscles and to changes in heterotopic ossification treatment. This may lead to better 
repair of tissue damage, reduction of new bone formation, and improvement of quality of 
life. The project social significance consists in changing demographic parameters of 
mortality and morbidity and increasing the rehabilitation success, leading to financial 
benefits to the health care system. 
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Appendix D: Abstracts and presentations 
Oral: 
2015 
 05/2015 – Australian Health and Medical Research Postgraduate Student 
Conference (oral presentation selected from abstract) – won People’s Choice 
Award in Oral Presentations 
2014 
 11/2014 – Australian Health and Medical Research Congress 2014 (oral 
presentation selected from abstract for Australian Society for Medical Research) 
 11/2014 – Australasian Stem Cell Science And Therapy Meeting 2014 (oral 
presentation selected from abstract) – won National Stem Cell Foundation of 
Australia travel award 
 10/2014 – TRI Poster Symposium 2014 (oral presentation selected from abstract) 
 09/2014 – Australian and New Zealand Bone and Mineral Society, 2014 Annual 
Scientific meeting (oral presentation selected from abstract) – won travel award, 
Roger Melick Young Investigator Award 
 06/2014 – Mater Research 3 Minute Thesis Competition, TRI, Brisbane (public talk) 
2013 
 09/2013 – TRI Friday Seminar Series, Brisbane (invited seminar) 
Poster: 
2014 
 09/2014 – Australian and New Zealand Bone and Mineral Society, 2014 Annual 
Scientific meeting (poster selected from abstract) – won travel award 
 05/2014 – Postgraduate Medical Research Student Conference, the Australian 
Society for Medical Research, Brisbane 
2013 
 10/2013 – 6th Australian Society for Stem Cell Research Annual Meeting, Brisbane 
(poster selected from abstract) – won the best student poster prize, travel award 
 05/2013 – Postgraduate Medical Research Student Conference, The Australian 
Society for Medical Research, Brisbane (poster selected from abstract) – won travel 
award 
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2012 
 11/2012 – 5th Australian Society for Stem Cell Research Meeting, Leura, NSW 
(poster selected from abstract) – won the best student poster prize, travel award 
 11/2012 – Early Career Researcher Poster Symposium, Brisbane 
 05/2012 – Mater Medical Research Institute 2012 Stem Cell Symposium, Brisbane 
 05/2012 – Australian Society for Medical Research Postgraduate Medical Research 
Student Conference, University of Queensland, Brisbane  
 04/2012 – The TRI Student Retreat, Brisbane  
2011 
 10/2011 – 4th Australian Society for Stem Cell Research Annual Meeting, Leura, 
NSW (poster selected from abstract) 
Awards: 
2015 
 2015 – People’s Choice Award in Oral Presentations,  Australian Society for 
Medical Research, Postgraduate Student Conference 
2014 
 2014 – Mater Research Higher Degree Award 
 2014 – National Stem Cell Foundation of Australia travel award to attend the 
Australasian Stem Cell Science and Therapy meeting 2014 
 2014 – Roger Melick Young Investigator Award 
 2014 – Winner of Australian and New Zealand Bone and Mineral Society Travel 
Grant 
 2014 – Winner of a Mater Student Travel Award  
2013 
 2013 – Winner of a Poster Prize at the 6th Australasian Society for Stem Cell 
Research Meeting 
 2013 – National Stem Cell Foundation of Australia Conference Education Award 
2012 
 2012 – Winner of a Student Poster Prize at the 5th Australasian Society for Stem 
Cell Research Meeting 
 2012 – Australian Society for Medical Research Student Travel Subsidy to attend 
Congress in Adelaide 
 2012 – Travel Award to attend the Australasian Society for Stem Cell Research 
2012 meeting 
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2011 
 2011 – Mater Medical Research Institute Top-up scholarship. This scholarship 
commenced in July 2011 
 2011 – University of Queensland International Scholarship (tuition fees award and 
living allowance). This scholarship commenced in July 2011 
